name,mean_cp,mean_odds,uniq_a,uniq_b,shared,score
Antithymoglobulin (phsu),2.42e-10,1.55,12,699,4,12.21
Enteral Nutrition (topp),1.94e-15,3.12,73,552,25,82.65
Endometrium (bpoc),2.42e-17,0.37,89,237,8,122.42
hepatoma cell (cell),2.29e-17,0.13,3,42,0,3.21
Caseins (aapp),4.71e-06,0.26,24,22,0,42.17
Cytoplasmic Granules (celc),2.29e-20,0.08,1,30,0,1.03
Multiparity (orgf),2.52e-08,2.98,138,205,9,230.9
Calmodulin (aapp),6.17e-65,0.02,2,16,0,2.25
Etoposide (carb),5.08e-39,0.82,3,925,2,3.01
Phosphorylation (moft),4.57e-134,0.15,29,415,0,31.03
procalcitonin (aapp),1.06e-06,1.73,13,572,1,13.3
DNA Binding (genf),2.35e-21,0.09,2,36,0,2.11
"Myocytes, Smooth Muscle (cell)",1.45e-225,0.13,30,571,1,31.58
"Aged, 80 and over (aggp)",6.03e-13,5.11,22,161,14,25.01
teleost (fish),1.55e-07,0.12,2,14,0,2.29
Schistosomiasis (dsyn),1.48e-07,0.43,11,200,0,11.61
impulsivity (inbe),1.33e-07,1.49,38,10,0,12.63
Clients (popg),1.11e-06,0.43,41,127,3,54.24
Vasodilator Agents (phsu),9.15e-09,0.88,7,274,3,7.18
Hypothalamic amenorrhea (dsyn),1.29e-10,2.79,38,1,0,1.03
Allogeneic bone marrow transplantation (topp),8.27e-14,1.29,2,417,0,2.01
Veterans (popg),1.1e-12,1.63,169,607,51,216.05
Seizures (sosy),1.19e-21,0.9,175,1979,30,190.47
Thrombocytopenia (dsyn),9.93e-37,1.16,23,1490,8,23.36
small molecule (orch),4.39e-12,0.36,4,301,1,4.05
Reporting (hlca),8.67e-40,2.96,171,574,8,221.94
Drug Interactions (moft),2.09e-27,0.33,101,294,4,135.7
Octreotide|BGLAP (aapp),4.55e-18,83.6,13,126,1,14.34
Upper Extremity (bpoc),1.64e-18,1.43,520,2061,37,651.2
CD2 gene|CD2 (gngm),9.49e-15,0.14,5,36,0,5.69
Autopsy (diap),6.09e-23,2.71,31,3349,18,31.29
Supportive care (topp),1.03e-07,2.78,13,1205,6,13.14
Non-alcoholic fatty liver (dsyn),2.21e-35,3.63,1828,724,77,1010.75
sorafenib (phsu),2.29e-20,1.24,5,670,1,5.04
"Rats, Inbred WKY (mamm)",3.56e-14,0.09,3,19,0,3.47
American Indians (popg),8.16e-19,4.47,79,131,5,126.64
Cancer Model (emod),2.64e-07,0.87,3,190,2,3.05
Immunologic Deficiency Syndromes (dsyn),3.15e-28,0.87,15,742,1,15.3
Pedicles (bpoc),1.41e-09,0.48,48,231,5,57.97
Epoprostenol (bacs),8.19e-56,0.25,9,312,3,9.26
Thyroid associated opthalmopathies (dsyn),1.56e-09,0.12,8,9,0,15.11
oxaliplatin (orch),1.81e-12,1.83,15,1032,5,15.22
Quercetin (vita),2.56e-27,0.18,22,87,2,27.56
Peripheral Nerves (bpoc),4.31e-15,0.24,19,82,0,23.4
Dapsone (phsu),1.65e-10,0.21,4,47,0,4.34
Pancreatitis (dsyn),6.81e-22,1.18,103,2440,59,107.35
Epitopes (imft),7.8e-84,0.15,7,245,1,7.2
Hypothalamic structure (bpoc),1.62e-50,0.2,106,129,3,193.1
Chart evaluation by healthcare professional (hlca),2.73e-79,5.87,153,456,15,204.34
Antibiotic therapy (topp),2.54e-09,1.88,14,829,3,14.24
Difluoromethylornithine (aapp),6.52e-11,0.08,1,14,0,1.07
ORALIT (inch),1.64e-14,7.75,205,134,8,221.59
"Deficiency, immune (dsyn)",1.16e-06,1.03,1,153,0,1.01
Socioeconomic Factors (grpa),2.07e-18,7.35,26,53,4,38.75
Stromal Cells (cell),1.3e-39,0.27,31,264,0,34.64
"Insulin, Glargine, Human|INS (aapp)",2.47e-19,282.38,83,18,2,21.9
Distal subtotal pancreatectomy (topp),4.99e-10,4.61,23,333,21,24.59
pro-brain natriuretic peptide (1-76)|NPPB (aapp),7.5e-09,5.91,12,37,4,15.89
Female reproductive neoplasm malignant NOS (neop),6.44e-09,2.39,49,205,7,60.71
"Lymphoma, Follicular (neop)",2.06e-11,1.59,7,642,3,7.08
integral to membrane (celc),8.14e-26,0.29,7,178,1,7.28
Complement System Proteins (aapp),2.22e-64,0.32,39,536,4,41.84
Transcript (nnon),5.1e-28,0.27,28,191,0,32.1
Lycopersicon esculentum (plnt),4.12e-20,0.15,2,61,0,2.07
Hemophilia A (dsyn),2.23e-11,0.5,32,318,3,35.22
Radioisotopes (elii),1.18e-15,0.25,8,88,0,8.73
Kidney Transplantation (topp),2.46e-43,3.18,237,2266,104,261.79
Alkaline Phosphatase (aapp),2.32e-13,0.48,154,439,7,208.02
Coenzymes (bacs),6.03e-07,0.08,2,6,0,2.67
Virus (virs),1.54e-08,0.6,26,2123,1,26.32
Levamisole (orch),1.45e-07,0.28,11,50,0,13.42
Focal Adhesion Protein-Tyrosine Kinases (aapp),2.77e-24,0.17,1,84,0,1.01
Greece (geoa),8.54e-08,4.62,15,43,2,20.23
Total mesorectal excision (topp),4.99e-21,5.4,42,353,22,47.0
Chitin (carb),3.89e-09,0.24,1,45,0,1.02
RAC-Alpha Serine/Threonine Kinase|AKT1 (aapp),1.29e-16,0.16,3,54,0,3.17
Nitroglycerin (phsu),7.26e-20,0.26,12,119,2,13.21
melanocyte (cell),4.17e-30,0.12,1,74,0,1.01
clinical aspects (clna),3.32e-73,5.43,171,874,29,204.46
Left ventricular diastolic dysfunction (dsyn),7.94e-24,5.11,80,131,16,128.85
Mesothelial cell (cell),5.08e-06,0.26,1,35,0,1.03
Protein complex (aapp),3.16e-27,0.11,7,48,0,8.02
Anastomotic leak (patf),2.53e-20,7.67,26,360,25,27.88
Free Calcium (elii),1.4e-29,0.03,2,11,0,2.36
Activated Charcoal (orch),2.12e-17,0.13,1,43,0,1.02
Minilaparotomy (diap),1.69e-06,4.67,29,42,5,49.02
Multienzyme Complexes (aapp),6.49e-09,0.12,1,20,0,1.05
Gastrin (aapp),4.26e-07,0.2,5,28,0,5.89
Hyperplasia (patf),4.07e-21,0.42,69,355,1,82.41
Fluorescein Angiography (diap),9.24e-08,0.12,5,11,0,7.27
Thalidomide (hops),1.35e-08,0.7,4,478,2,4.03
Cell Death (celf),2.37e-183,0.22,6,888,1,6.04
Heparin (bacs),1.57e-11,0.51,55,1125,12,57.69
EPHB2|MAPK1 (gngm),5.98e-73,0.19,7,283,0,7.17
Lipoma (neop),1.07e-06,0.27,20,35,0,31.43
Penicillamine (aapp),1.47e-24,0.08,1,38,0,1.03
Fibrin (phsu),2.8e-18,0.35,10,169,2,10.59
Myosin Light Chain Kinase (aapp),1.55e-09,0.1,1,17,0,1.06
"Hospitals, Maternity (hcro)",5.05e-13,5.61,23,66,3,31.02
Epstein-Barr Virus Infections (dsyn),1.33e-08,0.78,1,230,0,1.0
Pain score (fndg),4.75e-06,1.95,69,44,3,72.06
Transferrin|TF (aapp),6.52e-12,0.22,14,43,5,18.56
beta-Galactosidase (aapp),9.73e-33,0.05,2,30,0,2.13
Reactive Oxygen Species (bacs),4.53e-149,0.3,123,1199,4,135.62
Risk (qlco),2.15e-192,4.51,475,1033,78,693.42
"Fracture Fixation, Internal (topp)",4.5e-12,0.53,46,321,6,52.59
imbalance (sosy),4.54e-06,1.82,175,409,9,249.88
Pilum (celc),8.82e-17,0.14,1,45,0,1.02
Structure of cerebral artery (bpoc),1.41e-09,0.28,4,62,1,4.26
Potassium (bacs),7.68e-14,0.46,99,343,7,127.57
Follow-up visit (hlca),4.63e-06,3.02,19,48,3,26.52
Dacarbazine (phsu),2.21e-09,0.93,1,191,0,1.01
Buffers (bacs),1.01e-65,0.1,19,101,0,22.57
Jumping (dora),9.06e-08,2.39,36,6,0,7.0
Etanercept|EDNRA (aapp),8.66e-19,69.39,12,37,1,15.89
Acetaldehyde (orch),1.96e-13,0.09,4,17,0,4.94
Biological Assay (lbpr),1.32e-11,1.17,7,420,0,7.12
Tobacco use (fndg),9.26e-08,4.09,17,58,3,21.98
Clusterin|CLU (aapp),9.95e-08,0.2,3,31,0,3.29
Local Anesthetics (phsu),3.63e-15,0.18,9,54,0,10.5
Uterus (bpoc),1.47e-48,0.45,199,1031,15,237.41
sexual dimorphism (ortf),1.41e-06,1.49,52,45,2,83.94
Entire radius (bpoc),1.01e-34,1.31,253,67,1,84.74
Brain Abscess (dsyn),2.39e-09,1.29,1,271,0,1.0
Health education - diet (topp),6.98e-08,8.95,130,67,9,101.53
Point Mutation (genf),5.83e-21,0.28,8,137,0,8.47
Gastric Emptying (ortf),2.42e-09,1.16,117,122,5,229.2
Urge Incontinence (sosy),8.49e-09,1.6,40,9,0,11.03
Pseudotumor Cerebri (dsyn),3.01e-28,2.25,121,17,2,19.39
hypertensive medication (phsu),7.09e-08,13.49,12,15,2,21.6
Chromatography (lbpr),4.31e-44,0.06,10,30,0,13.33
"Protein Processing, Post-Translational (moft)",1.31e-08,0.17,1,30,0,1.03
Right ventricular structure (bpoc),9.66e-15,0.97,42,830,7,44.13
Radioactivity (npop),2.96e-07,0.06,1,5,0,1.2
Cytochromes c' (aapp),4.34e-26,0.08,2,37,1,2.11
Defensins (aapp),3.79e-08,0.15,1,23,0,1.04
Brain Neoplasms (neop),1.02e-19,0.79,23,834,2,23.63
"3,4-Dihydroxyphenylacetic Acid (bacs)",1.34e-12,0.04,2,5,0,2.8
Nerve Regeneration (celf),3.27e-06,0.08,2,5,0,2.8
Dyslipidemias (dsyn),1.95e-185,7.59,1519,1247,141,2270.71
Hydroxyl Radical (inch),7.04e-17,0.09,2,26,0,2.15
Adrenergic beta-Antagonists (phsu),2.29e-07,1.87,112,2824,34,116.44
hindbrain (bpoc),5.86e-07,0.22,3,30,2,3.3
Latex (orch),1.66e-07,0.22,6,33,0,7.09
Creatinine (bacs),1.32e-123,3.52,356,1180,75,463.4
Gonadal Steroid Hormones (horm),1.51e-11,2.35,243,143,15,227.15
Retinitis Pigmentosa (dsyn),8.49e-14,0.09,6,13,0,8.77
Electroconvulsive Therapy (topp),6.89e-14,0.31,18,116,0,20.79
"PTH protein, human|PTH (horm)",4.63e-18,1.18,259,336,14,458.65
"Kidney Tubules, Proximal (bpoc)",5.23e-45,0.15,10,133,0,10.75
pregnane X receptor (aapp),2.19e-07,0.08,2,7,0,2.57
Running (dora),6.46e-13,2.64,119,34,3,43.71
Prostaglandins E (eico),7.64e-12,0.2,11,45,0,13.69
DNA Repair (genf),3.67e-10,0.44,17,241,0,18.2
Adrenal Medulla (bpoc),3.06e-18,0.09,3,27,0,3.33
Data Collection (resa),1.85e-08,2.48,70,438,8,81.19
Carcinoma (neop),3.04e-29,0.66,87,4749,31,88.59
Cystic Fibrosis (dsyn),1.52e-13,1.1,531,1459,89,724.26
Neuraminidase (aapp),6.03e-33,0.17,1,110,0,1.01
Nonagenarians (aggp),3.27e-06,6.49,11,222,10,11.55
Xenograft Model (emod),4.15e-11,0.75,3,382,0,3.02
Adrenoleukodystrophy (dsyn),6.23e-07,0.31,3,50,0,3.18
Bone Marrow (bpoc),4.74e-40,0.47,117,1968,3,123.96
Transcranial magnetic stimulation (topp),6.13e-07,0.13,5,10,0,7.5
Dimethyl Sulfoxide (orch),1.43e-42,0.09,1,74,0,1.01
Acute otitis media (dsyn),1.71e-17,0.13,2,45,0,2.09
Sexual function (orgf),7.05e-26,2.09,163,53,1,70.23
Argipressin|AVP (aapp),2.18e-23,0.37,22,252,1,23.92
Regulatory Element (nusq),9.7e-14,0.09,4,18,0,4.89
Stem cells (cell),9.37e-85,0.32,30,1053,2,30.85
Skeletal bone (bpoc),1.21e-09,0.45,63,214,3,81.55
Thrombolytic Therapy (topp),2.8e-13,1.66,26,1183,5,26.57
Bacterial Infections (dsyn),1.22e-29,1.39,23,1478,3,23.36
Cytoskeleton (celc),2.15e-42,0.11,5,88,0,5.28
Epidermal growth factor receptor inhibitor (phsu),4.11e-20,1.39,2,629,0,2.01
Graft acceptance (phsf),1.11e-12,1.62,4,553,0,4.03
Native Americans (humn),1.85e-17,3.72,56,122,7,81.7
Hyperinsulinism (dsyn),9.21e-23,4.31,644,150,26,184.94
Ultrasonography of abdomen (diap),2.6e-11,3.5,34,88,0,47.14
Caucasoid Race (popg),2.18e-125,3.77,1699,2182,154,3021.92
Macular retinal edema (dsyn),3.3e-10,0.08,4,8,0,6.0
Antibiotics (antb),1.22e-120,1.11,220,6600,34,227.33
infliximab|CA2 (phsu),3.99e-58,817.31,26,57,3,37.86
Busulfan (orch),3.48e-08,1.47,5,371,0,5.07
Insulin (aapp),1.1e-196,3.07,3896,1405,122,1911.68
Placental Lactogen (aapp),8.3e-07,0.05,1,3,0,1.33
Dermatitis (dsyn),3.34e-20,0.26,10,122,0,10.82
Eyelid structure (bpoc),2.87e-07,0.28,3,47,0,3.19
Deep Brain Stimulation (topp),2.36e-13,0.27,19,84,1,23.3
Raised intraocular pressure (fndg),5.64e-10,2.08,34,4,0,4.47
Lidocaine (phsu),1.65e-39,0.16,21,114,0,24.87
"Pleural Effusion, Malignant (dsyn)",6.92e-09,1.11,1,257,2,1.0
Sulfhydryl Compounds (orch),5.7e-24,0.18,26,75,0,35.01
Memory impairment (mobd),1.55e-14,0.27,27,97,0,34.52
Quinidine (bacs),2.89e-14,0.07,2,15,0,2.27
Historical Cohort Studies (qnco),6.37e-07,9.68,9,42,1,10.93
Gingiva (bpoc),3.97e-28,0.23,43,141,0,56.11
Cytostatic Agents (phsu),3.81e-38,0.19,1,146,0,1.01
Diazepam (orch),1.19e-41,0.18,5,155,2,5.16
"Macrophages, Alveolar (cell)",2.81e-58,0.17,2,201,0,2.02
TNFRSF6 gene|FAS (gngm),5.78e-08,0.23,2,38,0,2.11
Case-Control Studies (resa),7e-120,6.76,366,527,26,620.19
Alveolar (bpoc),1.21e-08,0.72,30,858,3,31.05
modern society (humn),2.48e-10,3.67,26,71,3,35.52
Pigment (chvf),3.82e-08,0.24,10,40,0,12.5
Physical Examination (hlca),1.25e-27,3.13,334,527,20,545.68
Granular cell tumor (neop),2.94e-07,0.09,1,10,0,1.1
N-Acetylneuraminic Acid (bacs),3.4e-08,0.25,17,41,1,24.05
PARP1|COL11A2 (gngm),1.85e-06,0.35,3,86,0,3.1
second messenger (bacs),8.42e-10,0.13,3,18,1,3.5
Chemoembolisation (topp),8.47e-18,2.33,5,1226,3,5.02
Neuroendocrine Cell (cell),3.8e-08,0.22,1,36,0,1.03
Retina (bpoc),9.04e-233,0.08,88,189,3,128.97
Ependymoma (neop),3.61e-12,0.87,1,231,0,1.0
Tyrosine Phosphorylation (moft),2.39e-18,0.09,4,26,0,4.62
Substance (sbst),1.67e-09,0.34,24,98,2,29.88
Physical assessment (diap),2.6e-10,1.86,113,326,9,152.17
Cell Cycle (celf),2.85e-34,0.34,11,553,3,11.22
Proteome (aapp),1.64e-29,0.28,16,199,0,17.29
L Cells (Cell Line) (cell),1.05e-12,0.07,3,11,0,3.82
Phospholipids (bacs),5.31e-46,0.25,152,199,3,268.1
Protein Kinase C|SPANXC (aapp),2.1e-133,0.04,5,87,0,5.29
E-Cadherin (aapp),1.32e-06,0.64,3,565,1,3.02
Somatostatin analog|GRHL3 (horm),1.39e-11,135.81,7,31,0,8.58
"Antidepressive Agents, Tricyclic (phsu)",5.22e-14,0.33,11,123,1,11.98
Cyanides (inch),2.82e-14,0.11,1,31,0,1.03
Mitral valve replacement NOS (topp),3.69e-06,2.2,2,488,4,2.01
B-Lymphocytes (cell),4.61e-177,0.23,13,858,4,13.2
Paper (mnob),2.14e-18,0.54,69,495,3,78.62
Mercury (elii),7.5e-13,0.3,40,99,1,56.16
Microbubbles (medd),4.07e-06,0.26,1,34,0,1.03
Anovulatory (dsyn),2.68e-14,2.4,52,4,0,4.31
Hematopoietic Stem Cell Transplantation (topp),6.05e-11,3.98,23,2873,11,23.18
Concentric hypertrophy (comd),3.55e-07,5.75,17,28,4,27.32
Carcinoembryonic Antigen (aapp),7.73e-11,0.85,21,480,6,21.92
Scrotum (bpoc),5.53e-07,0.37,16,81,0,19.16
Motor Cortex (bpoc),1.9e-24,0.06,2,24,0,2.17
Asthenia (sosy),6.62e-08,1.77,422,954,39,608.67
Disks (medd),6.56e-14,0.17,9,43,0,10.88
physical health (fndg),2.42e-15,4.02,148,193,19,261.49
Asymptomatic (fndg),1.98e-72,2.32,550,2383,46,676.94
Transgenes (gngm),1.2e-61,0.19,3,233,0,3.04
Prophylactic treatment (topp),5.97e-10,1.92,902,8784,106,994.62
Palate (bpoc),1.07e-13,0.28,33,92,0,44.84
CYP1A2 gene|CYP1A2 (gngm),2.82e-07,0.17,8,18,0,11.56
Homologous Recombination (genf),2.73e-14,0.13,1,38,0,1.03
Neurologic Symptoms (sosy),9.51e-11,1.13,9,413,0,9.2
Folate (orch),3.26e-28,1.63,252,184,13,318.35
Gonadorelin|BRD2 (horm),3.39e-16,38.55,19,21,0,36.19
Microscopy (lbpr),1.22e-19,0.36,11,403,1,11.3
Granuloma (patf),4.13e-15,0.34,7,228,0,7.21
Phosphoric Monoester Hydrolases (aapp),7.12e-41,0.2,4,169,1,4.09
Arginine|GNAI1 (phsu),5.29e-42,206.56,23,59,1,31.97
Autoantigens (imft),2e-13,0.16,4,42,0,4.38
Recombinant Erythropoietin (aapp),2.7e-36,0.28,21,248,4,22.78
Pyrenes (hops),1.25e-11,0.15,6,30,0,7.2
Tissue Kallikrein (aapp),4.73e-06,0.15,1,17,0,1.06
Glycine (phsu),8.06e-35,0.17,33,98,0,44.11
Laser treatment (topp),1.95e-06,0.28,3,41,0,3.22
Mitomycin (antb),6.64e-33,0.27,3,295,0,3.03
Integrins (aapp),3.66e-71,0.13,5,181,0,5.14
Partial nephrectomy NOS (topp),2.59e-38,3.68,110,319,11,147.93
Blind Vision (dsyn),1.12e-07,0.56,55,280,4,65.8
ADRA1D (gngm),6.81e-12,0.18,7,40,0,8.22
Lithotripsy (topp),4.68e-16,1.55,82,19,1,23.4
Tyramine (nsba),2.59e-08,0.03,1,1,0,2.0
Beta-glucuronidase (aapp),5.24e-19,0.07,3,18,0,3.5
MERTK gene|MERTK (gngm),5.96e-07,0.17,1,23,0,1.04
Vesicle (acab),2.12e-157,0.07,13,197,0,13.86
6-Phosphofructokinase (aapp),1.9e-08,0.03,1,1,0,2.0
Zona Glomerulosa (bpoc),6.54e-09,0.05,1,5,0,1.2
Osteoid osteoma (neop),4.36e-07,0.06,1,5,0,1.2
Hernia repair (topp),2.71e-18,4.39,121,167,17,208.67
Ultraviolet Rays (npop),2.04e-17,0.19,4,70,1,4.23
Hypertrophic Cardiomyopathy (dsyn),1.38e-11,0.77,31,807,6,32.19
Octreotide|OXT (aapp),8.17e-20,366.47,10,75,1,11.33
"Phantoms, Imaging (medd)",1.04e-12,0.24,57,31,0,47.86
Germ cell tumor (neop),5.04e-12,0.8,5,355,0,5.07
Genome (gngm),2.26e-80,0.18,19,296,0,20.22
Nicotinic Receptors (aapp),2.2e-43,0.07,1,57,0,1.02
Glucuronosyltransferase (aapp),1.89e-12,0.06,1,11,0,1.09
Improved (qlco),7.69e-08,2.74,31,114,4,39.43
ghrelin (aapp),2.39e-99,3.1,801,127,20,147.14
Cessation of smoking (inbe),1.05e-25,3.64,74,248,11,96.08
Dyes (irda),3.92e-13,0.15,7,32,0,8.53
Cell Transplantation (topp),3.12e-06,3.04,11,1005,3,11.12
Nickel (bacs),6.88e-15,0.16,9,42,0,10.93
Health evaluation (hlca),1.62e-07,4.44,22,41,4,33.8
Protein p53|TP53 (aapp),4.72e-06,0.41,4,201,2,4.08
Spindle (celc),2.64e-09,0.27,4,58,1,4.28
Academic Medical Centers (hcro),5.22e-63,4.15,203,951,20,246.33
Influenza (dsyn),3.24e-37,1.62,36,2624,17,36.49
Superoxides (elii),3.69e-60,0.2,26,259,1,28.61
Diastolic blood pressure (clna),1.94e-14,9.1,695,263,44,362.52
"Resins, Plant (orch)",7.66e-25,0.12,4,54,0,4.3
Surgical approach (spco),5.92e-08,7.15,11,38,2,14.18
Ferritin (aapp),5.67e-35,1.4,392,434,17,746.06
Rubella (dsyn),1.96e-08,0.28,2,52,1,2.08
Neuroblast (cell),4.97e-09,0.23,1,43,0,1.02
arterial stiffness (phsf),1.39e-98,8.72,437,420,61,823.66
Structure of corpus luteum of ovary (bpoc),4.57e-11,0.03,1,4,0,1.25
"Glomerulonephritis, Membranous (dsyn)",8.2e-11,0.26,4,64,0,4.25
Protein-Energy Malnutrition (patf),8.95e-11,3.03,60,131,34,87.48
Esophagojejunostomy (topp),2.64e-08,4.77,10,41,8,12.44
Neural Crest Cell (cell),6.87e-09,0.12,1,21,0,1.05
Vertex presentation (fndg),1.9e-06,5.09,12,38,1,15.79
Thyroglobulin (aapp),3.54e-06,0.36,6,58,0,6.62
Bone Marrow Transplantation (topp),4.15e-32,1.04,7,870,2,7.06
R-38486 (phsu),3.38e-13,0.07,2,15,0,2.27
Structure of thyroid parafollicular cell (cell),1.6e-06,0.14,2,16,0,2.25
Hemoptysis (sosy),5.28e-09,1.53,2,432,4,2.01
Neurofibromatoses (neop),4.19e-08,0.31,3,63,0,3.14
Behcet Syndrome (dsyn),1.06e-09,0.49,23,195,0,25.71
Cerebrovascular Disorders (patf),5.62e-09,2.31,93,810,35,103.68
Osteomyelitis (dsyn),2.51e-38,0.29,10,279,2,10.36
"Malaria, Cerebral (dsyn)",3.16e-08,1.39,3,329,1,3.03
polyphenols (orch),6.71e-07,0.47,27,141,0,32.17
Rectum excision (topp),1.92e-16,4.14,34,239,23,38.84
dopamine transporter (aapp),1.43e-11,0.12,10,8,0,14.4
GAG Gene (aapp),2.16e-16,0.08,2,21,0,2.19
Urban (geoa),9.65e-07,5.47,31,40,0,55.02
Amino Acids (aapp),3.49e-126,0.22,192,582,6,255.34
ITGB2 gene|ITGB2 (gngm),6.63e-07,0.41,7,84,1,7.58
high school student (popg),6.38e-12,2.92,108,26,0,32.26
Melanocortin 4 Receptor (aapp),1.02e-11,2.3,40,3,0,3.23
Protein phosphatase (aapp),5.91e-26,0.11,4,53,0,4.3
Flumazenil (orch),4.78e-09,0.17,1,30,0,1.03
Migraine Disorders (dsyn),5.31e-12,0.34,152,96,1,156.63
Brachytherapy (topp),3.84e-09,1.66,20,904,7,20.44
Corpus Callosum (bpoc),5.87e-12,0.32,9,99,0,9.82
"Transcription, Genetic (genf)",1.27e-150,0.23,79,787,6,86.93
socioeconomic differences (fndg),8.48e-07,6.16,11,36,1,14.36
Signal Transduction Pathways (celf),6.47e-56,0.33,29,532,1,30.58
Sensory nerve (bpoc),1.39e-07,0.1,3,10,0,3.9
Pruritus (sosy),9.68e-16,0.3,19,126,0,21.87
Platelet aggregation (celf),1.41e-18,0.37,45,236,4,53.58
Human tissue (tisu),1.13e-09,0.6,133,554,1,164.93
Visual Analog Scale (diap),4.88e-23,1.88,110,33,1,42.9
Transcription Repressor/Corepressor (gngm),1.92e-27,0.12,4,61,0,4.26
Testosterone (horm),1.16e-112,1.2,1067,455,47,649.03
Nasal Polyps (anab),9.32e-09,0.13,8,7,1,13.12
Vancomycin|NDUFB6 (antb),9.99e-34,1556.39,15,186,2,16.21
Adsorption (lbpr),5.94e-52,0.04,1,43,0,1.02
Prescription of prophylactic anticoagulant (topp),2.39e-09,3.39,38,238,7,44.07
Simvastatin (phsu),4.72e-07,0.56,79,309,3,99.2
Males (popg),1.24e-84,4.62,656,840,38,1168.3
inorganic phosphate (inch),1.95e-13,0.12,3,30,0,3.3
Alprostadil (eico),1.28e-30,0.12,6,71,0,6.51
Surgical Wound Infection (patf),2.41e-07,2.92,24,114,8,29.05
Proto-Oncogene Proteins c-jun|JUN (aapp),2.24e-13,0.13,1,35,0,1.03
rofecoxib (orch),1.1e-06,0.32,5,52,0,5.48
Cell Survival (celf),6.86e-41,0.31,9,558,0,9.15
"Receptor, Serotonin, 5-HT1A (aapp)",1.27e-08,0.04,1,4,0,1.25
anthracene (orch),4.34e-06,0.14,2,15,0,2.27
Severe chronic obstructive pulmonary disease (dsyn),5.06e-35,3.99,65,210,33,85.12
Cathepsins B|CTSB (aapp),2.33e-11,0.19,5,42,1,5.6
deoxypyridinoline (aapp),3.09e-07,1.84,27,6,0,7.33
Singleton (famg),1.12e-199,7.78,428,678,46,698.18
Thyroxine|TH (aapp),2.48e-37,30.99,70,61,1,114.16
Benign paroxysmal positional vertigo (dsyn),2.64e-06,0.07,3,1,0,1.33
Serum urate level result (lbtr),1.48e-07,10.58,36,28,2,49.78
Retinal Degeneration (dsyn),4.73e-11,0.05,1,7,0,1.14
Minocycline (antb),5.44e-14,0.27,3,86,0,3.1
Yolk Sac (emst),7.23e-08,0.2,1,31,0,1.03
Rutin (phsu),9.88e-07,0.18,2,21,1,2.19
Nervousness (fndg),7.32e-07,0.37,32,85,2,44.05
Pretreatment (sbst),7.3e-44,0.13,1,112,0,1.01
Menstruation (orgf),5.98e-13,2.81,145,44,2,57.35
BIRC5 gene|BIRC5 (gngm),6.27e-09,0.73,1,306,0,1.0
Interleukin-10 (aapp),9.15e-07,0.65,116,949,6,130.18
Acceptors (humn),3.17e-11,0.05,2,5,0,2.8
"Receptors, Purinergic P1 (aapp)",3.42e-19,0.15,2,56,0,2.07
6/6 (fndg),1.28e-29,6.72,46,129,8,62.4
neurotransmitter secretion (celf),1.57e-09,0.06,1,8,0,1.12
monocyte (cell),8.6e-85,0.29,109,660,5,127.0
Ochratoxins (bacs),2.03e-06,0.11,4,5,0,7.2
Stillbirth (patf),7.85e-15,5.31,44,370,8,49.23
Vitamin supplementation (phsu),5.54e-34,3.29,158,330,3,233.65
Oral mucous membrane structure (bpoc),3.19e-22,0.29,6,169,0,6.21
Tetrahydrocannabinol (orch),8.25e-19,0.14,8,44,0,9.45
student (prog),1.17e-300,1.92,1210,215,11,253.2
Pathogenicity (orga),2.09e-42,1.15,71,2238,3,73.25
"Adhesins, Bacterial (aapp)",9.97e-11,0.2,1,44,0,1.02
Rosa (plnt),1.29e-12,3.3,39,127,5,50.98
CD79A (aapp),4.68e-35,0.21,24,160,1,27.6
Extracellular Signal Regulated Kinases (aapp),5.11e-22,0.24,2,111,0,2.04
Secondary malignant neoplasm of lung (neop),7.04e-31,1.69,4,1256,1,4.01
Dislocations (inpo),1.63e-10,0.42,56,196,1,72.0
Ondansetron (phsu),1.24e-10,0.16,10,20,1,15.0
Fibroblast Growth Factor 2 (aapp),5.78e-67,0.1,4,126,0,4.13
Estrone (horm),1.84e-21,1.65,94,8,6,8.68
Birth outcome (clna),3.71e-17,5.19,35,93,2,48.17
Guidelines (inpr),4.37e-09,4.72,36,56,5,59.14
Macaca (mamm),4.93e-37,0.15,3,115,1,3.08
Tumor Promoters (hops),1.55e-09,0.18,1,35,0,1.03
Cytolysis (celf),1.28e-88,0.13,4,237,0,4.07
carvedilol (orch),3.78e-06,0.72,5,334,2,5.07
16s (bpoc),3.06e-39,0.29,28,299,1,30.62
U 0126 (orch),3.84e-12,0.18,1,43,0,1.02
Autistic Disorder (mobd),2.72e-30,0.17,58,35,0,56.12
JUN gene|JUN (gngm),3.62e-26,0.1,1,53,0,1.02
Proto-Oncogene Proteins c-akt|AKT1 (aapp),1.58e-70,0.35,44,987,3,45.96
neurofibroma (neop),6.37e-07,0.29,2,46,0,2.09
von Willebrand Disease (dsyn),2.61e-09,0.19,5,34,0,5.74
Plates (medd),1e-18,0.24,22,100,1,26.84
"RNA, Small Interfering (bacs)",1.16e-24,0.36,11,631,0,11.19
CYP1A1 gene|CYP1A1 (gngm),1.02e-11,0.17,8,34,0,9.88
Marrow (bpoc),2.67e-15,0.44,27,510,2,28.43
Muscle strength (ortf),8.43e-07,4.95,535,146,34,185.84
Systolic heart failure (dsyn),3.65e-20,6.46,38,603,31,40.39
Myocarditis (dsyn),1.43e-17,1.13,8,590,1,8.11
Codeine (phsu),5.36e-08,0.19,1,31,0,1.03
Nerve Degeneration (comd),2.11e-29,0.3,16,224,0,17.14
Erythromycin (antb),7.39e-29,0.17,7,102,0,7.48
Ventricular Fibrillation (dsyn),3.8e-13,1.36,18,892,10,18.36
Amitriptyline (phsu),6.73e-10,0.18,12,27,0,17.33
Eating (orgf),2.03e-107,2.97,1018,219,26,266.11
ERBB2|NEU1|NEURL1 (gngm),6.18e-09,0.9,3,222,1,3.04
Guanosine Triphosphate Phosphohydrolases (aapp),6.92e-14,0.11,4,24,0,4.67
Mammalian Oviducts (bpoc),3.08e-29,0.24,14,165,2,15.19
Anovulation (dsyn),1.46e-16,4.31,111,5,0,5.23
"Puberty, Precocious (dsyn)",6.32e-26,2.51,136,21,1,24.24
Entire diaphragm (bpoc),4.54e-21,0.39,31,268,1,34.59
Globin (gngm),6.41e-15,0.04,1,9,0,1.11
Interferon-beta|EREG|ESR1 (aapp),1.61e-06,29.67,5,12,0,7.08
membrane fraction (celc),3.62e-26,0.04,1,16,0,1.06
Trachea (bpoc),6.41e-16,0.43,25,685,2,25.91
Urothelium (tisu),5.28e-14,1.05,11,517,2,11.23
Increased systolic arterial pressure (fndg),1.34e-11,13.25,26,27,3,51.04
TNFRSF5 gene|CD40 (gngm),1.84e-21,0.23,13,115,0,14.47
"Defibrillators, Implantable (medd)",3.86e-25,1.76,22,1957,15,22.25
Hypoxia (patf),2.79e-16,0.68,192,1147,16,224.14
Systemic arterial pressure (fndg),8.15e-97,3.71,3006,3177,264,5850.2
Nutrition management (hlca),2.48e-22,5.12,49,100,7,73.01
EGR1 gene|EGR1 (gngm),2.38e-06,0.19,1,24,0,1.04
SODIUM BUTYRATE (lipd),4.63e-11,0.09,1,19,0,1.05
Enterocytes (cell),4.66e-16,0.23,10,84,1,11.19
Papaverine (phsu),3.23e-09,0.12,1,21,0,1.05
IMAGE QUALITY (fndg),5.33e-26,1.95,97,13,1,14.74
Tissue damage (inpo),4.85e-10,0.85,12,349,3,12.41
Disintegration (acab),3.19e-10,0.29,24,77,0,31.48
Cytomegalovirus Retinitis (dsyn),1.9e-07,0.28,1,56,0,1.02
Insecta (invt),1.01e-11,0.7,1,509,0,1.0
Ketoprofen (phsu),1.6e-09,0.08,1,13,0,1.08
Epinephrine (horm),3.7e-38,0.36,97,470,5,117.02
interstitial cell (cell),5.75e-12,0.16,1,39,0,1.03
Endopeptidases (aapp),1e-92,0.15,13,270,1,13.63
Spontaneous abortion (dsyn),1.68e-06,1.12,128,218,4,203.16
Glioblastoma (neop),3.82e-100,1.14,7,2524,1,7.02
Hepatic (blor),4.24e-10,1.01,281,2309,14,315.2
Carbon Dioxide (bacs),3.62e-29,0.33,48,286,2,56.06
Cytosine (bacs),6.91e-09,0.13,3,18,0,3.5
Fibroblast Growth Factor Receptors (aapp),1.64e-07,0.26,4,44,0,4.36
Malignant neoplasm of skin (neop),1.72e-08,1.08,19,454,1,19.8
Archaea (arch),1.32e-26,0.06,9,11,0,16.36
Satiation (menp),3.98e-10,4.03,83,6,3,6.43
Ibuprofen (phsu),3.72e-22,0.25,13,130,0,14.3
Lizards (rept),2.26e-11,0.18,3,40,0,3.23
hypercholesterolemia (dsyn),1.9e-09,2.75,487,637,50,859.32
Polyethylene Glycols (phsu),6.53e-14,0.19,9,53,0,10.53
hydroxyurea (orch),1.44e-16,0.35,8,260,0,8.25
Sambucus (plnt),7.99e-11,4.05,55,89,9,88.99
glycosylation (npop),7.56e-11,0.25,5,63,0,5.4
Dental crowns (medd),3.68e-06,0.12,3,10,0,3.9
amidronate (orch),2.81e-11,0.23,8,54,2,9.19
Ovum (cell),8.82e-26,0.34,29,254,1,32.31
Esophagus (bpoc),1.24e-18,1.15,100,1939,27,105.16
Infarction (patf),1.97e-43,0.83,38,1579,15,38.91
Glutathione S-Transferase (aapp),2.27e-23,0.26,19,150,1,21.41
Aortic Valve Insufficiency (dsyn),4.55e-08,1.58,20,766,5,20.52
Palliative Care (hlca),1.26e-08,2.4,6,876,6,6.04
Speech (orgf),5.16e-19,0.16,9,55,0,10.47
Respiratory physiology (ortf),9.08e-71,3.56,377,706,56,578.32
Rheumatoid Factor (aapp),1.5e-06,0.29,15,44,0,20.11
Relaxin (aapp),6.56e-11,0.16,6,30,1,7.2
Inactivation (comd),6.17e-58,0.26,20,358,1,21.12
Cholesterol levels raised (fndg),3.15e-18,7.69,144,111,22,196.56
Vertigo (sosy),9.79e-09,0.22,9,38,0,11.13
Rheumatism (dsyn),1.21e-11,0.56,53,431,5,59.52
Reproductive History (fndg),7.03e-09,6.89,58,53,6,101.43
"Alcoholic Intoxication, Chronic (mobd)",1.25e-10,0.53,59,320,5,69.88
Measles (dsyn),2.45e-15,0.81,3,384,0,3.02
High Density Lipoprotein Cholesterol (bacs),1.77e-10,8.16,1760,566,126,748.02
[X]Unspecified osteoporosis with pathological fracture (dsyn),1.41e-23,3.11,201,356,20,314.49
Renal Tissue (tisu),1.14e-10,0.38,9,171,0,9.47
Brush Border (celc),1.61e-13,0.1,2,24,0,2.17
Hypercapnia (sosy),3.39e-12,2.3,62,185,16,82.78
"Energy, Physics (npop)",4.43e-29,0.98,499,267,27,409.86
Seeds (plnt),6.89e-42,0.17,9,152,0,9.53
olanzapine (phsu),4.79e-42,1.83,268,116,13,166.21
Anergy (celf),1.14e-09,0.19,1,38,0,1.03
Valproic Acid (phsu),4.19e-06,0.42,46,118,0,63.93
alpha-Synuclein (aapp),1.23e-23,0.09,3,35,0,3.26
Polymerase (aapp),2.06e-12,0.24,1,65,0,1.02
"NOS1 protein, human|NOS1 (aapp)",4.5e-06,0.12,2,12,0,2.33
Mannose (bacs),8.22e-14,0.07,1,16,0,1.06
Column (bpoc),8.67e-123,0.07,15,146,1,16.54
Tissue specimen (tisu),4.88e-30,1.11,22,1164,4,22.42
Felis catus (mamm),2.78e-245,0.15,17,724,1,17.4
Sarcoplasmic Reticulum (celc),1.78e-39,0.07,2,52,0,2.08
Neurologic Deficits (fndg),2.89e-08,1.8,26,960,2,26.7
Secondary malignant neoplasm of bone (neop),3.7e-27,1.07,11,932,7,11.13
Seminal Vesicles (bpoc),1.03e-15,0.13,3,40,0,3.23
"Adolescents, Female (humn)",9.79e-27,6.73,700,76,6,84.25
"Translation, Genetic (genf)",3e-63,0.21,27,291,0,29.51
"Myocytes, Cardiac (cell)",5.57e-58,0.33,24,755,2,24.76
Pentetic Acid (orch),4.49e-06,0.2,7,21,0,9.33
Perinatal (tmco),5.48e-08,5.34,17,138,6,19.09
Cervical Squamous Cell Carcinoma (neop),8.61e-13,1.82,6,797,4,6.05
Prolactin (aapp),8.12e-07,0.35,83,58,1,98.53
Wing (bpoc),1.6e-21,0.21,2,92,2,2.04
Power tool (mnob),2.74e-07,0.26,3,41,0,3.22
Binge Eating (mobd),5.14e-33,7.26,539,26,6,27.25
Neuropeptides (aapp),3.35e-14,0.3,65,102,1,106.42
Saphenous Vein (bpoc),3.51e-06,0.31,12,49,0,14.94
Light (npop),1.03e-15,0.1,3,28,0,3.32
Visual Cortex (bpoc),4.22e-35,0.02,3,5,0,4.8
Analyte (chvf),2.86e-06,0.19,9,14,1,14.79
Methicillin resistant Staphylococcus aureus (organism) (bact),7.31e-08,1.35,1,237,0,1.0
Score (qnco),1.89e-08,3.04,29,92,2,38.14
Primates (mamm),5.2e-49,0.23,41,260,1,47.47
TRYPTASE (aapp),2.56e-08,0.25,6,45,0,6.8
Actins (aapp),5.49e-80,0.15,9,243,0,9.33
Luciferases (aapp),6.84e-22,0.35,13,244,1,13.69
Ovulatory (fndg),2.66e-17,4.22,112,4,1,4.14
Degenerative abnormality (patf),8.52e-31,0.45,102,610,5,119.06
Methylnitrosourea (orch),8.2e-07,0.1,1,11,0,1.09
Renal tubular disorder (dsyn),2.35e-37,0.21,15,172,1,16.31
preadolescent (aggp),1.24e-08,3.89,99,17,0,19.92
Post transplant diabetes mellitus (dsyn),1.75e-10,7.74,37,37,15,74.0
"Metals, Heavy (elii)",1.04e-08,0.37,26,110,1,32.15
Postherpetic neuralgia (dsyn),1.28e-08,0.13,1,21,0,1.05
Local excision (topp),3.27e-10,1.77,3,505,1,3.02
Hepatocyte Growth Factor (gngm),1.1e-23,0.3,20,182,5,22.2
Saccharomyces cerevisiae (fngs),0.0,0.05,4,290,0,4.06
Empirical therapy (topp),1.75e-07,2.72,4,701,2,4.02
Aerosols (chvs),6.36e-07,0.23,1,33,0,1.03
"DNA, Single-Stranded (bacs)",3.93e-12,0.05,2,6,0,2.67
Periodontal Ligament (bpoc),5.56e-30,0.05,6,11,0,9.27
Anaplastic astrocytoma (neop),5.13e-08,1.39,1,248,0,1.0
primary group (humn),4.54e-13,3.59,41,155,4,51.85
Low-Density Lipoproteins (aapp),7.14e-30,1.12,361,239,24,397.23
Malnutrition (dsyn),0.0,5.64,1612,2210,451,2787.81
Submandibular gland (bpoc),8.5e-32,0.11,5,65,0,5.38
Lipid-lowering therapy (topp),2.32e-06,3.27,27,193,6,30.78
Peptides (aapp),3.57e-85,0.21,100,356,6,128.09
infliximab (aapp),1.03e-13,0.42,82,271,5,106.81
NEW ONSET (fndg),8.83e-15,4.96,33,97,1,44.23
"MMP14 protein, human|MMP14 (aapp)",2.58e-08,0.2,1,34,0,1.03
FRAGMENTS (bdsu),4.27e-35,0.22,31,163,3,36.9
glial cell-line derived neurotrophic factor|GDNF (aapp),2.62e-12,0.07,2,11,0,2.36
Metronidazole (orch),6.4e-19,0.35,11,185,2,11.65
Cardiac Glycosides (phsu),5.13e-09,0.3,5,64,0,5.39
Magnetic field (npop),1.05e-11,0.11,2,23,0,2.17
"Respiratory Distress Syndrome, Adult (dsyn)",7.2e-14,2.31,22,2530,41,22.19
KCNK3 (gngm),5.3e-09,0.13,9,8,0,15.11
Freezing (npop),2.55e-08,0.13,1,20,0,1.05
Incisional hernia (inpo),9.92e-22,8.37,113,101,15,191.27
Lactose (bacs),9.28e-07,0.2,10,19,0,15.26
"Dislocation, complete (inpo)",2.67e-06,0.14,3,14,0,3.64
Frail (fndg),1.91e-38,7.65,54,461,32,60.33
Abscess (patf),4.62e-14,0.99,44,864,9,46.24
cytotoxicity (comd),5.45e-88,0.21,11,389,0,11.31
hepatic lipase (aapp),1.1e-08,1.67,35,4,1,4.46
Intraocular melanoma (neop),2.27e-13,1.15,2,360,0,2.01
Analgesic effect (fndg),2.71e-08,0.04,1,3,0,1.33
Entire vestibule (bpoc),1.8e-14,0.1,4,23,0,4.7
U937 Cells (cell),7.83e-14,0.05,1,12,0,1.08
Herbicides (hops),2.24e-06,0.4,6,189,0,6.19
Chinese Hamster Ovary Cell (cell),9.2e-32,0.1,17,36,0,25.03
Immune response (orgf),1.58e-16,0.74,124,2377,11,130.47
Walking distance (fndg),2.99e-13,3.9,38,83,3,55.4
Tertiary referral hospital (hcro),4.89e-76,5.85,181,956,20,215.27
"Tachycardia, Ventricular (patf)",1.8e-24,0.98,16,825,5,16.31
Glutathione S-Transferase|SLCO6A1|GSTK1 (aapp),1.42e-06,0.32,8,54,1,9.19
Aspartate (aapp),2.7e-16,0.14,8,37,1,9.73
CYTOCHROME C OXIDASE (aapp),1.75e-18,0.14,7,44,0,8.11
Iodides (inch),2.18e-11,0.08,2,15,0,2.27
Entire coronary sinus (bpoc),2.68e-09,0.24,5,50,0,5.5
Urokinase (phsu),1.36e-33,0.26,2,242,1,2.02
Acanthosis Nigricans (dsyn),4.65e-07,6.21,114,9,2,9.71
Serum prealbumin (fndg),2.69e-06,8.69,7,13,3,10.77
anticoagulation (topp),9.31e-07,2.05,54,1759,14,55.66
Molar tooth (bpoc),2.78e-27,0.06,6,18,0,8.0
High density lipoprotein decreased (fndg),1.05e-08,10.42,65,39,8,62.4
Nerve Endings (celc),7.88e-10,0.05,1,7,0,1.14
Acute diarrhea (dsyn),3.87e-07,0.77,1,198,0,1.01
Cytochromes b (aapp),6.2e-07,0.09,1,11,0,1.09
Tumor Necrosis Factor Ligand Superfamily Member 6|FASLG (gngm),1.07e-07,0.29,3,51,0,3.18
Prostatectomy (topp),2.53e-15,2.67,66,175,1,90.89
Granulocyte-Macrophage Colony-Stimulating Factor (aapp),6.87e-39,0.22,6,186,1,6.19
pectin (carb),1.67e-06,0.08,2,6,0,2.67
Heparitin Sulfate (bacs),8.52e-19,0.13,4,47,0,4.34
Interstitial Collagenase (aapp),9.99e-09,0.31,14,71,0,16.76
Glycoside Hydrolases (aapp),3.58e-06,0.15,6,11,0,9.27
Adjustment Action (hlca),9.19e-37,5.93,103,165,23,167.3
Proto-Oncogene Protein pp60 (c-src)|SRC (aapp),3.34e-40,0.14,1,112,0,1.01
TRPV1 (gngm),1.41e-09,0.1,2,15,0,2.27
Hela Cells (cell),1.46e-52,0.06,1,59,0,1.02
Subgroup (clas),3.15e-20,5.06,49,216,5,60.12
[D]Musculoskeletal pain (sosy),4.95e-22,2.12,96,18,0,21.38
Vascular Diseases (dsyn),5.94e-30,2.05,285,1433,59,341.68
Liquid substance (sbst),4.67e-09,0.43,13,124,0,14.36
"hypothermia, natural (sosy)",9.93e-08,1.47,22,718,5,22.67
DNA Damage (comd),3.63e-15,0.43,73,292,0,91.25
Streptokinase (aapp),9.32e-11,0.32,1,187,0,1.01
Somatropin (aapp),8.64e-07,0.24,23,22,0,43.04
Methamphetamine (phsu),3.52e-20,0.19,13,79,0,15.14
Brain-Derived Neurotrophic Factor|BDNF (aapp),4e-07,0.17,7,16,0,10.06
Mycoses (dsyn),2.73e-42,1.96,7,2137,3,7.02
Melanins (bacs),4.05e-22,0.11,4,42,0,4.38
Autoantibodies (aapp),9.98e-31,0.41,115,524,1,140.24
Placenta (emst),1.01e-27,0.37,111,389,2,142.67
Malignant Bone Neoplasm (neop),2.32e-06,0.97,1,138,0,1.01
Equus caballus (mamm),1.23e-144,0.2,6,587,1,6.06
patient characteristics (clna),3.23e-47,7.09,74,299,18,92.31
Electricity (npop),1.59e-16,0.22,5,79,0,5.32
CD4 Positive T Lymphocytes (cell),7.57e-14,0.29,7,99,0,7.49
Astrocytoma (neop),1.2e-07,0.69,2,375,0,2.01
fluorophore (phsu),4.5e-07,0.06,1,5,0,1.2
Mammary gland (bpoc),2.41e-49,0.14,10,136,1,10.74
Ivermectin (phsu),1.94e-08,0.32,1,106,1,1.01
Excretory function (phsf),1.27e-14,0.89,492,489,44,975.02
Osteocalcin (aapp),1.04e-51,1.54,276,42,3,48.39
Recombinant Growth Hormone|HSD3B1 (aapp),1.43e-54,663.62,47,35,5,61.06
Bile Salts (bacs),1.34e-09,0.13,3,22,0,3.41
Follow-Up Studies (resa),2.49e-55,4.72,113,283,18,158.12
Dyspareunia (fndg),2.06e-06,1.93,24,5,0,6.04
Prader-Willi Syndrome (cgab),1.46e-10,3.79,208,50,10,62.02
Menopausal hot flushes (sosy),8.19e-13,1.77,59,20,2,26.78
Cornea (bpoc),1.02e-73,0.08,28,64,0,40.25
"Diabetes, Gestational (dsyn)",1.94e-29,6.01,1415,255,33,300.95
Phosphorylcholine (opco),1.54e-07,0.15,2,20,0,2.2
Depressive disorder (mobd),5.41e-16,0.98,920,1893,44,1367.12
Sex Characteristics (orga),3.03e-141,5.39,384,690,41,597.7
Sulpiride (phsu),9.75e-09,0.08,5,1,0,1.2
Consumption-archaic term for TB (dsyn),5.51e-33,2.47,1966,1443,93,2502.13
Proinsulin (aapp),1.4e-19,1.59,94,16,4,18.72
Statistical Analysis (resa),1.04e-64,3.18,252,593,18,359.09
Brain natriuretic peptide|XK (phsu),1.06e-115,1969.28,39,399,18,42.81
Living Donors (popg),1.19e-50,4.42,116,383,22,151.13
Ofloxacin (antb),6.51e-13,0.12,2,28,0,2.14
Breast Cancer Cell (cell),1.96e-09,0.4,8,410,0,8.16
reproductive hormone (horm),2.08e-06,3.17,42,6,0,6.86
Follicle Stimulating Hormone (aapp),1.81e-28,1.29,197,16,1,17.3
Nicotiana (plnt),2.76e-13,0.13,3,33,0,3.27
Connexin 43 (aapp),2.72e-21,0.15,1,62,0,1.02
Lipopolysaccharides (lipd),7.95e-156,0.34,88,1719,3,92.5
Lymph Node Dissection (topp),6.44e-08,3.59,76,1078,18,81.36
Entire eyelid (bpoc),8.97e-08,0.34,3,116,0,3.08
Entire hair follicle (bpoc),5.29e-07,0.12,3,11,0,3.82
zeaxanthin (orch),6.05e-07,1.46,35,10,1,12.86
Nephrons (bpoc),4e-09,0.25,8,51,0,9.25
Biogenic Amines (horm),1.13e-11,0.06,1,11,0,1.09
Nose (bpoc),2.7e-23,0.48,173,671,2,217.6
Amyloid beta-Protein (aapp),1.75e-06,0.07,1,6,0,1.17
AIDS patient (humn),5.45e-07,0.95,23,402,4,24.32
CD59 (gngm),5.81e-07,0.17,1,23,0,1.04
Apigenin (orch),9.87e-08,0.13,3,15,0,3.6
Acupuncture procedure (topp),1.07e-06,0.37,85,77,2,146.75
Heart Atrium (bpoc),1.1e-09,0.54,44,488,5,47.97
Consultation (hlca),8.57e-11,1.96,97,381,8,121.7
Protoplasm (celc),1.18e-223,0.21,153,1054,8,175.21
"Hepatitis, Chronic Active (dsyn)",8.96e-08,0.15,6,16,0,8.25
High Schools (orgt),1.44e-07,2.96,60,12,1,14.4
Nucleic Acids (bacs),7.31e-35,0.16,4,114,0,4.14
Gentamicins (antb),2.95e-37,0.28,9,266,1,9.3
Lung Neoplasms (neop),4.97e-15,0.86,6,359,0,6.1
Hypoxic-Ischemic Encephalopathy (dsyn),1.17e-08,1.6,3,395,1,3.02
Lepidoptera (invt),1.05e-07,1.46,1,254,0,1.0
Taste Perception (ortf),1.11e-07,1.74,29,3,0,3.31
Albumins (aapp),1.25e-29,1.93,314,951,92,417.68
coumarin (orch),1.42e-08,0.19,2,33,0,2.12
protrusion (anab),1.08e-06,0.46,45,155,0,58.06
Physostigmine (orch),2.78e-08,0.1,3,10,0,3.9
Therapeutic agent (substance) (phsu),6.54e-07,0.71,8,414,0,8.15
25-hydroxyvitamin D (strd),3.49e-12,9.68,330,142,16,203.1
Cochlear implant procedure (topp),6.65e-11,0.05,1,9,0,1.11
"Serum Albumin, Bovine (aapp)",5.15e-37,0.05,3,27,1,3.33
Phytohemagglutinins (aapp),2.96e-16,0.12,10,26,0,13.85
"Etiology, operative procedure, as cause of (fndg)",6.49e-42,7.54,62,429,28,70.96
Glutathione (aapp),9.04e-52,0.25,66,311,3,80.01
Villus (bpoc),2.06e-09,0.26,9,58,0,10.4
"Anti-Inflammatory Agents, Non-Steroidal (phsu)",3.96e-16,0.57,143,707,9,171.92
Radical nephrectomy (topp),5.69e-11,3.84,50,506,15,54.94
Endocrine cell (cell),1.42e-06,0.21,9,22,0,12.68
Employee (prog),1.01e-16,2.35,296,160,15,246.49
Cataplexy (dsyn),1.41e-07,1.51,35,3,0,3.26
Mixed Salivary Gland Tumor (neop),1.11e-13,0.17,1,46,0,1.02
Australia (geoa),6.59e-10,3.44,43,231,2,51.0
human leukocyte interferon|IFNA1 (aapp),1.37e-44,0.31,20,346,0,21.16
LAMC2 (gngm),1.37e-26,0.26,9,157,0,9.52
Regular exercise (dora),7.09e-10,9.23,120,69,8,108.67
Spasm (sosy),2.62e-12,0.32,7,98,0,7.5
Cytochrome P450 (aapp),1.35e-67,0.13,23,153,2,26.46
Heparan Sulfate Proteoglycan (aapp),2.7e-16,0.08,1,25,0,1.04
Perforators (medd),7.74e-08,1.35,52,30,2,47.31
Cerebrovascular accident (dsyn),8.61e-13,2.06,882,11185,318,951.55
Nerve Tissue (tisu),1.88e-16,0.17,1,58,0,1.02
"Melanoma, B16 (neop)",2.12e-12,0.24,1,64,0,1.02
PARITY (fndg),6.15e-21,6.52,408,280,19,472.16
Echinococcosis (dsyn),1.25e-09,0.37,2,363,0,2.01
Dermoid Cyst (neop),7.93e-07,0.28,4,43,0,4.37
Radiotherapy Research (resa),4.67e-06,2.32,42,223,6,49.91
Entire tooth (bpoc),2.88e-08,0.19,16,15,0,29.06
Unemployment (fndg),6.14e-11,2.48,68,167,8,95.69
Chemotherapy-Oncologic Procedure (topp),2.97e-13,2.27,50,2413,11,51.04
Eicosanoids (eico),5.63e-10,0.25,11,58,0,13.09
linezolid (orch),2.25e-06,0.9,9,227,1,9.36
Genus Mycobacterium (bact),6.3e-11,0.32,4,119,0,4.13
regulatory (rnlw),5.46e-17,0.3,14,134,1,15.46
Mesenchymal cell (cell),1.18e-10,0.18,2,39,0,2.1
Encounter due to stillbirth (fndg),1.55e-31,7.28,46,211,15,56.03
Databases (inpr),4.02e-08,3.2,90,1176,22,96.89
Ketamine (phsu),1.83e-32,0.21,14,151,0,15.3
DIO3 (aapp),2.32e-06,0.1,1,11,0,1.09
Heat-Shock Proteins 70|HSPA4 (aapp),1.74e-28,0.25,12,161,1,12.89
Maltose (bacs),2.47e-06,0.05,1,3,0,1.33
COGNITIVE DEFICIT (mobd),1.25e-06,0.42,30,110,1,38.18
"Osteoarthritis, Hip (dsyn)",2.77e-18,3.27,141,19,3,21.56
Vulnerable Populations (popg),1.91e-14,4.42,44,282,8,50.87
Phosphatidylserines (lipd),1e-21,0.1,8,32,0,10.0
Acute Lung Injury (inpo),7.36e-11,2.23,7,1113,11,7.04
"Red blood cells, blood product (phsu)",7.33e-07,0.24,7,36,0,8.36
Fitness (dora),1.34e-34,11.66,607,227,85,311.89
Hospitalization (hlca),1.12e-44,4.83,293,6628,165,305.95
Angioneurotic Edema (patf),2.81e-06,0.35,5,55,0,5.45
Staining method (lbpr),3.14e-07,0.35,3,115,0,3.08
MATCHING (resa),1.07e-31,4.28,95,515,17,112.52
Reflux (patf),1.12e-15,1.08,222,178,9,320.72
Endothelium (tisu),8.82e-42,0.34,35,388,1,38.16
Adenocarcinoma (neop),7.42e-83,1.23,145,5297,46,148.97
Bacteremia (dsyn),7.84e-56,1.83,10,2877,10,10.03
Endocarditis (dsyn),4.14e-34,1.29,3,1072,3,3.01
Malignant neoplasm of urinary bladder (neop),7.67e-11,1.39,83,1781,24,86.87
Recombinants (orgm),9.9e-119,0.32,80,1029,2,86.22
Dermis (tisu),1.66e-16,0.24,10,92,0,11.09
granulocyte (cell),1.06e-24,0.2,10,103,0,10.97
Newly diagnosed diabetes (fndg),2.02e-11,10.53,47,39,6,71.36
Stem Cell Factor (aapp),7.4e-17,0.12,4,38,0,4.42
Globus Pallidus (bpoc),1.04e-16,0.11,4,29,0,4.55
Adriamycin (orch),9.57e-41,0.24,2,241,0,2.02
Stem cell transplant (topp),1.02e-17,3.98,7,2385,5,7.02
Repair of umbilical hernia NOS (topp),4.28e-06,6.92,9,18,0,13.5
Metabolites (bacs),7.45e-11,0.41,80,206,3,111.07
Thromboxanes (bacs),1.37e-09,0.21,5,43,0,5.58
Anticonvulsants (phsu),1.57e-06,0.52,26,323,3,28.09
"Receptors, Progesterone (aapp)",2.1e-09,0.23,6,47,0,6.77
Shoulder (bpoc),2.69e-06,0.83,256,221,11,411.79
Surface Antigens (imft),1.47e-16,0.17,2,59,0,2.07
Captopril (aapp),1.36e-54,0.13,10,134,2,10.75
CNS (MMHCC) (tisu),5.28e-08,1.34,3,289,0,3.03
Permeability (npop),1.99e-64,0.23,12,322,1,12.45
Autoimmune Diseases (dsyn),2.14e-10,0.58,101,1070,6,110.53
Anorexia Nervosa (mobd),5.03e-19,5.66,1114,212,68,252.34
Immunoprecipitation (lbpr),2.03e-08,0.13,3,19,0,3.47
Chitosan (carb),4.75e-17,0.2,11,69,0,12.75
Vision (orgf),1.66e-35,0.24,51,194,4,64.41
Temporomandibular Joint Disorders (dsyn),1.65e-08,0.13,10,4,0,5.6
Carbon dioxide laser device (medd),4.11e-07,0.27,4,42,0,4.38
"Intestines, Small (bpoc)",3.37e-54,0.46,109,1166,10,119.19
Pathologic Neovascularization (patf),1.59e-20,0.42,40,312,1,45.13
Stratification (resa),2.39e-25,5.81,72,711,18,79.29
Animal Model (anim),3.29e-16,0.91,141,1486,11,154.38
Oils (lipd),2.96e-10,0.5,108,344,4,141.91
IgG4 (aapp),9.29e-14,0.11,3,25,0,3.36
"Dislocation, incomplete (inpo)",4.17e-11,0.18,12,31,1,16.65
Noninfiltrating Intraductal Carcinoma (neop),6.59e-07,0.91,27,399,3,28.83
Thyroxine|SLC25A5 (aapp),2.29e-46,140.23,41,41,1,82.0
Muscle Fibers (cell),2.7e-22,0.21,50,62,0,90.32
Tyrosine 3-Monooxygenase|TH (aapp),2.15e-40,0.05,3,30,0,3.3
Aneuploidy (comd),6.5e-09,0.4,11,109,0,12.11
SHBG gene|SHBG (gngm),8.27e-13,4.45,128,10,4,10.78
Bacteriophages (virs),2.35e-47,0.12,2,109,0,2.04
Calcium-Binding Proteins (aapp),1.29e-12,0.08,2,17,0,2.24
Insulin|HSD3B1 (horm),2.6e-24,1587.1,38,17,0,24.61
Phenylephrine (orch),7.11e-34,0.1,7,58,0,7.84
heart disease risk (fndg),8.84e-13,11.57,12,22,7,18.55
Psychotherapy (topp),1.18e-07,0.33,19,70,4,24.16
Violence (mobd),2.64e-16,0.46,34,289,5,38.0
ABCB1 gene|ABCB1 (aapp),2.25e-12,0.33,11,109,0,12.11
Pancreas (bpoc),1.54e-45,0.86,290,4198,77,310.03
Seminiferous tubule structure (bpoc),3.53e-11,0.07,1,14,0,1.07
Serum C reactive protein level (lbpr),4.35e-10,11.52,30,29,2,57.03
Endothelin (aapp),2.9e-25,0.3,20,199,3,22.01
Heparin-induced thrombocytopenia (dsyn),1.63e-06,0.9,6,209,2,6.17
Goblet Cells (cell),6.75e-15,0.12,2,35,0,2.11
Microtubule-Associated Proteins (aapp),6.11e-13,0.22,13,61,0,15.77
fludarabine (nnon),6.46e-15,1.99,1,642,0,1.0
Fiber (phsu),3.49e-08,0.9,192,131,7,220.38
Eye Movements (ortf),2.6e-09,0.08,2,11,0,2.36
Fracture-dislocation (inpo),1.14e-06,0.16,1,19,1,1.05
ileum (bpoc),1.33e-67,0.23,27,361,3,29.02
Phosphatidylinositols (bacs),2.62e-38,0.03,1,21,0,1.05
Premedication (topp),3.04e-07,0.34,14,70,1,16.8
Patient identification (hlca),5.73e-17,5.24,41,234,7,48.18
Connective Tissue (tisu),4.47e-18,0.31,18,149,0,20.17
Institutes (orgt),1.4e-26,3.32,121,629,11,144.28
infliximab|GIF (aapp),6.55e-38,742.09,16,41,3,22.24
Misalignment (anab),1.03e-08,1.78,71,43,0,69.04
Moyamoya Disease (dsyn),4.15e-14,0.26,2,85,0,2.05
lymph nodes (bpoc),5.72e-30,0.71,44,2235,12,44.87
Food (food),4.27e-06,2.42,359,277,13,490.73
Hydroxymethylglutaryl-CoA Reductase Inhibitors (phsu),1.63e-09,2.35,248,2735,54,270.49
VENTRICULAR MORPHOLOGY (fndg),1.49e-06,5.34,10,23,2,14.35
Ovarian Carcinoma (neop),2.59e-39,1.15,131,3212,43,136.34
Genetic Structures (gngm),4.36e-06,0.26,2,34,0,2.12
Acetic Acid (phsu),1.15e-23,0.2,6,99,0,6.36
Age (orga),0.0,6.84,3407,4360,316,6069.3
Metallothionein (aapp),1.27e-38,0.14,8,107,0,8.6
Polyamines (orch),9.69e-43,0.05,1,38,0,1.03
DNA Adducts (bacs),1.63e-07,0.21,7,31,0,8.58
Monkeys (mamm),4e-109,0.08,21,138,1,24.2
Morphine (phsu),5.77e-100,0.13,38,228,0,44.33
Antiepileptic Agents (phsu),9.03e-07,0.59,47,263,1,55.4
Radiation (npop),2.7e-92,0.16,12,305,0,12.47
Glycolysis (moft),4.69e-08,0.27,4,48,1,4.33
Specialty Group (hcro),7.62e-152,689.6,68,166,9,95.86
Research Design (resa),4e-66,3.69,180,456,20,251.05
Oximes (orch),1.17e-06,0.22,1,30,0,1.03
"Cholecystectomy, Laparoscopic (topp)",8.16e-24,2.22,152,565,21,192.89
Ataxia Telangiectasia (dsyn),4.25e-10,0.36,9,100,1,9.81
Cellulose (bacs),2.79e-17,0.09,5,19,0,6.32
Registries (inpr),2e-21,10.37,29,326,14,31.58
Caspofungin (aapp),1.2e-06,1.66,1,252,0,1.0
Propranolol (phsu),4e-69,0.14,19,179,1,21.02
Myeloproliferative disease (neop),9.42e-19,1.0,6,518,1,6.07
Adipocytes (cell),4.58e-86,1.29,643,146,16,179.15
Hip Fractures (inpo),5.96e-90,4.36,259,1548,68,302.33
Rho-associated kinase (aapp),1.62e-06,0.17,2,21,0,2.19
Antihistamines (phsu),8.3e-16,0.16,2,49,0,2.08
Endarterectomy (topp),2.6e-06,2.34,1,418,2,1.0
Subcellular Fractions (celc),3.09e-07,0.05,2,1,0,1.5
Larynx (bpoc),4.06e-19,0.77,37,1131,5,38.21
peer (popg),9.99e-28,2.34,225,71,8,93.4
Phosphoenolpyruvate Carboxylase (gngm),5.22e-10,0.08,5,3,0,4.8
Cilia (celc),6.33e-11,0.11,2,22,0,2.18
Poverty (grpa),9.86e-07,3.5,47,478,6,51.62
Heart failure (dsyn),1.14e-28,2.99,697,15094,476,729.19
U-44619 (eico),1.27e-08,0.08,1,12,0,1.08
Behavior Therapy (topp),8.65e-11,2.43,304,187,27,302.03
Postoperative fistula (patf),6.53e-12,3.69,34,252,17,38.59
Plant Growth Regulators (horm),4.78e-11,0.05,1,9,0,1.11
Hypothyroidism (dsyn),6.86e-08,0.91,250,274,9,478.1
muscle metabolism (ortf),5.14e-07,1.75,28,8,1,10.29
Atom (elii),2.43e-58,0.03,3,19,0,3.47
"Polycyclic Hydrocarbons, Aromatic (orch)",1.01e-10,0.39,33,151,0,40.21
Chelating Agents (phsu),3.38e-40,0.17,1,138,0,1.01
Indomethacin (orch),5.49e-112,0.1,9,216,0,9.38
Structure (spco),7.19e-09,0.2,3,37,0,3.24
"Purpura, Thrombotic Thrombocytopenic (dsyn)",1.94e-22,1.09,1,540,1,1.0
Autologous Stem Cell Transplantation (topp),3.25e-13,3.52,2,1104,0,2.0
keratinocyte (cell),1.53e-101,0.09,8,171,0,8.37
Protein Disulfide Isomerase (aapp),4.18e-07,0.09,1,11,0,1.09
"TSLP protein, human|TSLP (aapp)",2.34e-06,0.09,1,9,0,1.11
Mesocricetus auratus (mamm),6.35e-25,0.09,2,42,0,2.1
Audiological observations (fndg),1.01e-10,0.23,16,49,0,21.22
Colorectal cancer metastatic (neop),1.75e-13,2.28,15,1618,14,15.14
BONE MASS (dsyn),5.45e-53,3.29,644,144,13,176.2
Primary carcinoma of the liver cells (neop),4.25e-164,1.19,189,8626,73,193.14
Entire diencephalon (bpoc),2.85e-07,0.16,3,22,0,3.41
Blood Platelets (cell),1.82e-38,0.37,50,435,5,55.75
Parkinson Disease (dsyn),1.94e-67,0.31,184,621,8,238.52
Bulla (patf),2.2e-06,0.43,10,183,0,10.55
Action Potentials (celf),3.52e-33,0.06,2,36,0,2.11
dietary intervention (topp),2.94e-50,9.05,354,261,45,453.43
Antineoplastic Agents (phsu),4.14e-11,0.68,16,939,2,16.27
Osteoporosis (dsyn),4.89e-08,2.56,1359,1132,76,2074.92
Cell Cycle Arrest (celf),6.4e-12,0.34,1,260,0,1.0
Glycoproteins (aapp),2e-116,0.21,52,549,3,56.93
alpha-Actin (aapp),6.02e-45,0.23,10,229,1,10.44
RUNX2 (gngm),6.82e-09,0.19,5,32,0,5.78
Homeostasis (orgf),9.31e-20,1.07,508,836,20,816.69
Instrumental activities of daily living (fndg),4.51e-06,4.02,14,31,2,20.32
triptolide (phsu),2.94e-07,0.12,1,15,0,1.07
synthetic peptide (aapp),3.24e-23,0.09,2,38,0,2.11
Pancytopenia (dsyn),2.44e-14,1.0,4,383,1,4.04
INS (gngm),4.48e-07,1.6,34,15,0,21.62
Amnesia (mobd),6.05e-10,0.17,4,31,0,4.52
Mucocutaneous Lymph Node Syndrome (dsyn),5.39e-17,0.32,17,150,0,18.93
Mild chronic obstructive pulmonary disease (dsyn),1.77e-14,6.1,24,49,7,35.76
Black race (popg),5.33e-120,4.12,362,767,52,532.85
NADPH Oxidase (aapp),1.5e-20,0.24,8,111,0,8.58
Creatinine clearance (fndg),6.81e-36,3.27,104,276,25,143.19
Radiosurgery (topp),2.38e-30,1.42,2,940,0,2.0
Cysteine (gngm),1.27e-32,0.19,38,106,1,51.62
Vascular Endothelial Cells (cell),2.5e-18,0.3,15,142,0,16.58
White blood cell count increased (fndg),2.48e-10,7.0,16,82,4,19.12
Cell Maturation (celf),2.34e-06,0.17,1,21,0,1.05
"Rupture, Spontaneous (patf)",5.26e-14,0.84,1,281,0,1.0
NADH (bacs),2.04e-20,0.05,3,10,0,3.9
metastatic qualifier (qnco),3.02e-15,3.27,57,227,5,71.31
1/60 (fndg),2.28e-09,11.89,23,24,2,45.04
Sterols (strd),2.21e-11,0.23,22,47,0,32.3
Metastatic melanoma (neop),1.04e-21,1.46,4,859,3,4.02
Saccades (ortf),2.27e-11,0.03,1,3,0,1.33
Systemic vasculitis (dsyn),7.31e-07,0.94,3,175,0,3.05
Didelphidae (mamm),1.6e-09,0.05,1,6,0,1.17
Mid upper arm circumference (fndg),4.85e-07,29.84,26,9,6,12.12
Corticotropin-Releasing Hormone (aapp),8.57e-33,0.12,27,40,0,45.23
"Insulin, Lispro, Human (aapp)",2.7e-06,2.39,47,15,1,19.79
Graft Survival (ortf),1.6e-12,3.29,58,864,52,61.89
Enterobacteriaceae (bact),1.16e-11,0.79,2,307,0,2.01
Cytosol (celc),1.32e-174,0.09,20,273,0,21.47
bone metabolism (ortf),1.69e-10,3.5,283,99,4,133.63
Myelin Basic Proteins (aapp),3.73e-18,0.03,1,7,0,1.14
Encephalitis (dsyn),8.99e-43,0.96,2,870,0,2.0
VICTIM (humn),2.37e-20,1.61,31,1718,14,31.56
Trigeminal Neuralgia (dsyn),1.26e-16,0.19,1,65,0,1.02
Homovanillic Acid (bacs),2.17e-07,0.12,4,10,0,5.6
Ultraviolet B Radiation (npop),1.03e-21,0.12,7,41,0,8.2
JNK Mitogen-Activated Protein Kinases|JUN (aapp),2.3e-07,0.31,4,55,0,4.29
Amyotrophic Lateral Sclerosis (dsyn),9.87e-11,0.63,74,748,35,81.32
macrophage (cell),1.97e-228,0.29,130,1648,7,140.25
Thrombectomy (topp),3.93e-06,2.78,6,699,2,6.05
Multicenter Studies (resa),5.36e-16,4.66,62,577,11,68.66
"Antibodies, Anti-Idiotypic (aapp)",7.83e-123,0.31,55,963,2,58.14
Streptozocin (antb),5.65e-41,0.17,13,143,1,14.18
Macrophage Colony-Stimulating Factor (aapp),6.6e-17,0.11,1,35,0,1.03
NADP (bacs),7.33e-36,0.05,3,30,0,3.3
Osteoclasts (cell),1.07e-27,0.16,12,83,0,13.73
Breast surgery (topp),2.94e-11,3.2,39,134,3,50.35
C-reactive protein (aapp),6.95e-234,5.92,2123,2059,207,4055.93
Pericardial effusion (dsyn),3.48e-08,1.31,7,363,0,7.13
Protein Tyrosine Kinase (aapp),1.32e-12,0.05,1,10,0,1.1
Malignant neoplasm of stomach (neop),3.71e-10,1.82,255,6059,114,265.73
simulation (resa),7.9e-13,0.62,106,760,4,120.78
Blood glucose normal (fndg),4.91e-24,9.06,185,138,7,240.94
topical application (topp),7.83e-07,0.28,5,45,1,5.56
Myopia (dsyn),7.01e-08,0.19,22,5,0,6.14
Supernatant (bdsu),3.8e-55,0.18,24,205,2,26.81
Wounds and Injuries (inpo),3.74e-17,1.86,287,7351,101,298.21
Germ Line (cell),5.45e-06,0.25,1,31,0,1.03
Infertility (dsyn),1.66e-54,1.13,568,180,6,237.04
Heme (bacs),2.05e-32,0.12,5,75,0,5.33
Etiology (ftcn),1.31e-11,4.95,33,413,17,35.64
Hernia (dsyn),3.76e-07,1.12,276,722,29,381.51
Puberty (orgf),2.13e-52,3.45,351,28,8,30.23
Histones (aapp),2.78e-52,0.1,1,100,0,1.01
Mare (mamm),1.09e-18,0.14,2,52,0,2.08
Myofibroblast (cell),2.07e-14,0.24,1,79,0,1.01
deoxynivalenol (hops),4.51e-09,0.06,1,9,0,1.11
Cardiomyopathies (dsyn),9.49e-15,1.42,54,1618,18,55.8
Transcriptional Activation (genf),1.33e-24,0.33,23,228,1,25.32
Hodgkin Disease (neop),1.11e-51,0.91,15,1287,3,15.17
chromatin immunoprecipitation (lbpr),1.73e-10,0.13,4,22,0,4.73
Apolipoproteins (aapp),1.66e-08,1.16,81,47,3,74.27
"NOS2A protein, human|NOS2 (aapp)",3.67e-99,0.26,17,607,1,17.48
"Chromatography, Affinity (lbpr)",4.17e-27,0.05,2,23,0,2.17
Regulatory Protein (aapp),5.36e-15,0.19,7,59,0,7.83
Aspartic Endopeptidases (gngm),5.25e-08,0.15,1,23,0,1.04
Primigravida (fndg),1.67e-12,3.38,58,115,0,87.25
Breast (bpoc),1.31e-06,1.06,542,3887,48,617.58
Chronic sinusitis NOS (dsyn),2.05e-15,0.17,16,39,1,22.56
Lectin (aapp),1.31e-75,0.1,4,153,0,4.1
Cell Respiration (celf),2.92e-06,0.29,8,41,2,9.56
Mediastinum (blor),9.25e-07,1.01,9,269,1,9.3
Boys (popg),7.21e-99,2.7,2593,1330,30,2012.18
Coronary Occlusion (dsyn),9.62e-08,0.81,5,239,1,5.1
Phagocytosis (celf),1.25e-56,0.24,6,284,0,6.13
Malignant Squamous Cell Neoplasm (neop),1.74e-08,1.65,5,522,4,5.05
omalizumab (phsu),1.34e-06,0.24,7,33,0,8.48
associated conditions (patf),3.12e-10,3.88,25,92,5,31.79
Cholecystectomy (topp),1.15e-17,2.38,125,616,18,150.37
Laser-generated electromagnetic radiation (phpr),2.61e-06,0.15,3,16,0,3.56
"Rats, Wistar (mamm)",5.06e-36,0.38,36,439,0,38.95
Filarioidea (invt),5.73e-08,0.16,2,25,0,2.16
donepezil (phsu),4.67e-08,0.22,5,36,0,5.69
Temporal Arteritis (dsyn),5.3e-07,0.43,10,135,0,10.74
Hordeum (plnt),1.08e-09,0.14,6,18,0,8.0
Feeding and dietary regimes (topp),1.24e-14,4.29,31,109,8,39.82
Embryonic Development (ortf),1.75e-52,0.23,10,265,0,10.38
Signal Transduction (celf),1.01e-119,0.28,76,834,6,82.93
apical membrane (celc),3.8e-21,0.07,1,26,0,1.04
pimagedine (orch),8.12e-08,0.27,1,56,0,1.02
Cardiac Death (patf),9.15e-11,7.37,17,912,38,17.32
Entire thigh (bpoc),2.72e-07,1.8,194,196,5,386.02
CORONARY ARTERY DISEASE RISK FACTORS (dsyn),1.18e-18,10.67,32,45,6,54.76
Pulmonary function tests (diap),3.12e-15,3.86,117,172,7,196.59
CAROTID (bpoc),7.43e-16,2.3,386,720,33,592.94
Sexual Dysfunction (dsyn),7.3e-13,1.88,90,42,0,61.6
Colitis (dsyn),7.94e-07,0.44,13,381,0,13.44
Galanin (aapp),3.27e-07,0.21,23,9,0,12.52
Supernumerary mandibular left second molar (bpoc),2.34e-10,0.29,6,73,1,6.49
Deep Vein Thrombosis (dsyn),2.63e-06,1.52,208,1225,46,243.32
HSD11B1 (gngm),1.04e-10,2.8,296,145,15,216.03
Photochemotherapy (topp),4.27e-62,0.2,2,256,0,2.02
Deferoxamine (bacs),1.23e-14,0.28,1,132,0,1.01
Finding / disorder (ftcn),3.94e-18,6.01,41,442,18,44.8
copeptins|COP (aapp),4.03e-11,211.31,7,88,0,7.56
Nested Case-Control Studies (resa),1.15e-14,9.31,35,45,2,62.22
NG-Nitroarginine Methyl Ester (aapp),9.48e-14,0.23,5,68,0,5.37
Cholangitis (dsyn),1.43e-06,1.34,2,247,1,2.02
Infection by Cryptococcus neoformans (dsyn),2.24e-06,1.37,1,220,1,1.0
Somatic cell (cell),1.12e-15,0.13,2,38,1,2.11
mullerian-inhibiting hormone (horm),8.37e-43,2.45,155,9,1,9.52
Surveys (resa),4.46e-07,1.62,539,1315,37,759.93
very low density lipoprotein triglyceride (aapp),7.64e-08,2.48,44,9,0,10.84
Pentoxifylline (orch),1.09e-18,0.31,9,146,0,9.55
Atrial Natriuretic Factor (aapp),8.4e-44,0.2,42,172,1,52.26
Atrophic (patf),8.44e-22,0.43,95,423,3,116.34
Carbamazepine (phsu),6.81e-16,0.27,29,105,0,37.01
Clinical Trials (resa),1.51e-71,2.91,830,7871,115,917.52
summer (tmco),1.34e-06,2.16,40,110,0,54.55
Molecule (sbst),9.78e-13,0.25,6,72,1,6.5
demographic characteristics (grpa),4.4e-07,5.09,18,32,0,28.12
Liposomes (lipd),1.29e-115,0.11,9,244,1,9.33
HCT116 Cells (cell),8.41e-08,0.23,2,38,0,2.11
Leukotriene B4 (bacs),1.17e-18,0.1,4,29,0,4.55
Slabs (medd),4.86e-06,0.06,1,4,0,1.25
Cerebellar Nuclei (bpoc),7.25e-18,0.03,1,7,0,1.14
Fractionation (lbpr),2.95e-32,0.14,5,91,0,5.27
Serum Albumin (aapp),8.35e-45,3.05,141,397,59,191.08
Contraction (patf),5.45e-204,0.17,131,684,4,156.09
GABPA|NFE2L2 (gngm),9.64e-21,0.29,6,150,0,6.24
Cytochrome P450 3A4|CYP3A4 (gngm),1.66e-07,0.25,11,40,1,14.03
cDNA Library (gngm),2.35e-43,0.04,1,32,0,1.03
Ovalbumin (aapp),8.82e-27,0.09,2,43,0,2.09
MAPK8 gene|MAPK8 (gngm),5.55e-54,0.17,9,184,1,9.44
"ASPERGILLOSIS, INVASIVE (dsyn)",1.35e-08,2.58,4,693,1,4.02
Subfertility (dsyn),1.61e-12,1.48,67,14,0,16.93
inner membrane (celc),3.24e-13,0.04,1,8,0,1.12
Estimated blood loss (fndg),3.58e-19,12.86,55,52,5,101.16
Lyme Disease (dsyn),6.93e-17,0.1,2,30,0,2.13
Reproductive function (phsf),1.93e-06,1.21,53,29,1,44.87
Health Care Systems (hcro),3.9e-07,2.83,39,218,4,45.98
B-Cell Lymphomas (neop),1.29e-22,1.37,6,880,3,6.04
human herpesvirus 8 (virs),5.13e-14,0.29,5,94,0,5.27
Chitinase (aapp),1.11e-11,0.13,1,30,0,1.03
Peripheral Blood Lymphocyte (cell),3.33e-35,0.12,11,76,0,12.59
Breast cancer invasive NOS (neop),1.48e-19,3.79,98,1019,31,107.42
Cytoplasm (celc),3.67e-189,0.22,13,859,0,13.2
PubMed (inpr),3.3e-15,3.93,86,906,17,94.16
Colchicine (orch),7.52e-23,0.23,12,117,1,13.23
Esters (orch),1.04e-34,0.11,18,53,0,24.11
Spinal Stenosis (dsyn),3.59e-08,1.28,62,38,4,61.29
Wolff-Parkinson-White Syndrome (dsyn),8.34e-10,0.22,1,45,0,1.02
Hydrogen Peroxide (phsu),3.35e-129,0.09,22,205,2,24.36
AUSTRALIAN (fndg),2.4e-47,4.68,587,628,37,1135.68
FOS gene|FOS (gngm),1.55e-32,0.08,9,36,0,11.25
Gerbils (mamm),6.94e-17,0.1,2,30,0,2.13
Polymers (chvs),9.99e-59,0.1,8,111,1,8.58
Malate Dehydrogenase (gngm),7.8e-08,0.03,1,1,0,2.0
Superinfection (dsyn),2.66e-08,0.92,1,170,0,1.01
Microalbuminuria (dsyn),2e-26,3.82,389,473,45,708.92
Gastric mucosa (tisu),1.07e-28,0.22,28,140,0,33.6
Lecithin (bacs),2.24e-41,0.11,25,43,0,39.53
Recombinant Proteins (aapp),5.83e-52,0.18,1,190,0,1.01
1/24 (fndg),2.54e-26,14.27,21,42,9,31.5
Kupffer Cells (cell),2.61e-15,0.26,2,96,0,2.04
heart rate (orga),1.19e-82,3.0,384,904,70,547.12
Stable Disease (fndg),2.75e-09,4.06,103,1611,14,109.59
Forskolin (bacs),4.81e-49,0.03,3,17,0,3.53
Acute onset pain (sosy),2.42e-06,0.33,7,55,0,7.89
Lung Transplantation (topp),2.03e-06,4.3,30,1042,43,30.86
Long (qlco),3.41e-25,4.73,59,470,29,66.41
Squamous epithelial cell (cell),5.88e-07,0.93,1,158,1,1.01
Lysosomal enzyme (aapp),2.4e-10,0.06,2,8,0,2.5
Exanthema (dsyn),1.54e-07,0.5,34,643,1,35.8
Vigabatrin (phsu),1.04e-08,0.12,2,19,0,2.21
Adipogenesis (moft),1.21e-08,1.32,55,16,1,20.65
Fibrinolytic Agents (phsu),2.43e-13,1.67,10,823,3,10.12
racial differences (fndg),4.7e-74,8.62,99,214,13,144.8
HMGB1 Protein (bacs),2.27e-07,0.92,4,203,1,4.08
Citalopram (phsu),2.24e-08,0.26,12,48,0,15.0
Potassium Channel (aapp),4.56e-15,0.23,8,79,0,8.81
End stage renal failure (dsyn),8.53e-93,3.42,467,5514,275,506.55
Malaria (dsyn),4.35e-91,0.97,37,2648,10,37.52
"Macrophages, Peritoneal (cell)",8.34e-52,0.12,1,123,0,1.01
Hole (fndg),1.97e-11,0.17,5,38,0,5.66
Sterility (patf),1.43e-12,0.27,5,80,0,5.31
Hepatitis (dsyn),5.24e-11,0.93,43,661,4,45.8
Interleukin-1 beta (aapp),9.15e-99,0.35,182,1098,3,212.17
malate (bacs),2.74e-06,0.21,4,25,1,4.64
Alloys (inch),4.55e-11,0.07,3,8,0,4.12
Functional RNA (bacs),4.02e-14,0.9,12,430,0,12.33
Intervertebral disc structure (bpoc),4.43e-10,0.12,7,11,0,11.45
Kanamycin (antb),4.57e-06,0.12,1,12,0,1.08
Emission (orgf),3.14e-47,0.11,9,97,0,9.84
Excitation (fndg),1.77e-19,0.08,3,23,0,3.39
Tonsillectomy and adenoidectomy (topp),6.63e-09,3.08,72,14,0,16.72
Cyclophosphamide (phsu),7.12e-45,1.02,81,2248,16,83.92
Brain Stem (bpoc),3.47e-24,0.37,13,670,0,13.25
Amiloride (phsu),3.38e-19,0.08,3,24,0,3.38
Respiration (phsf),5.15e-16,1.79,761,1754,70,1091.17
Renal Cell (cell),2.42e-44,0.14,9,126,0,9.64
H/O: surgery NOS,1.65e-69,6.36,9,126,0,9.64
nursing home resident (popg),9.71e-18,2.51,67,299,33,82.01
Organic Chemicals (orch),8.32e-16,0.18,5,58,0,5.43
Tryptophan (aapp),2.62e-26,0.2,35,92,2,48.32
Microscopic observation (lbpr),2.49e-06,0.21,1,27,0,1.04
higher education institution (orgt),3.63e-09,4.29,21,46,2,30.59
Overweight (sosy),8.55e-29,28.26,11660,475,939,494.35
Residual Tumor (neop),3.94e-09,2.47,14,1069,2,14.18
Eyelash (bpoc),7.81e-14,0.11,2,29,0,2.14
Immunoglobulin G subclass (aapp),1.39e-08,0.08,1,12,0,1.08
Centrosome (celc),6.58e-10,0.1,1,16,1,1.06
Norepinephrine (nsba),1.25e-115,0.21,119,517,9,146.39
Leukocyte Elastase (aapp),2.86e-11,0.27,14,75,0,16.61
Matched Groups (humn),2.34e-15,3.86,57,112,7,86.01
albino rat (mamm),3.2e-12,0.21,10,54,0,11.85
Protein Structure (aapp),1.81e-09,0.09,3,11,0,3.82
Dual-Energy X-Ray Absorptiometry (diap),4.73e-10,11.54,797,57,22,61.08
Immunohistochemistry (lbpr),1.56e-45,1.42,64,2879,5,65.42
Dentin (bpoc),1.04e-36,0.02,1,11,0,1.09
Factor VIII|S100A6 (aapp),3.05e-17,310.43,9,14,0,14.79
Blastocyst structure (emst),1.08e-24,0.07,2,27,1,2.15
Signal Pathways (celf),2.24e-41,0.37,28,773,5,29.01
Prolactin|PRL (gngm),4.37e-30,0.19,64,61,1,119.14
aldehyde dehydrogenases (aapp),2.68e-13,0.1,4,20,0,4.8
Cross-Sectional Studies (resa),1.26e-127,7.23,1522,1155,60,2031.49
Internal carotid artery structure (bpoc),1.74e-06,0.76,11,349,1,11.35
Microtus (mamm),5.88e-07,0.23,4,34,0,4.47
Physiologic Organization (phsf),4.82e-38,0.11,7,70,1,7.7
"Phobia, Social (mobd)",2.72e-06,0.19,16,7,0,10.06
Encounter due to In vitro fertilization (fndg),1.1e-23,1.39,162,72,4,104.0
Bands (medd),5.01e-13,1.48,314,486,106,516.87
Contracture (acab),1.39e-16,0.21,15,68,1,18.31
Extracellular Matrix Proteins (aapp),1.46e-15,0.25,6,90,1,6.4
"Muscular Dystrophy, Duchenne (dsyn)",1.07e-06,0.44,41,135,0,53.45
Techniques (ftcn),5.13e-128,1.83,1489,6183,207,1847.58
Bacteria (bact),1.32e-86,0.37,46,2299,3,46.92
Interleukin-17 (aapp),4.45e-15,0.44,26,228,0,28.96
Health behavior (inbe),1.74e-12,8.6,421,186,25,268.18
STERNUM WOUND INFECTION (dsyn),1.18e-10,6.05,12,173,17,12.83
Parenchyma (bpoc),7.36e-15,0.79,57,1118,4,59.91
Trabeculectomy (topp),1.61e-13,0.03,1,6,0,1.17
Blood Tests (lbpr),7.96e-08,2.57,34,94,0,46.3
Matrix (hcro),9.05e-27,0.14,10,70,0,11.43
Ornithine (bacs),1.01e-06,0.12,3,11,0,3.82
Glutamic Acid (aapp),6.13e-07,0.17,9,15,0,14.4
Upper arm (blor),4.7e-21,2.45,127,496,9,159.52
Normal pregnancy (fndg),2.16e-06,1.97,106,79,5,137.88
Headache (sosy),1.58e-10,0.66,108,627,2,126.6
Homologous Gene (gngm),1.78e-187,0.12,21,437,1,22.01
Transient Receptor Potential Channels (gngm),1.47e-07,0.16,1,24,0,1.04
"Microsomes, Liver (celc)",3.97e-78,0.02,5,15,0,6.67
Sympathetic Ganglia (bpoc),6.54e-09,0.07,1,10,0,1.1
hydrochloride (inch),9.54e-09,0.24,5,45,0,5.56
Heme Oxygenase-1 (aapp),6.7e-21,0.33,13,178,0,13.95
Sarcolemma (celc),3.32e-14,0.11,3,26,0,3.35
Synovial (bpoc),7.79e-14,0.19,22,38,0,34.74
Radical cystectomy (topp),6.58e-16,4.34,76,1132,35,81.1
Somatotropin deficiency (dsyn),1.52e-10,2.53,235,122,25,185.34
Carnitine|CASR|CXADR|PRKAR1A|SPG7|NR1I3|TRIM13|CXADRP1 (phsu),6.71e-13,87.38,8,15,0,12.27
Glioma (neop),1.58e-20,0.65,24,2169,5,24.27
Limb structure (bpoc),2.42e-14,0.96,148,1570,11,161.95
risk factors (qnco),4e-229,9.56,292,560,46,444.26
Stimulant (phsu),5.43e-08,0.34,37,86,1,52.92
Ischemic (ftcn),5.02e-08,6.19,12,307,18,12.47
Radioimmunoassay (lbpr),1.64e-08,0.9,150,48,5,63.36
Adhesions (dsyn),1.54e-148,0.26,77,946,9,83.27
Geriatric Patients (podg),5.55e-08,2.63,54,481,23,60.06
Motor Skills (orgf),1.18e-06,2.97,38,5,0,5.66
Electric Stimulation (lbpr),4.41e-44,0.13,37,61,1,59.44
Entire nerve (bpoc),3.9e-41,0.25,96,233,1,135.55
Terbutaline (orch),2.85e-06,0.22,5,27,0,5.93
Nutrition Assessment (diap),1.13e-23,18.64,106,54,20,81.51
Systolic blood pressure (ortf),7.29e-173,7.3,1442,1203,152,2206.61
Male gender (orga),4.25e-82,2.35,850,1947,89,1221.08
Chlamydia Infections (dsyn),5.76e-07,0.18,4,22,0,4.73
Leprosy (dsyn),3.91e-17,0.19,13,62,0,15.73
"Dysplasia, fibrous (dsyn)",2.42e-06,0.14,1,17,0,1.06
"Hospitals, General (hcro)",1.56e-06,2.57,56,384,5,64.17
Thyrotropin-Releasing Hormone|TRH (horm),2.89e-12,0.08,3,10,1,3.9
Foot Ulcer (dsyn),2.82e-08,2.29,44,122,3,59.87
Amyloidosis (dsyn),1.47e-15,0.88,16,530,5,16.48
Adrenal Cortex (bpoc),1.27e-18,0.14,7,49,0,8.0
Hydralazine (phsu),3.73e-07,0.37,7,72,1,7.68
Human plasma (phsu),5.03e-27,0.17,39,56,0,66.16
Dyslexia (mobd),1.47e-17,0.02,1,3,0,1.33
chemosensitization/potentiation (topp),9.72e-14,0.14,4,35,0,4.46
Heat shock proteins (aapp),9.02e-31,0.27,15,196,0,16.15
Schwann Cells (cell),1.93e-26,0.06,1,31,0,1.03
Down-Regulation (celf),3.49e-21,0.46,52,688,0,55.93
"Twins, Dizygotic (humn)",7.39e-09,2.86,35,86,2,49.24
NODE (bpoc),7.15e-12,1.27,55,1197,8,57.53
neighbor (humn),1.84e-13,0.3,16,103,1,18.49
Breast cancer metastatic (neop),6.15e-20,1.57,32,1675,14,32.61
Need for immunization against unspecified infectious disease (fndg),3.7e-06,0.68,1,338,1,1.0
bud (celc),6.08e-16,0.18,4,59,0,4.27
Salmo trutta (fish),6.17e-09,0.28,1,74,0,1.01
Herpes zoster disease (dsyn),3.59e-10,0.32,4,98,0,4.16
anti-IgG (aapp),2.9e-17,0.25,9,103,0,9.79
Stereotyped Behavior (mobd),1.87e-08,0.04,1,4,0,1.25
STAT3 gene|STAT3 (gngm),2.33e-27,0.33,11,341,0,11.35
Cysteine Protease (aapp),6.03e-13,0.23,12,63,1,14.29
"Lights, manufactured (medd)",3.88e-09,0.26,6,56,0,6.64
network (humn),8.08e-56,0.51,159,1405,20,176.99
"ATPase, Aminophospholipid Transporter-Like, Class I, Type 8A, Member 2|ATP8A2 (aapp)",5.46e-177,0.1,38,298,1,42.85
vascular bed (bpoc),1.01e-08,0.45,24,155,2,27.72
gabapentin (orch),2.77e-10,0.21,12,39,0,15.69
Insulin-Like Growth Factor I (aapp),8.51e-57,1.05,837,532,46,870.14
"Phosphorus, homeopathic preparation (inch)",5.62e-08,0.45,23,140,0,26.78
Adenocarcinoma of esophagus (neop),2.08e-29,3.68,94,423,17,114.89
Alanine Transaminase (aapp),3.05e-12,3.29,415,479,17,774.55
Hepatic artery (bpoc),5.95e-08,1.05,2,234,2,2.02
Antioxidants (phsu),1.17e-11,0.65,430,1443,12,558.14
Not Hispanic or Latino (popg),1.37e-14,8.75,18,35,4,27.26
Neuroendocrine Tumors (neop),1.44e-24,1.17,14,922,2,14.21
Tachyarrhythmia (patf),6.05e-08,0.87,8,254,2,8.25
Fluorouracil (phsu),1.98e-101,0.9,21,2376,7,21.19
Response Elements (bacs),2.06e-20,0.09,2,31,1,2.13
METABOLIC DISTURBANCE (dsyn),8.01e-08,6.37,206,125,16,200.85
filtration (lbpr),5.14e-07,0.35,12,72,0,14.0
"Metabolic Detoxication, Drug (orgf)",5.58e-07,0.47,15,119,0,16.89
logistic regression analysis (resa),3.63e-66,7.13,102,248,13,143.95
Multiple Trauma (inpo),1.13e-09,2.01,3,640,4,3.01
Amphotericin B (antb),1.47e-36,0.85,2,753,0,2.01
Chagas Disease (dsyn),5.97e-10,0.78,11,497,7,11.24
Thrombospondins (aapp),4.23e-07,0.08,1,9,0,1.11
Pyruvate (bacs),2.28e-23,0.13,6,55,0,6.65
Androgens (horm),4.64e-26,1.06,434,378,10,707.23
Gel Electrophoresis (lbpr),1.87e-07,0.22,13,29,0,18.83
glucose metabolism (moft),1.41e-06,3.27,198,82,3,115.96
Diabetic care (topp),2.69e-09,3.68,62,98,2,101.22
Anemic (fndg),6.25e-12,2.67,70,394,12,82.44
Phospholipase D (aapp),2.86e-19,0.02,1,6,0,1.17
Endometrial Stromal Cell (cell),2.2e-09,0.05,1,6,0,1.17
apolipoprotein B-48 (aapp),2.66e-06,2.24,21,2,0,2.19
early identification (topp),1.54e-28,4.45,82,373,8,100.03
Beagle (mamm),7.21e-40,0.12,1,91,0,1.01
Biotin (orch),4.13e-19,0.08,4,24,0,4.67
Strabismus (dsyn),4.34e-12,0.08,3,12,0,3.75
Composition (clna),2.02e-37,1.38,297,221,9,385.45
"SHC1 protein, human|SHC1 (bacs)",1.19e-06,0.09,1,9,0,1.11
Amylases (aapp),1.13e-06,0.59,32,245,5,36.18
"Interferon Alpha, Human|IFNA1 (aapp)",4.08e-17,0.23,5,88,0,5.28
CANADIAN (fndg),8.09e-24,3.62,370,469,23,661.9
Eukaryota (orgm),7.75e-115,0.05,3,106,0,3.08
Pelvic lymphadenectomy (topp),2.91e-13,3.76,37,192,11,44.13
Witnesses (humn),1.64e-16,4.01,44,117,1,60.55
Perceived quality of life (fndg),6.43e-08,2.46,39,102,3,53.91
innate immune response (patf),1.11e-09,0.95,12,356,1,12.4
Somatostatin analog|TAT (phsu),5.38e-27,1683.38,12,38,1,15.79
"Sperm Injections, Intracytoplasmic (topp)",4.35e-08,1.21,70,38,0,58.63
ELUTION (lbpr),3.05e-19,0.07,1,23,0,1.04
Intraoperative Complications (patf),3.2e-18,5.45,37,129,4,47.61
Intervention regimes (hlca),0.0,3.97,3845,10488,330,5254.61
Plants (plnt),1.65e-230,0.18,52,859,0,55.15
Peptide Hydrolases (aapp),1.36e-101,0.15,9,311,0,9.26
Phosphoproteins (aapp),1.01e-20,0.08,2,28,0,2.14
Patient in hospital (fndg),2.16e-13,3.49,69,769,30,75.19
lactic acid bacteria (bact),3.26e-06,0.11,1,11,0,1.09
wortmannin (bacs),9.08e-19,0.07,1,25,0,1.04
Hand grip strength (fndg),1.49e-06,12.55,26,18,4,30.46
Lipoxygenase (aapp),1.2e-34,0.05,1,30,0,1.03
Dopamine-beta-monooxygenase (aapp),5.83e-10,0.03,1,2,0,1.5
Choroidal Neovascularization (patf),1.48e-22,0.03,3,3,0,6.0
phosphoric diester hydrolase (aapp),7.27e-34,0.07,3,42,0,3.21
ewes (mamm),5.09e-27,0.13,4,70,0,4.23
Empyema (dsyn),1.37e-08,1.24,2,334,4,2.01
Chronic Lymphocytic Leukemia (neop),1.05e-33,0.75,6,1199,0,6.03
Arginine (phsu),1.24e-11,0.47,170,380,5,246.05
"Carcinoma, Non-Small-Cell Lung (neop)",3.86e-100,1.94,77,8530,64,77.7
acid secretion (celf),1.71e-10,0.07,3,7,0,4.29
Hippocampal Formation (bpoc),1.71e-10,0.08,2,12,0,2.33
Polyunsaturated Fatty Acids (bacs),1.57e-16,1.28,182,220,7,332.56
Amputation (topp),1.66e-06,1.75,25,951,11,25.66
APLN (gngm),1.18e-07,1.82,53,27,3,40.75
Roentgen Rays (npop),7.8e-22,0.18,31,58,1,47.57
Tobramycin (antb),3.79e-07,0.33,7,62,1,7.79
MS4A1 gene|MS4A1 (gngm),3.09e-07,0.85,2,156,0,2.03
Musculoskeletal Diseases (dsyn),1.63e-17,1.49,99,37,4,50.83
"Parietal Cells, Gastric (cell)",1.36e-10,0.04,1,5,0,1.2
dopaminergic neuron (cell),1.18e-50,0.04,5,26,0,5.96
electrode (mnob),5.73e-38,0.1,14,46,3,18.26
Vitrectomy (topp),6.18e-25,0.07,5,21,0,6.19
Seasons (tmco),2.1e-08,2.05,72,310,6,88.72
sporulation (celf),1.3e-08,0.1,1,16,0,1.06
Fibroblasts (cell),0.0,0.09,25,669,2,25.93
hyperkalemia (patf),1.93e-06,1.17,3,253,3,3.04
Overhydration (patf),1.66e-14,8.49,12,36,9,16.0
Lesion of stomach (dsyn),4.38e-08,0.27,2,47,0,2.09
Plasminogen Activator (gngm),3.63e-18,0.22,4,86,1,4.19
Graves' Disease (dsyn),9.77e-22,0.24,37,116,0,48.8
Allergic rhinitis NOS (dsyn),1.04e-06,0.34,80,46,1,72.45
"TNF protein, human|TNF (aapp)",2.18e-13,0.95,628,1036,17,1008.68
Paroxetine (orch),6.52e-09,0.22,13,39,0,17.33
alemtuzumab (imft),1.34e-09,1.3,3,328,0,3.03
Cyclosporine (phsu),2.17e-107,0.37,100,1163,9,108.6
Squamous cell carcinoma (neop),4.93e-181,1.0,56,5170,21,56.61
6/9 (fndg),6.02e-17,5.36,33,93,3,44.71
Salts (chvs),3.81e-10,0.07,1,12,0,1.08
FAS (gngm),6.34e-13,0.41,42,206,3,50.56
Pheochromocytoma (neop),8.33e-14,0.48,35,279,9,39.39
pulmonary complications (patf),8.79e-11,4.79,42,667,21,44.64
Ethylene (orch),4.25e-26,0.03,3,5,0,4.8
Culicidae (invt),2.11e-24,0.89,3,515,1,3.02
Semiconductors (mnob),6.87e-10,0.07,2,8,0,2.5
Plant Roots (plnt),5.12e-35,0.18,5,130,0,5.19
pemetrexed (orch),1.97e-14,1.3,2,435,0,2.01
Libraries (orgt),3.57e-17,0.86,29,704,7,30.19
Fetal Liver (emst),1.03e-11,0.08,2,15,0,2.27
Conjunctivitis (dsyn),2.87e-07,0.28,3,46,0,3.2
"Genes, Regulator (gngm)",1.21e-06,0.39,7,72,1,7.68
"Seizures, Focal (sosy)",1.78e-08,0.31,9,69,0,10.17
Aspirin (phsu),4.43e-23,0.94,223,2482,37,243.04
glycogen synthase kinase 3 beta (aapp),6.63e-06,0.3,2,40,0,2.1
Entire trunk (bpoc),1.39e-09,1.41,228,802,12,292.82
Lipogenesis (orgf),2.31e-06,1.1,65,34,2,51.78
Adrenal Glands (bpoc),1.75e-40,0.27,16,257,2,17.0
partial response (fndg),1.47e-16,2.96,5,1378,1,5.02
Epidermal Growth Factor Receptor|EGF (aapp),9.03e-13,0.17,2,45,0,2.09
Methylphenidate (phsu),2.61e-07,0.23,26,18,0,30.46
Lower urinary tract symptoms (sosy),8.21e-33,1.68,160,49,0,64.01
Complete atrioventricular block (patf),2.03e-06,1.09,1,206,3,1.0
Hypoxemia (fndg),2.33e-21,2.71,115,567,19,138.32
Hysterectomy (topp),9.38e-32,2.71,235,504,19,344.57
Immunoblotting (lbpr),3.4e-11,0.24,7,60,0,7.82
Brain tissue (bpoc),4.89e-16,0.39,14,424,1,14.46
WDTC1 (gngm),1.61e-23,0.17,19,67,0,24.39
Secondary physiologic amenorrhea (dsyn),3.09e-07,1.78,26,2,0,2.15
Nitrites (chvs),1.35e-08,0.21,3,36,0,3.25
Electrophoresis (lbpr),3.08e-12,0.18,11,39,0,14.1
Cardiovascular Diseases (dsyn),0.0,7.22,3732,10574,974,5049.18
Clarithromycin (antb),4.9e-19,0.27,5,116,0,5.22
Adventitia (tisu),2.79e-09,0.28,2,60,0,2.07
NMDA receptor antagonist (phsu),1.22e-06,0.18,1,23,0,1.04
Hepatitis Delta Virus (virs),5.39e-07,0.28,3,44,0,3.2
offender (popg),1.8e-11,0.29,7,80,0,7.61
Craniopharyngioma (neop),1.96e-11,2.25,55,171,12,72.69
Extracellular Space (bsoj),8.33e-10,0.14,1,26,0,1.04
Fentanyl (orch),1.47e-06,0.43,54,137,2,75.28
Imipramine (phsu),3.57e-34,0.03,1,18,0,1.06
Self Esteem (inbe),2.86e-19,3.11,170,32,3,38.02
eosinophil (cell),2.71e-42,0.11,9,84,1,9.96
Tumor Necrosis Factor Ligand Superfamily Member 6 (aapp),6.8e-18,0.23,4,91,0,4.18
Salivary Glands (bpoc),2.46e-38,0.28,9,301,0,9.27
Random Allocation (resa),8.93e-42,4.2,101,234,7,144.59
Cleft Palate (dsyn),2.06e-16,0.18,9,58,0,10.4
Temporal Lobe (bpoc),2.25e-20,0.28,20,144,0,22.78
Transforming Growth Factor beta|TGFB1 (aapp),1.59e-07,0.19,1,29,0,1.03
leiomyosarcoma (neop),2.24e-09,0.74,1,318,0,1.0
Disinfection (topp),1.49e-08,0.26,1,56,0,1.02
Bicuculline (orch),4.58e-13,0.05,1,10,0,1.1
Hydrocarbons (orch),4.33e-18,0.17,8,61,0,9.05
"Signs and Symptoms, Respiratory (sosy)",1.98e-14,2.02,100,334,13,129.94
Ovarian Stimulation (topp),1.27e-19,1.83,78,13,2,15.17
"PLA2G2A protein, human|PLA2G2A (aapp)",5.67e-07,0.18,4,22,0,4.73
Renal impairment (dsyn),2e-10,2.46,122,971,19,137.33
EGFR gene|EGFR (gngm),1.21e-12,1.4,8,622,3,8.1
Capsaicin (lipd),2.54e-42,0.07,16,24,0,26.67
Exocytosis (celf),9.93e-42,0.28,150,286,1,228.67
Acute hemorrhage (patf),2.76e-08,2.06,1,388,0,1.0
Nephrotic Syndrome (dsyn),7.01e-18,0.4,28,238,1,31.29
CRYGC|CRYGEP (gngm),2.55e-08,0.2,1,33,0,1.03
KCNH2 (gngm),1.5e-06,0.26,4,38,0,4.42
SMAD3 gene|SMAD3 (gngm),1.67e-08,0.25,4,47,0,4.34
Entire suprachiasmatic nucleus (blor),1.45e-08,0.06,2,4,0,3.0
Microglia (cell),1.18e-60,0.12,2,145,0,2.03
Antimalarials (phsu),1.19e-10,0.8,8,350,0,8.18
Blood - brain barrier function (ortf),4.49e-11,0.37,7,234,0,7.21
Control Groups (humn),6.06e-75,2.38,2279,3944,106,3595.9
skin disorder (dsyn),1.05e-22,0.35,48,259,4,56.9
SMAD5-AS1 (gngm),5.93e-11,0.31,4,87,0,4.18
Gonadorelin|PLOD1 (horm),1.88e-17,56.14,24,21,0,39.38
Morphologically altered structure (anab),4.94e-28,0.34,53,298,4,62.43
Fibrinogen assay (lbpr),1.1e-06,3.77,17,39,6,24.41
Alleles (gngm),2.88e-22,1.59,318,307,8,603.38
Impaired cognition (fndg),8.52e-15,1.13,413,895,24,603.58
comatose (dsyn),2.93e-14,1.53,8,746,3,8.09
MDM2 gene|MDM2 (gngm),6.3e-07,0.36,3,140,0,3.06
docetaxel (phsu),2.42e-36,1.25,15,1474,9,15.15
Hemoglobin concentration result (lbtr),2.53e-12,3.33,34,140,11,42.26
Recurrent Carcinoma (neop),4.23e-13,1.47,6,605,2,6.06
Time (tmco),9.33e-41,3.24,297,2523,45,331.96
"Respiratory Distress Syndrome, Newborn (dsyn)",4.29e-15,1.49,12,812,2,12.18
Algae (alga),4.33e-27,0.21,2,118,0,2.03
Tamoxifen (orch),4.47e-32,0.49,83,996,18,89.92
Disorder of pregnancy (dsyn),2.29e-09,5.71,28,43,2,46.23
Retinal Cone (cell),4.82e-11,0.03,1,4,0,1.25
Craving (inbe),7.22e-07,2.94,46,8,0,9.39
Walking (dora),1.21e-12,3.63,276,74,17,93.84
beta-Lactamase (aapp),1.5e-22,0.24,2,117,0,2.03
Trachoma (dsyn),4.56e-06,0.12,1,13,0,1.08
N terminal pro-brain natriuretic peptide level (lbpr),1.51e-06,8.48,10,16,2,16.25
Cell Cycle Progression (celf),9.41e-22,0.28,2,185,1,2.02
Multimorbidity (sosy),6.02e-12,4.26,28,137,8,33.72
CAMP (gngm),2.22e-10,0.2,11,37,0,14.27
Myocardium (tisu),1.6e-38,0.46,83,945,5,90.29
Relaxation (topp),1.33e-23,0.21,27,96,1,34.59
Pathological accumulation of air in tissues (patf),4.22e-06,1.67,86,468,26,101.8
kinase activity (moft),1.5e-14,0.11,2,28,0,2.14
Biological Models (resd),6.49e-25,0.17,1,85,0,1.01
Memory (menp),2.3e-17,0.2,19,63,2,24.73
Beta Carotene (orch),3.72e-06,1.06,114,160,9,195.22
Glial Fibrillary Acidic Protein (aapp),3.14e-22,0.17,3,75,0,3.12
Materials (sbst),2.62e-51,0.21,20,229,2,21.75
Dopamine Antagonists (nsba),1.91e-08,0.1,4,6,1,6.67
Hypnosis (topp),3.3e-06,0.07,2,4,0,3.0
Transcriptional Regulation (celf),1.29e-19,0.19,6,80,0,6.45
Magnetic Resonance Angiography (diap),3.99e-08,0.44,13,134,0,14.26
Choline (bacs),1.57e-13,0.22,22,51,1,31.49
BOWEL RESECTION (topp),2.3e-08,4.46,22,166,7,24.92
Xenobiotics (bacs),9.87e-17,0.15,2,51,0,2.08
Lymph (bdsu),1.11e-06,0.16,4,17,0,4.94
Angiotensin I (aapp),1.52e-07,0.16,2,23,0,2.17
Systemic infection (dsyn),3.8e-08,1.62,9,518,1,9.16
Capsid Proteins (aapp),1.53e-43,0.14,1,117,0,1.01
Not significant (fndg),1.86e-62,7.0,223,289,12,395.07
Tubulin (aapp),5.29e-35,0.05,1,32,0,1.03
Blood flow (orgf),3.72e-17,0.48,205,587,16,276.59
Sodium Channel (aapp),1e-17,0.18,4,67,0,4.24
Chordoma (neop),8.93e-09,0.82,2,204,0,2.02
beta-adrenergic receptor (aapp),2.83e-09,0.21,6,39,0,6.92
Cyanobacterium (bact),1.57e-38,0.1,2,73,0,2.05
"Opiates, Endogenous (bacs)",5.11e-08,0.09,1,12,0,1.08
conjunctiva (bpoc),6.16e-38,0.14,5,107,0,5.23
Somatotropin|ELANE (horm),8.05e-59,136.85,46,50,3,88.32
Neurotoxins (hops),9.66e-11,0.25,1,65,0,1.02
"Insulin, Glargine, Human|GLA (horm)",6.66e-13,664.52,58,10,1,11.72
Aldehydes (orch),3.98e-24,0.07,1,31,0,1.03
"Biological function, NOS (biof)",2.05e-12,0.47,29,287,0,31.93
K ATPase (aapp),3.64e-12,0.07,2,13,0,2.31
Birth (orgf),0.0,3.64,1315,2888,93,1913.76
Opportunistic Infections (dsyn),1.8e-12,1.87,6,933,9,6.04
Retrospective Studies (qnco),1.15e-137,9.02,227,1658,56,258.08
Sirolimus (substance) (antb),1.29e-43,0.31,13,424,4,13.4
Antifungal Agents (phsu),4.15e-18,1.46,3,636,0,3.01
"Cardiomyopathy, Dilated (dsyn)",1.79e-18,1.05,34,964,7,35.2
3/6 (fndg),6.36e-35,6.35,60,166,7,81.69
Amino-terminal pro-brain natriuretic peptide (aapp),1.7e-30,5.95,59,421,23,67.27
Intentional weight loss (fndg),5.91e-14,36.26,30,11,14,15.03
Azithromycin (antb),9.46e-10,0.4,10,189,1,10.53
Arachidonic Acid (eico),2.34e-23,0.25,66,112,4,104.89
Pleura (bpoc),1.13e-14,0.87,1,276,0,1.0
Chloroquine (orch),7.96e-34,0.23,3,163,0,3.06
Exostoses (patf),1.34e-17,1.68,77,8,1,8.83
Trophoblastic Cell (cell),1.6e-06,0.22,2,29,0,2.14
whey protein (aapp),2.46e-09,1.53,46,11,0,13.63
"Adolescents, Male (humn)",8.58e-08,5.62,228,37,5,43.0
Base Sequence (nusq),9.41e-32,0.09,2,51,0,2.08
Methotrexate (orch),1.36e-18,0.49,68,1194,5,71.87
Hypercapnic respiratory failure (patf),2.05e-12,2.9,38,163,16,46.86
Anticoagulants (phsu),7.71e-08,1.54,62,1336,6,64.88
Daunorubicin (phsu),6.07e-09,0.33,1,133,1,1.01
Micrometastasis (fndg),2.3e-13,1.21,2,377,0,2.01
Electroencephalography (diap),1.15e-17,0.31,4,188,1,4.09
Fluconazole (phsu),1.07e-21,1.06,7,637,1,7.08
Ventral Tegmental Area (bpoc),2.34e-21,0.04,4,5,0,7.2
Pseudogenes (gngm),2.98e-07,0.06,1,5,0,1.2
HSP90 Heat-Shock Proteins|HSP90AA1 (aapp),1.18e-21,0.14,2,60,0,2.07
Liver tissue (tisu),3.33e-07,0.52,33,406,1,35.68
Erinaceidae (mamm),5.3e-12,0.24,1,66,0,1.02
Deafness (dsyn),5.4e-10,0.24,11,51,0,13.37
Obese build (orga),1.53e-07,14.45,1947,124,90,131.9
monoamine (orch),1.59e-11,0.08,3,13,0,3.69
Inosine (bacs),3.1e-06,0.14,2,14,0,2.29
pulmonary function (ortf),5.08e-26,3.12,236,411,32,371.51
Cholinesterase Inhibitors (orch),4.13e-07,0.39,6,99,1,6.36
"Hypertension, Portal (dsyn)",4.16e-16,1.09,27,829,5,27.88
Solanum tuberosum (plnt),3.62e-09,0.15,2,26,0,2.15
Growth arrest (patf),2.02e-14,0.19,1,56,0,1.02
Entire heart (bpoc),9.73e-36,7.65,38,489,46,40.95
Zea mays (plnt),3e-30,0.14,4,84,0,4.19
Ions (elii),6.34e-221,0.07,26,240,0,28.82
Gastric acid secretion (ortf),8.98e-15,0.08,4,14,0,5.14
Metastatic malignant neoplasm to brain (neop),2.1e-29,2.19,4,1611,2,4.01
Spermidine (nsba),1.19e-17,0.07,1,19,1,1.05
Haloperidol (orch),4.6e-31,0.21,23,135,0,26.92
Open approach (topp),1.06e-52,4.47,167,1401,57,186.91
Carboplatin (phsu),9.95e-23,1.39,19,1289,10,19.28
Vertebral column (bpoc),3.01e-36,1.18,539,659,7,979.85
exenatide (aapp),1.46e-16,2.08,126,50,3,69.84
TNFSF13B (gngm),2.14e-08,0.2,2,34,0,2.12
Prostate (bpoc),3.85e-07,0.94,349,2471,68,398.29
osteopontin (aapp),1.77e-16,0.4,30,223,2,34.04
NF-kappa B (aapp),1.93e-113,0.29,35,847,3,36.45
Conscious (menp),2.5e-58,0.05,1,54,0,1.02
Refeeding syndrome (dsyn),2.52e-07,9.77,17,18,6,33.06
Population at Risk (popg),6.01e-42,5.17,94,307,7,122.78
Ejection fraction (fndg),4.9e-29,4.23,148,1947,55,159.25
rapid technique (diap),9.2e-10,0.23,2,48,0,2.08
Gene Expression Regulation (genf),4.03e-07,0.37,20,84,1,24.76
Fc Receptor (aapp),1.93e-12,0.09,2,20,0,2.2
Radionuclide Imaging (diap),9.83e-38,0.37,74,465,4,85.78
"Stress Disorders, Post-Traumatic (mobd)",2.81e-25,0.31,98,209,5,143.95
Thyroxine|T (horm),2.89e-07,72.7,7,7,0,14.0
Tardive Dyskinesia (dsyn),1.51e-11,0.05,2,7,0,2.57
Excision of sigmoid colon NOS (topp),2.17e-10,4.69,17,71,8,21.07
Structure of cortex of kidney (bpoc),3.16e-11,0.1,4,14,0,5.14
Spinal Cord (bpoc),5.37e-224,0.17,14,760,0,14.26
Postoperative Complications (patf),2.3e-264,6.99,421,3207,213,476.27
Relationships (qlco),3.29e-78,4.68,1019,1061,122,1997.66
Amputation Stumps (acab),8.5e-07,0.81,16,393,7,16.65
Vitamin D Deficiency (dsyn),3.88e-19,5.73,567,391,22,660.63
Hypoplastic Left Heart Syndrome (dsyn),3.82e-06,2.68,3,482,0,3.02
plant growth/development (orgf),1.43e-12,0.07,1,16,0,1.06
hypoglycemia (dsyn),6.95e-32,1.87,310,930,20,413.33
MAPT (gngm),1.04e-33,0.11,7,70,0,7.7
Habits (inbe),4.98e-27,5.07,892,655,91,1135.97
Delayed gastric emptying (fndg),2.04e-07,2.87,31,73,2,44.16
Receptor Activation (celf),1.21e-15,0.27,12,102,0,13.41
Carbapenems (antb),2.57e-09,1.59,2,361,0,2.01
Brackets (medd),8.14e-10,0.05,1,7,0,1.14
Triglycerides (bacs),6.01e-63,4.49,2615,676,120,850.75
Ventricular Septal Defects (cgab),3.52e-11,1.33,9,539,2,9.15
Phenylalanine (phsu),3.05e-18,0.2,31,54,0,48.8
Very high (fndg),4.67e-16,3.05,66,245,4,83.78
Cell membrane (celc),1e-250,0.09,42,409,1,46.31
Entire choroid plexus (bpoc),1.04e-19,0.11,1,42,0,1.02
Fetal Membranes (emst),2.34e-06,0.16,1,20,0,1.05
Mutant Proteins (aapp),5.6e-18,0.15,3,54,0,3.17
Saponins (strd),4.08e-12,0.17,4,39,0,4.41
ascorbate (phsu),5.45e-14,0.17,12,38,1,15.79
Adenylate Cyclase (aapp),5.58e-85,0.02,2,23,0,2.17
Organ (bpoc),1.11e-36,1.29,450,7072,61,478.63
"Pituitary Gland, Posterior (bpoc)",8.46e-10,0.12,4,17,0,4.94
Ventral Hernia (dsyn),4.32e-09,7.71,57,48,7,88.42
Hepatoblastoma (neop),7.59e-08,0.9,2,188,1,2.02
Ratio (inpr),8.58e-18,2.54,88,314,10,112.66
Carbon Tetrachloride (hops),2.49e-06,0.14,1,16,0,1.06
Manganese Superoxide Dismutase (aapp),1.43e-07,0.31,13,62,0,15.73
brush border membrane (celc),4.29e-29,0.04,2,17,0,2.24
Nucleus Accumbens (bpoc),6.74e-51,0.04,9,11,0,16.36
Ion-Exchange Chromatography Procedure (lbpr),1.52e-07,0.07,1,8,0,1.12
"Cell Line, Tumor (cell)",4.03e-42,0.14,1,117,0,1.01
Wound dehiscence (acab),7.36e-11,3.95,24,64,4,33.0
Cartilaginous exostosis (neop),1.63e-06,0.13,1,16,0,1.06
Entire lip (bpoc),1.94e-06,0.45,11,120,0,12.01
Acetylcysteine (aapp),1.63e-25,0.39,25,422,0,26.48
Dermatan Sulfate (bacs),4.58e-06,0.09,1,8,0,1.12
Nucleotides (nnon),1.84e-34,0.15,12,99,0,13.45
Insulin-Like Growth-Factor Binding Protein 1 (aapp),6.51e-16,2.13,91,24,6,30.33
Plasma C-reactive protein (aapp),3.98e-07,9.57,50,35,2,59.5
resistance education (topp),3.46e-07,5.27,204,37,4,43.71
Multiple Myeloma (neop),3.39e-77,1.03,43,2611,11,43.71
White Blood Cell Count procedure (lbpr),6.44e-17,2.97,61,220,11,77.91
Natriuretic Peptides|T (aapp),8.66e-08,556.12,2,43,2,2.09
granulosa cell (cell),4.09e-30,0.08,18,6,0,8.0
Cisplatin (inch),1.65e-111,0.77,24,3643,3,24.16
Endoribonucleases (aapp),1.04e-13,0.07,4,10,0,5.6
loss; bone (patf),7.41e-44,1.73,369,225,7,362.2
Spleen (bpoc),6.61e-152,0.32,36,2287,8,36.57
Acoustics (npop),5.43e-12,0.09,5,12,0,7.08
Cancer Diagnosis (diap),4.27e-16,4.18,52,552,27,56.9
Core Protein (aapp),1.97e-08,0.11,1,18,0,1.06
Recombinant human granulocyte colony stimulating factor (gngm),5.85e-08,0.24,1,39,0,1.03
Aqueous Humor (bdsu),1.45e-08,0.07,2,4,1,3.0
Amygdaloid structure (bpoc),3.62e-46,0.07,16,23,0,27.13
Thermogenesis (orgf),3.14e-13,1.26,97,22,0,26.99
Tension (mobd),4.22e-27,0.25,48,151,3,63.26
Essential Hypertension (dsyn),3.39e-61,1.87,671,420,28,682.89
Decreased renal function (fndg),5.68e-11,5.15,22,60,1,30.07
Phospholipase C (aapp),3.13e-30,0.03,2,14,0,2.29
Depressed mood (fndg),4.35e-19,2.06,660,1321,53,989.75
Neuroglia (cell),1.1e-56,0.11,2,117,0,2.03
pancreatic neoplasm (neop),2.56e-06,1.48,4,377,5,4.04
Body Size (orga),4.95e-08,15.11,454,91,35,109.24
Cerebral cortex (bpoc),1.21e-115,0.09,5,199,0,5.13
Continuous Positive Airway Pressure (topp),1.14e-11,3.69,457,453,26,902.04
Xylose (bacs),1.27e-08,0.05,1,5,0,1.2
Metalloproteases (aapp),8.72e-15,0.38,21,176,0,23.51
Cephalometry (diap),3.52e-09,1.3,56,2,0,2.07
Natural Products (bacs),4e-12,0.25,4,68,0,4.24
Class 1 (clas),1.58e-07,8.38,10,18,2,15.56
Wheezing (sosy),2.56e-08,1.08,110,85,1,150.68
Cochlear Implants (medd),1.32e-24,0.03,2,8,0,2.5
nucleocapsid location (celc),3.58e-77,0.12,13,178,1,13.95
Alternative Splicing (genf),1.55e-11,0.17,4,38,0,4.42
Diabetic Nephropathy (dsyn),6.67e-19,1.82,208,857,30,258.48
nervous system disorder (dsyn),1.44e-07,0.56,58,642,3,63.24
Synaptic Transmission (ortf),5.82e-24,0.04,2,14,0,2.29
Anemia (dsyn),3.11e-18,1.98,407,3287,101,457.4
Graft-vs-Host Disease (dsyn),2.3e-15,2.48,5,1039,0,5.02
Melatonin (horm),2.8e-58,0.2,81,214,1,111.66
Muramidase|LYZ (aapp),1.84e-19,0.1,3,37,0,3.24
Tunicamycin (antb),4.02e-12,0.08,4,9,0,5.78
Parkinsonian Disorders (dsyn),3.94e-18,0.26,12,111,0,13.3
Muscularis propria (tisu),1.22e-07,0.36,4,75,1,4.21
pituitary adenylate cyclase activating polypeptide (aapp),4.87e-17,0.09,2,26,0,2.15
Degenerative polyarthritis (dsyn),1.68e-168,1.35,1173,290,36,361.7
Senile Plaques (acab),2.31e-10,1.09,328,732,33,474.97
Rodent (mamm),1.79e-27,0.44,130,563,3,160.02
Pain intensity (fndg),1.49e-14,1.61,71,19,0,24.08
Urea (bacs),1.02e-13,0.47,69,332,13,83.34
Insulin used (fndg),8.84e-10,10.79,28,26,7,50.14
Physical shape (fndg),2.24e-15,1.5,127,105,3,191.81
Controlled Study (resa),1.24e-15,3.74,45,123,1,61.46
Toxin (bacs),1.9e-19,0.4,14,822,6,14.24
Bone Marrow Stem Cell (cell),6.58e-10,0.21,2,43,0,2.09
Leukopenia (dsyn),2.37e-06,1.29,12,397,2,12.36
Xenopus laevis (amph),2.88e-29,0.09,2,51,0,2.08
oncostatin M|OSM (aapp),7.24e-08,0.05,1,5,0,1.2
Terminally Ill Patients (humn),1.48e-06,1.03,3,198,1,3.05
Tracer (irda),1.15e-07,0.28,21,46,1,30.59
univariate analysis (resa),6.22e-28,8.24,49,304,8,56.9
Islets of Langerhans (bpoc),9.26e-14,0.26,46,66,2,78.06
Turtles (rept),1.59e-08,0.32,1,113,1,1.01
Sunlight (npop),1.38e-10,0.33,24,102,0,29.65
Hyperphagia (mobd),2.81e-11,4.0,162,29,4,34.19
Dinoprostone (eico),9.57e-99,0.11,24,185,0,27.11
internal risk factors (clna),1.2e-08,7.92,16,25,2,26.24
Polyomavirus (virs),5.73e-08,0.32,2,96,0,2.04
Bone Marrow Cells (cell),2.22e-76,0.18,6,285,0,6.13
"Hyperlipidemia, Familial Combined (dsyn)",2.54e-13,2.18,62,12,1,14.32
High Resolution Computed Tomography (diap),5.2e-07,1.95,49,160,4,64.01
Epoxy Compounds (orch),4.45e-07,0.07,2,5,0,2.8
Retinoid X Receptors (aapp),2.01e-06,0.16,4,16,0,5.0
Pituitary Gland (bpoc),1.04e-19,0.2,18,76,2,22.26
Vancomycin|TNIP1 (antb),3.71e-19,145.59,12,198,2,12.73
Hydrocephalus (dsyn),6.77e-18,0.8,14,628,1,14.31
Cartilage (tisu),2.22e-12,0.33,155,82,0,125.38
Carbachol (phsu),3.3e-41,0.02,2,9,0,2.44
Guillain-Barre Syndrome (dsyn),3.57e-08,0.34,1,185,0,1.01
Cessation of life (orgf),1.2e-100,5.49,554,29624,963,564.36
Necrotizing fasciitis (dsyn),2.69e-09,2.52,2,715,3,2.01
Sinoatrial Node (bpoc),2.23e-11,0.28,2,88,0,2.05
Somatotropin|TH (aapp),2.02e-82,171.76,82,69,5,127.06
Interleukin-15 (aapp),1.61e-06,0.36,8,64,0,9.0
Pisum sativum (plnt),5.6e-08,0.09,2,10,0,2.4
Cochlear structure (bpoc),4.16e-56,0.03,4,21,0,4.76
Enucleation procedure (topp),8.02e-08,1.01,8,289,1,8.22
Cytarabine (hops),2.99e-24,1.04,1,638,5,1.0
Brain Injuries (inpo),1.45e-36,0.96,21,1099,1,21.4
Glycerol (bacs),2.56e-07,0.36,73,85,0,135.69
Manganese (bacs),4.85e-12,0.21,21,41,0,31.76
Huntington Disease (dsyn),3.23e-09,0.32,35,84,2,49.58
Learning (menp),2.64e-17,0.2,23,60,0,31.82
Systolic dysfunction (patf),1.69e-14,4.89,43,363,11,48.09
Aminopeptidase (aapp),3.97e-08,0.12,2,16,0,2.25
Avulsed wound (inpo),1.16e-06,0.32,15,57,0,18.95
Transforming Growth Factor alpha|TGFA (aapp),1.82e-08,0.08,1,11,0,1.09
Serotonin (nsba),2.82e-140,0.11,75,178,7,106.6
"Staplers, Surgical, Linear (medd)",2.47e-10,6.56,13,28,10,19.04
ATP phosphohydrolase|DNAH8 (aapp),2.44e-28,0.05,1,24,1,1.04
Dryness of eye (sosy),9.87e-08,0.08,3,5,0,4.8
Ileostomy (topp),2.08e-06,2.94,20,123,10,23.25
Trimethoprim (phsu),2.8e-08,0.22,2,37,0,2.11
Astrocytes (cell),1.92e-131,0.08,3,208,0,3.04
paradigm (resa),3.34e-08,0.39,23,112,0,27.72
Absence Epilepsy (dsyn),3.12e-07,0.09,2,9,0,2.44
Aging (orgf),3.6e-39,1.81,821,2187,94,1129.2
Entire humerus (bpoc),1.59e-07,0.39,17,97,0,19.98
Endometrial Hyperplasia (dsyn),9.85e-08,1.75,41,18,1,25.9
hearing impairment (sosy),4.38e-29,0.25,55,165,3,73.33
MG 132 (aapp),2.56e-08,0.06,1,7,0,1.14
Otitis Media with Effusion (dsyn),1.68e-07,0.11,6,3,0,4.5
Surgeon (humn),1.82e-97,2.91,436,1944,83,533.79
Testicular Tissue (tisu),7.23e-08,0.09,1,12,0,1.08
Applanation tonometry (diap),4.23e-10,6.38,21,35,7,33.6
Gastrin releasing peptide (aapp),4.33e-07,0.09,1,11,0,1.09
Plasmids (bacs),1.85e-198,0.09,7,332,0,7.15
Succinates (orch),7.22e-07,0.11,3,9,0,4.0
Body Surface Area (diap),7.7e-20,10.96,110,78,13,133.31
A-23187 (antb),2.28e-31,0.01,1,3,0,1.33
Vocal cord structure (bpoc),5.95e-11,0.19,6,42,0,6.86
"Rats, Inbred SHR (mamm)",4.8e-72,0.11,18,135,1,20.4
"Echocardiography, Doppler (diap)",3.76e-09,2.57,60,138,6,86.09
Ubiquitin (aapp),2e-20,0.15,4,62,0,4.26
"Musculoskeletal torsion, function (phsf)",4.05e-06,0.35,14,62,0,17.16
Hyperandrogenism (dsyn),1.81e-27,6.66,348,13,4,13.49
Cyclic AMP (bacs),6.85e-90,0.04,10,39,0,12.56
Personality Traits (fndg),3.21e-12,1.55,74,46,2,74.59
Total excision of stomach NOS (topp),4.93e-16,3.41,57,423,25,64.68
Penicillins (antb),9.75e-12,0.36,3,310,1,3.03
"Aneurysm, Ruptured (dsyn)",5.29e-13,1.48,7,585,0,7.08
Right eye (bpoc),1.37e-10,0.34,13,99,0,14.71
"Oligonucleotides, Antisense (bacs)",4.2e-20,0.2,2,84,0,2.05
Hemodialysis (topp),3.43e-09,3.78,34,369,17,37.13
Hepatic Encephalopathy (dsyn),1.19e-12,0.98,9,430,3,9.19
Nitric Oxide Synthase (aapp),1.89e-40,0.29,29,307,3,31.74
Taurine (gngm),8.69e-27,0.16,17,69,4,21.19
Shell (bpoc),4.01e-34,0.13,6,82,0,6.44
Transaminase Assay (lbpr),6.06e-15,3.9,47,98,1,69.54
Structure of blastomere (emst),4.64e-10,0.12,2,22,0,2.18
Entire atrium (bpoc),3.1e-34,0.16,5,108,0,5.23
Nicorandil (phsu),2.75e-07,0.28,1,45,2,1.02
Semiconductor laser device (medd),1e-06,0.16,3,18,0,3.5
Entire abdominal wall (bpoc),4.67e-11,2.04,101,276,11,137.96
Muscular Dystrophies (dsyn),1.3e-06,0.35,16,69,1,19.71
Interleukin-5 (aapp),1.38e-19,0.2,15,78,0,17.88
Length (qnco),5.74e-60,3.97,204,1534,71,231.13
Cancer cachexia (neop),9.44e-21,4.26,41,109,11,56.42
"Receptors, Cell Surface (aapp)",1.48e-16,0.19,4,65,0,4.25
Free Radicals (bacs),1.25e-16,0.39,47,235,2,56.4
Fever (fndg),1.3e-50,1.31,77,3158,16,78.88
Physical object (mnob),4.22e-07,0.2,6,27,0,7.33
Somatostatin (aapp),1.1e-17,0.26,32,105,0,41.75
"Vaccines, Attenuated (imft)",7.14e-15,0.83,2,336,0,2.01
BCL2-Related Protein 11|BCL2L11 (bacs),6.08e-07,0.27,1,39,1,1.03
Meleagris gallopavo (bird),2.74e-06,2.47,46,274,5,53.72
TRYPSIN (aapp),3.27e-90,0.05,4,80,0,4.2
COS-7 Cells (cell),8.02e-10,0.08,1,13,0,1.08
Immunofluorescence (lbpr),7.49e-19,0.29,9,133,0,9.61
Silicon (bacs),6.92e-13,0.07,1,15,0,1.07
Spectrometers (medd),4.43e-07,0.13,2,15,0,2.27
"Hospitals, Veterans (hcro)",6.84e-08,6.54,12,44,2,15.27
"ESR1 protein, human|ESR1 (aapp)",2.19e-14,0.51,47,346,8,53.38
Pathogenesis (patf),3.52e-41,1.42,1420,4709,58,1848.2
Myoclonus (sosy),3.04e-07,0.3,4,52,0,4.31
sulforafan (phsu),1.59e-09,0.15,1,29,0,1.03
Odds Ratio (qnco),4.35e-14,6.18,37,59,2,60.2
Fluorescence (npop),1.14e-38,0.12,16,69,0,19.71
Marfan Syndrome (dsyn),4.79e-07,1.08,16,390,2,16.66
Flurbiprofen (orch),5.84e-07,0.05,1,4,0,1.25
Septic Shock (patf),8.52e-15,3.63,19,3502,26,19.1
Bacillus Calmette-Guerin (bact),5.96e-08,0.35,2,174,0,2.02
"N,N-dimethylarginine|SPANXC (phsu)",4.21e-54,224.03,20,83,11,24.82
sarcoma (neop),2.18e-84,0.95,18,2081,5,18.16
Logistic Regression (resa),1.46e-301,7.36,451,1022,60,650.02
"Immunoglobulin A, Secretory (aapp)",1.8e-08,0.23,5,41,0,5.61
Recombinant DNA (bacs),1.18e-19,0.22,10,95,0,11.05
Cyclic AMP-Dependent Protein Kinases (aapp),2.63e-56,0.07,10,55,0,11.82
Metabolic Diseases (dsyn),1.75e-10,4.22,799,606,54,1065.62
Tool (mnob),4.56e-10,0.75,223,1242,26,263.04
Clinicians (prog),1.09e-13,2.36,205,1648,26,230.5
Diptera (invt),2.3e-27,0.95,5,627,0,5.04
Water Specimen (inch),8.13e-22,0.11,2,45,0,2.09
Neck (blor),4.13e-61,2.08,1307,2822,45,1912.33
Hypertrophy of tonsils (dsyn),3.41e-07,2.54,27,2,0,2.15
Hematological Disease (dsyn),1.03e-09,1.41,21,772,6,21.57
Nystagmus (dsyn),4.89e-10,0.1,2,16,0,2.25
Thioredoxin|TXN (aapp),3.18e-11,0.14,2,30,0,2.13
Transplanted tissue (tisu),1.12e-17,1.24,132,2662,58,138.55
Inflammatory Bowel Diseases (dsyn),9.78e-07,0.64,249,789,11,327.58
Anthracycline Antibiotics (antb),9.76e-07,1.15,7,313,3,7.16
Neuropathic pain (sosy),3.89e-12,0.22,27,43,0,43.95
Muromonab-CD3 (aapp),1.45e-26,0.2,4,111,0,4.14
Myelography (diap),1.6e-06,0.13,2,14,0,2.29
ATM gene|ATM (gngm),1.25e-14,0.38,13,172,0,13.98
Angioplasty (topp),2.52e-16,1.91,18,1470,10,18.22
Cholesterol (bacs),2.07e-160,1.44,1158,885,94,1561.36
Systolic Pressure (orgf),3.87e-10,6.73,209,131,16,213.11
Maternal hypertension (dsyn),1.48e-10,4.43,29,57,1,43.75
NTRK1 gene|NTRK1 (gngm),3.69e-12,0.15,2,35,0,2.11
angiogenin|ANG (aapp),4.45e-06,0.14,2,15,0,2.27
Phosphatidyl glycerol (bacs),2.36e-09,0.04,1,5,0,1.2
Interleukin-4|IL4 (aapp),2.27e-11,0.08,1,15,0,1.07
UCP2 (gngm),1.78e-06,1.6,28,7,0,8.75
Nodule (acab),2.55e-19,0.75,22,1003,4,22.48
Messages (inpr),4.57e-07,3.69,102,124,13,185.9
Monoamine Oxidase (aapp),1.34e-20,0.08,9,15,0,14.4
GABA Receptor (aapp),6.08e-09,0.13,3,17,1,3.53
Acute infectious disease (dsyn),5.2e-11,0.87,15,390,2,15.58
Supplementary Feeding (topp),1.51e-08,5.82,16,30,6,24.53
Na(+)-K(+)-Exchanging ATPase (aapp),9.96e-17,0.15,9,43,0,10.88
Kidney Calculi (patf),1.2e-36,2.15,210,55,5,69.4
Cardiovascular arteriosclerosis unspecified (dsyn),1.25e-48,7.35,74,244,14,96.44
Proton Pump (gngm),8.65e-07,0.07,2,5,0,2.8
Soy Proteins (aapp),5.39e-12,1.51,75,51,4,85.68
Falls (fndg),3.31e-21,1.65,321,1297,39,400.45
prevention of disorder (topp),3.97e-26,4.03,70,251,10,89.52
Monoamine Oxidase Inhibitors (phsu),5.74e-10,0.13,1,24,0,1.04
Verbal (orgf),5.98e-09,0.29,17,65,0,21.45
lysophosphatidic acid (lipd),6.03e-15,0.09,3,23,0,3.39
Combined Modality Therapy (topp),2.63e-06,1.56,268,3738,21,287.21
Naltrexone (phsu),9.32e-14,0.24,15,69,3,18.26
Interleukin-13 (aapp),1.41e-17,0.23,6,90,0,6.4
Aspartic Acid (gngm),4.27e-07,0.06,1,5,0,1.2
Binding Sites (rcpt),1.3e-141,0.06,14,148,1,15.32
Probes (medd),2.37e-57,0.28,108,428,2,135.25
Percutaneous endoscopic gastrostomy (topp),1.2e-08,2.96,27,195,18,30.74
Botulinum Toxin Type A (phsu),2.32e-10,0.05,2,5,0,2.8
Immunocompetent (clna),4.3e-22,1.38,3,711,0,3.01
Slide (resd),5.68e-14,0.38,12,176,0,12.82
Bronchoalveolar Lavage (diap),7.28e-07,0.73,4,287,0,4.06
Sickle Cell Anemia (dsyn),2.69e-07,0.87,113,1076,11,124.87
Erectile dysfunction (dsyn),4.98e-25,1.12,282,143,12,215.51
Cell Adhesion (celf),4.74e-31,0.27,7,204,0,7.24
Chromosomes (celc),1.88e-27,0.15,15,73,0,18.08
ethnic differences (fndg),3.65e-21,7.71,126,115,11,219.96
Bradykinin (aapp),8.8e-39,0.12,14,70,1,16.8
Recombinant Tumor Necrosis Factor-Alpha (aapp),1.48e-07,0.08,1,9,0,1.11
Uridine Triphosphate (bacs),3.39e-09,0.04,1,4,0,1.25
Gamma Knife Radiosurgery (topp),1.45e-07,1.5,1,254,0,1.0
Self Administration (topp),7.39e-22,0.07,6,19,0,7.89
Congestion (patf),9.96e-07,1.21,5,288,2,5.09
Hydrolase (aapp),2.96e-22,0.09,3,34,0,3.26
Splenocyte (cell),1.2e-15,0.3,2,197,0,2.02
Chronic inflammation (patf),3.36e-20,2.72,379,619,32,611.05
Somatosensory Evoked Potentials (ortf),1.84e-08,0.16,5,24,0,6.04
Graft loss (patf),4.42e-09,5.43,18,535,29,18.61
Integral Membrane Proteins (aapp),1.98e-17,0.16,4,54,2,4.3
Well nourished (fndg),3.46e-15,6.49,59,71,15,108.03
Adipose tissue (tisu),3.54e-172,2.85,1489,310,60,374.54
Verapamil (orch),5.7e-67,0.1,4,124,0,4.13
Transmission Electron Microscopy (lbpr),3.13e-16,0.24,4,87,0,4.18
Left atrial hypertrophy (fndg),7.42e-11,5.12,24,47,4,36.26
Mandible (bpoc),2.1e-40,0.25,74,242,0,96.63
Calcium ion (elii),4.16e-18,0.06,2,18,0,2.22
Normal cell (cell),7.09e-37,0.24,3,195,0,3.05
Papillomavirus Infections (dsyn),2.02e-07,0.44,13,377,1,13.45
intact cell (cell),8.62e-27,0.02,1,7,0,1.14
ARGINASE (aapp),3.29e-07,0.29,6,50,0,6.72
Inferior Colliculus (bpoc),2.14e-74,0.07,9,83,0,9.98
Putrescine (nsba),7.42e-17,0.05,1,12,1,1.08
Lymphoid Cells (cell),4.14e-21,0.14,1,61,0,1.02
HEXOKINASE (aapp),7.34e-12,0.07,2,11,0,2.36
Necrosis (patf),2.52e-34,1.05,96,2090,7,100.41
Diastasis (patf),6.27e-30,0.29,78,231,6,104.34
Amides (orch),1.47e-18,0.07,3,19,0,3.47
Fatty Liver (dsyn),4.44e-15,5.18,955,239,30,298.81
"Osteoarthritis, Knee (dsyn)",1.31e-120,4.91,876,20,7,20.46
anti-IgE|IGHE (aapp),1.04e-07,0.06,1,7,0,1.14
Wasting (dsyn),1.64e-32,3.93,136,256,41,208.25
Plant Leaves (plnt),9.32e-30,0.21,1,125,0,1.01
Endothelin-1 (aapp),3.69e-16,0.37,80,226,1,108.32
Bicuspid (bpoc),7.21e-22,0.21,1,96,0,1.01
Atresia (cgab),2.28e-16,0.77,4,507,0,4.03
Phenoxybenzamine (phsu),8.32e-07,0.07,1,7,0,1.14
Liver diseases (dsyn),7.76e-51,2.24,453,2369,68,539.62
Charts (medd),1.03e-76,4.31,191,511,14,262.39
END ORGAN DAMAGE (dsyn),4.63e-11,4.42,30,163,5,35.52
Transition zone of anal mucous membrane (bpoc),7.86e-26,8.07,35,118,8,45.38
Cardiovascular event (fndg),4.57e-286,8.66,393,3943,241,432.17
imatinib (phsu),3.03e-06,0.64,12,784,0,12.18
Glycyrrhizic Acid (phsu),2.2e-07,0.11,1,15,0,1.07
Staphylococcus aureus (bact),1.78e-54,0.9,19,1444,8,19.25
high-dose chemotherapy (topp),2.02e-11,2.14,7,848,2,7.06
Octreotide (horm),1.61e-19,0.42,27,293,1,29.49
targeted prevention (topp),3.16e-07,6.98,9,24,2,12.38
enzyme activity (moft),2.03e-42,0.14,18,109,1,20.97
Chenodeoxycholic Acid (bacs),7.16e-07,0.11,3,10,0,3.9
Monoclonal Antibodies (aapp),8.83e-217,0.25,23,1342,2,23.39
trafficking (celf),4.52e-77,0.13,15,197,0,16.14
winter (tmco),3.36e-07,2.43,44,199,4,53.73
Acetyl Coenzyme A (bacs),3.9e-08,0.08,1,10,0,1.1
Predisposition (orga),3.12e-07,2.19,132,269,6,196.77
Burn injury (inpo),8.7e-14,1.47,45,1523,19,46.33
Mitral Valve Insufficiency (dsyn),3.48e-12,1.74,30,1383,12,30.65
hepatic arterial infusion (topp),1.83e-09,1.1,1,250,1,1.0
Lactoferrin (aapp),2.33e-32,0.14,6,83,1,6.43
Angiotensin Receptor (aapp),5.97e-12,3.59,64,615,16,70.66
Chondrocytes (cell),3.7e-61,0.05,12,22,0,18.55
Glucosides (carb),6.47e-09,0.07,1,9,0,1.11
Furosemide (phsu),2.4e-19,0.33,13,170,0,13.99
Dorsal grey horn (bpoc),1.42e-33,0.01,1,6,0,1.17
Migrants (humn),4.18e-09,2.17,61,165,2,83.55
No status change (fndg),2.71e-06,1.95,118,273,5,169.0
Fragility (comd),2.64e-10,2.44,49,174,7,62.8
Antipsychotic Agents (phsu),9.09e-21,1.09,426,631,37,713.6
Glutamine (aapp),8.51e-20,0.37,47,248,4,55.91
Adrenergic Receptor (aapp),6.65e-25,0.29,88,187,2,129.41
Cardiovascular Abnormalities (dsyn),1.24e-06,3.02,23,100,4,28.29
Thymoma (neop),6.1e-16,0.92,2,337,0,2.01
Transcatheter arterial embolization (topp),2.14e-07,1.01,2,184,0,2.02
Periodontitis (dsyn),4.49e-11,0.86,257,98,4,135.37
bortezomib (orch),7.79e-15,0.74,4,562,0,4.03
Pericardial sac structure (bpoc),2.91e-06,0.95,8,239,2,8.27
Dendrites (celc),8.33e-52,0.02,1,13,0,1.08
Uterine Cancer (neop),6.16e-08,2.77,26,110,9,32.15
soluble fraction (celc),1.9e-16,0.05,1,14,0,1.07
Chloride Channels (aapp),3.93e-08,0.2,2,32,0,2.12
1-Phosphatidylinositol 3-Kinase (gngm),1.27e-31,0.15,15,84,0,17.68
contextual factors (ftcn),6.11e-36,2.88,222,1335,31,258.92
Sodium Chloride (bacs),7.08e-180,0.32,166,1592,9,183.31
JTB gene|JTB (gngm),7.18e-07,0.26,3,39,0,3.23
Hypertensive (fndg),1.15e-14,3.0,1995,2092,182,3897.5
Acute Promyelocytic Leukemia (neop),2.97e-15,0.85,5,438,8,5.06
Ischemia (dsyn),3.04e-75,0.89,130,3228,35,135.24
microbial (orgm),1.71e-20,0.42,28,641,2,29.22
Glass (mnob),4.24e-36,0.1,4,64,1,4.25
Cytoskeletal Proteins (aapp),2.34e-13,0.14,2,35,0,2.11
Entire ear (bpoc),1.42e-32,0.22,23,157,1,26.37
Aluminum (elii),1.76e-25,0.1,2,48,1,2.08
Macaca fascicularis (mamm),1.11e-15,0.18,6,58,0,6.62
Vesico-Ureteral Reflux (dsyn),6.95e-14,0.14,10,29,0,13.45
Hepatitis B Virus (virs),1.01e-06,0.92,61,631,6,66.9
"Diet, Mediterranean (topp)",2e-34,11.47,141,112,24,200.96
Venous malformation (cgab),4.92e-06,0.1,1,10,0,1.1
MAX (gngm),1.66e-08,1.23,77,65,7,119.87
mRNA Precursor (bacs),1.16e-06,0.07,1,7,0,1.14
STN gene|EEF1A2 (aapp),1.51e-09,3.23,48,379,12,54.08
"Fungi, Filamentous (fngs)",1.03e-12,0.92,2,287,1,2.01
ROS1 (gngm),3.53e-17,0.33,8,142,1,8.45
Households (famg),9.9e-39,2.71,264,579,8,384.37
overdose (inpo),7.33e-07,1.67,6,416,1,6.09
mycophenolate mofetil (orch),1.23e-09,0.99,28,572,7,29.37
Amyloid Fibrils (aapp),7.23e-08,0.17,1,27,0,1.04
Sclera (bpoc),1.08e-15,0.04,1,9,0,1.11
Ceramics (mnob),3.79e-14,0.12,11,17,0,18.12
Urinary concentration (ortf),7.33e-07,3.04,158,66,2,93.57
Incontinence (dsyn),2.64e-26,1.53,165,101,0,162.82
Tissue fiber (tisu),5.09e-84,0.1,31,105,1,40.15
Myosin Heavy Chains (aapp),2.1e-19,0.13,4,46,0,4.35
Calcium Channel (aapp),9.72e-29,0.18,5,105,0,5.24
Mitral Valve (bpoc),1.23e-07,1.22,7,360,3,7.14
Immune thrombocytopenic purpura (dsyn),3.81e-06,0.32,2,61,0,2.07
Membrane Glycoproteins (aapp),1.52e-16,0.24,3,86,1,3.1
Closure by clip procedure (topp),9.87e-09,1.6,2,372,1,2.01
Tuberculosis (dsyn),5.12e-47,0.89,224,3268,55,239.35
multicatalytic endopeptidase complex (aapp),3.43e-47,0.15,6,138,0,6.26
Phenytoin (orch),3.1e-28,0.24,8,153,1,8.42
Gait (fndg),7.55e-16,1.44,102,62,6,99.69
Dendritic Cells (cell),4.43e-106,0.19,3,407,1,3.02
father (humn),9.08e-13,1.7,190,168,5,316.55
Fluoxetine (orch),9.86e-18,0.22,35,70,1,52.5
Coronary artery calcification (dsyn),2.16e-34,6.46,176,200,15,330.88
Secretory Vesicles (celc),1.03e-18,0.05,3,11,0,3.82
Precipitation (npop),1.02e-06,0.3,2,53,0,2.08
Electron Transport (moft),1.11e-07,0.07,2,5,0,2.8
SDS-PAGE (lbpr),1.27e-32,0.09,3,55,0,3.16
pioglitazone (orch),5.91e-10,1.91,200,166,9,303.78
epigallocatechin gallate (orch),5.69e-10,0.32,44,86,0,66.51
Plasminogen Activator Inhibitor 1 (aapp),2.78e-26,1.5,244,212,5,396.2
Protein Isoforms (gngm),1.38e-06,0.2,7,23,0,9.13
Gestational Age (orga),3.75e-147,4.35,367,914,18,514.36
Methodology (inpr),3.04e-06,1.76,116,688,20,135.56
Skin fibroblast (cell),2.52e-39,0.05,3,34,0,3.26
STAT5A gene|STAT5A (gngm),4.11e-12,0.19,3,46,0,3.2
Angiotensins (aapp),2.48e-08,0.39,20,111,2,23.6
Tremor (sosy),8.51e-20,0.23,7,99,1,7.49
Pre-Eclampsia (dsyn),3.77e-47,2.3,774,1589,49,1151.01
Proteoglycan (aapp),8.43e-52,0.08,7,65,0,7.75
"Antibiotics, Aminoglycoside (antb)",6.9e-08,0.38,7,115,0,7.43
Residual function (diap),2.51e-40,3.98,86,420,46,103.61
Heart Ventricle (bpoc),1.73e-16,0.36,12,169,1,12.85
3/9 (fndg),2.16e-26,6.21,48,130,3,65.72
Renal mass (fndg),2.03e-14,2.58,62,178,5,83.6
Channel Blockers (phsu),3.41e-10,0.12,2,22,0,2.18
Methemoglobin (aapp),4.98e-06,0.29,2,38,0,2.11
ITGAM gene|ITGAM (gngm),2.23e-08,0.42,11,118,0,12.03
Bacterial Endocarditis (dsyn),2.97e-30,1.99,3,1370,0,3.01
Nerve (tisu),1.35e-06,0.33,19,63,0,24.73
Chronic liver disease NOS (dsyn),3.39e-24,2.03,225,991,29,276.08
Ovary (bpoc),2.39e-54,0.37,135,718,6,160.38
Early complication (sosy),5.34e-28,6.37,40,232,22,46.9
Vertebrates (vtbt),4.86e-110,0.12,13,266,0,13.64
"Osteoporosis, Postmenopausal (dsyn)",4.34e-08,1.64,89,76,4,140.9
Cannabinoids (orch),9.6e-14,0.18,5,51,0,5.49
Genus Capra (mamm),8.68e-21,0.15,1,64,0,1.02
Encounter due to singleton (fndg),5.21e-60,8.94,165,209,8,295.26
Hormone-refractory prostate cancer (neop),2.76e-06,1.17,3,220,1,3.04
Filament (celc),1.75e-27,0.19,3,105,1,3.09
Ewings sarcoma (neop),6.01e-17,0.89,4,393,1,4.04
Restenosis (acab),1.47e-11,1.33,23,847,8,23.62
Incisor (bpoc),2.31e-22,0.11,15,22,0,25.23
Jaw (bpoc),1.29e-25,0.29,17,185,1,18.56
"Malaria, Falciparum (dsyn)",2.7e-14,0.88,9,399,1,9.2
Glucagon-Like Peptide 1 (aapp),9.12e-20,2.2,172,68,3,94.88
Feeding behaviors (inbe),1.48e-19,13.3,948,42,11,43.86
QTc (fndg),6.86e-09,3.41,29,126,4,35.67
Interleukin 2 Receptor (aapp),6.81e-15,0.23,5,76,0,5.33
Demyelination (patf),4.46e-20,0.22,2,94,0,2.04
Narcotic Antagonists (phsu),6.1e-08,0.25,11,44,0,13.75
Gold (elii),6.96e-23,0.18,15,74,1,18.04
Middle aged adult (humn),3.96e-10,9.2,142,74,15,112.56
"Pituitary Gland, Anterior (bpoc)",1.17e-15,0.11,2,32,0,2.12
Cancer Treatment (topp),4.9e-07,1.34,40,860,8,41.86
Interferon-alpha (aapp),4.77e-23,0.38,15,584,1,15.39
MAPK1 gene|MAPK1 (gngm),9.88e-07,0.13,2,11,1,2.36
Cytokinesis of the fertilized ovum (celf),3.17e-79,0.11,16,151,2,17.7
Aves (bird),6.66e-19,0.98,6,490,0,6.07
"T-Lymphocytes, Cytotoxic (cell)",1.91e-29,0.23,2,153,0,2.03
Erythrocytes (cell),4.08e-117,0.26,270,690,6,375.65
nerve supply (ortf),4.19e-29,0.1,9,47,0,10.72
Epirubicin (orch),1.12e-12,0.94,2,295,1,2.01
Craniocerebral Trauma (inpo),2.71e-20,1.54,14,1204,8,14.16
Specific antigen (imft),2.07e-10,0.15,1,31,0,1.03
Pulmonary arterial hypertension (dsyn),2.22e-10,1.59,36,1209,9,37.07
"Mitochondria, Heart (celc)",3.12e-09,0.05,1,7,0,1.14
study data (resa),2.31e-08,3.96,23,92,2,28.75
Autism spectrum disorder (mobd),2.36e-11,0.27,76,31,1,43.64
Diabetes Mellitus (dsyn),0.0,4.01,2228,4525,351,3325.01
In Situ Hybridization (lbpr),3.63e-46,0.25,2,331,0,2.01
Mycotoxins (bacs),8.54e-20,0.11,2,43,0,2.09
Chromatin (aapp),5.07e-64,0.1,6,115,0,6.31
Borderline Personality Disorder (mobd),3.63e-10,0.18,15,25,0,24.0
Streptococcus Group B (bact),9.15e-13,1.05,2,312,0,2.01
Subtype (clas),8.85e-07,3.37,45,445,8,49.55
"Stenosis, unspecified (patf)",5.91e-09,1.08,199,1981,21,218.99
RNA-Directed DNA Polymerase (aapp),5.97e-27,0.08,2,40,0,2.1
Hospitals (hcro),3.84e-123,3.07,1021,8664,158,1141.32
Singlet Oxygen (bacs),2.93e-07,0.09,1,11,0,1.09
everolimus (orch),6.09e-08,1.17,8,368,3,8.17
mesalamine (phsu),4.71e-10,0.19,8,35,1,9.83
ATP phosphohydrolase (aapp),2.5e-57,0.04,1,44,0,1.02
Spirometry (diap),1.24e-14,4.73,150,164,15,287.2
Electron Microscopy (lbpr),1.05e-43,0.19,10,180,2,10.56
Basal cell carcinoma (neop),1.24e-19,0.33,12,171,0,12.84
Control Animal (anim),9.69e-18,0.29,4,137,0,4.12
agonists (phsu),8.44e-59,0.42,239,1063,6,292.74
IMMUNOHISTOCHEMICAL (lbpr),2.82e-07,1.31,14,442,0,14.44
"Hospitals, Pediatric (hcro)",3.02e-06,3.08,38,262,2,43.51
Galactose (carb),6.68e-23,0.05,2,16,0,2.25
Factor VIIa (aapp),3.71e-22,0.84,3,489,0,3.02
Misoprostol (eico),1.64e-12,0.39,16,147,0,17.74
Wound complication (inpo),4.21e-51,9.02,132,164,25,238.24
"Analysis, Cohort (resa)",2.3e-19,5.13,38,246,17,43.87
Antidiabetics (phsu),7.73e-26,3.85,290,381,27,510.73
Lanugo (bpoc),1.94e-08,0.4,9,114,0,9.71
Alopecia Areata (dsyn),4.41e-08,0.08,4,2,0,3.0
Life Style (socb),1.07e-27,13.58,334,137,36,193.19
Chemical Surfactants (chvf),1.7e-06,1.65,1,245,0,1.0
Pregnant Women (humn),5.92e-79,2.71,1621,2625,74,2622.01
Aldehyde Reductase (aapp),1.95e-08,0.12,3,16,0,3.56
Monoamine Oxidase A (aapp),8.31e-07,0.09,2,7,0,2.57
Interferon Alfa-2a (aapp),2.69e-06,0.29,3,41,0,3.22
Gastrectomy (topp),0.0,7.56,1112,1586,331,1891.66
bevacizumab (phsu),3.99e-45,0.93,21,1336,9,21.33
Amphibia (amph),6.81e-11,0.31,1,165,0,1.01
Methyltransferase (aapp),5.79e-14,0.16,2,45,0,2.09
Synovial Membrane (bpoc),4.71e-26,0.11,17,26,0,28.12
Mammalian Cell (cell),3.9e-59,0.08,3,85,0,3.11
Laparoscopic adjustable gastric banding (topp),6.64e-25,18.14,316,49,97,56.6
Areae (plnt),1.86e-06,0.78,180,2102,19,195.41
Gastric ulcer (dsyn),1.54e-17,0.28,16,124,1,18.06
eIF-2 Kinase|PKLR|EIF2AK2 (aapp),1.96e-10,0.1,1,20,0,1.05
Public school (orgt),6.29e-07,8.46,105,3,1,3.09
Stress (fndg),6.32e-12,0.97,596,1129,24,910.63
"Fatty Acids, Nonesterified (lipd)",5.32e-72,1.56,391,103,8,130.13
High Risk Populations (popg),7.35e-72,5.46,170,906,29,201.9
Mannans (carb),1.17e-06,0.14,1,18,0,1.06
IL2 gene|IL2 (gngm),3.51e-64,0.2,11,278,0,11.44
Granulocyte-Macrophage Colony-Stimulating Factor|LAMC2 (aapp),3.43e-12,0.29,2,111,0,2.04
Gut (bpoc),1.59e-10,0.66,113,729,3,130.52
Tetanus (dsyn),4.11e-12,0.86,2,248,0,2.02
Corneal Diseases (dsyn),4.22e-32,0.06,5,24,0,6.04
Animalia (anim),1.02e-43,0.43,66,744,1,71.85
Basement membrane (tisu),3.28e-37,0.1,4,71,0,4.23
Absence of pain sensation (sosy),9.52e-13,0.32,36,113,4,47.47
Ciprofloxacin (orch),1.93e-32,0.29,5,284,1,5.09
LY 294002 (phsu),7.21e-18,0.17,1,62,0,1.02
Vitamin B 12 (vita),1.55e-07,1.82,167,156,7,301.72
Peritonitis (dsyn),4.3e-09,1.57,32,1289,26,32.79
cytarabine/daunorubicin protocol (topp),6.5e-09,3.8,20,60,4,26.67
purification (lbpr),2.64e-52,0.12,5,124,1,5.2
Formaldehyde (hops),2.77e-14,0.11,2,28,0,2.14
Insurance (idcn),5.9e-08,4.81,22,133,2,25.64
Vasculitis (dsyn),2.71e-15,0.73,12,768,0,12.19
INHIBIN (aapp),2.44e-07,0.21,16,21,0,28.19
Banding procedure (topp),2.75e-08,2.37,35,126,9,44.72
rho|RHO|RHOD (aapp),3.5e-15,0.07,2,18,0,2.22
Urethra (bpoc),1.97e-08,0.26,13,51,0,16.31
Lamivudine (nnon),1.05e-11,0.42,14,364,2,14.54
"Spectrum Analysis, Mass (lbpr)",3.21e-11,0.38,40,153,1,50.46
Carcinogenicity (neop),1.45e-09,0.28,2,65,0,2.06
Meningitis (dsyn),6.3e-49,1.23,9,1472,0,9.06
Microspheres (mnob),5.64e-10,0.18,1,36,0,1.03
Increased uric acid level (fndg),4.86e-08,9.99,19,23,0,34.7
Chemicals (chem),2.97e-43,0.39,45,505,0,49.01
Lymphocyte Function-Associated Antigen-1 (aapp),9.45e-10,0.1,3,14,0,3.64
Acquired Immunodeficiency Syndrome (dsyn),4.51e-54,0.98,239,3966,43,253.4
N-terminal pro-B-type natriuretic peptide|HSD3B1 (horm),1.35e-93,8130.7,33,256,11,37.25
Larva (invt),3.44e-27,1.21,3,751,0,3.01
T-Cell Receptor (aapp),7.41e-50,0.1,2,100,0,2.04
Gastric banding (topp),3.61e-19,16.38,222,38,77,44.5
Acetazolamide (orch),3.09e-06,0.25,14,30,0,20.53
Cavia (mamm),2.78e-251,0.04,4,183,0,4.09
Congenital Disorders (dsyn),2.87e-07,0.91,7,235,1,7.21
Entrapment (anab),8.71e-08,0.31,7,60,0,7.82
QUANTUM (phsu),3.81e-14,0.02,1,2,0,1.5
Transjugular intrahepatic portosystemic shunt procedure (topp),9.65e-10,0.82,27,519,1,28.4
Anions (elii),9.93e-72,0.05,7,56,0,7.88
Co-morbid conditions (fndg),3.13e-99,7.92,139,756,54,164.56
Hepatitis B Surface Antigens (imft),3.22e-07,0.43,13,105,3,14.61
Epilepsy (dsyn),4.1e-93,0.43,194,1497,7,219.14
Arylesterase (aapp),2.3e-06,1.25,52,46,5,86.69
Hematopoietic stem cells (cell),4.29e-38,0.27,8,247,0,8.26
Azoospermia (dsyn),2.32e-06,0.23,22,12,0,18.55
Coronary heart disease (dsyn),0.0,3.89,1321,4320,408,1724.94
Prognostic Factor (clna),3.65e-06,6.76,79,6836,120,79.91
BAX gene|BAX (gngm),3.28e-25,0.34,13,306,0,13.55
Stratum corneum (tisu),1.36e-16,0.04,1,10,0,1.1
Trimethoprim-Sulfamethoxazole Combination (orch),1.75e-15,0.86,8,481,9,8.13
Lupus Nephritis (dsyn),5.73e-12,0.79,9,429,1,9.19
Soluble antigen (imft),1.53e-07,0.16,1,22,1,1.05
Bromocriptine (phsu),4.74e-31,0.1,11,42,0,13.88
Opioids (phsu),9.62e-19,0.55,110,636,8,129.03
day (tmco),9.1e-23,3.58,187,2187,38,202.99
Structure of mucous membrane of nose (tisu),9.7e-20,0.09,1,33,0,1.03
Cytotoxic agent (phsu),9.26e-11,0.92,3,309,5,3.03
Sodium Nitroprusside (phsu),1.45e-17,0.19,16,60,3,20.27
Diethylstilbestrol (hops),1.21e-10,0.37,7,183,1,7.27
Delayed Graft Function (patf),2.37e-10,3.52,26,168,15,30.02
Interstitial Cystitis (dsyn),8.3e-07,0.11,5,4,0,7.2
Lymphoid Tissue (tisu),6.24e-13,0.28,2,109,0,2.04
Diabetic (fndg),5.98e-175,3.31,4497,5643,454,8080.73
Universities (orgt),1.26e-82,2.54,643,1463,45,925.6
Classification (clas),1.09e-75,3.59,230,731,28,302.37
Plasticity (npop),1.69e-71,0.08,18,87,0,21.72
Term Birth (orgf),9.05e-10,5.96,31,45,2,52.36
Left ventricular mass (fndg),1.22e-44,8.67,401,261,72,430.88
Entire paraventricular nucleus (blor),5.43e-11,0.1,5,13,0,6.92
Head (blor),2.12e-55,0.99,151,3093,12,158.37
Nephrolithiasis (dsyn),6.09e-13,2.28,114,43,2,59.22
Streams (npop),4.49e-11,0.23,1,53,1,1.02
Mucormycosis (dsyn),3.09e-07,2.49,1,413,0,1.0
RIBOSOMAL (celc),2.06e-14,0.14,2,41,0,2.1
CD40 Ligand (aapp),7.74e-08,0.24,2,40,0,2.1
6-Mercaptopurine (phsu),9.42e-09,0.27,5,54,0,5.46
Concanavalin A (aapp),2.67e-35,0.09,5,54,0,5.46
Smoker (fndg),1.76e-34,2.7,512,901,55,802.95
Laparoscopic-assisted right colectomy (topp),1.04e-09,9.37,17,25,2,28.56
Centrifugation (lbpr),4.19e-12,0.1,3,18,0,3.5
Leukotrienes (bacs),2.58e-16,0.15,3,49,0,3.18
Dinoprost (horm),1.08e-31,0.11,15,44,1,20.11
Fetal Growth Retardation (patf),4.01e-18,2.17,142,602,15,175.5
Phytohemagglutinins|LBR (aapp),1.22e-07,0.14,4,13,1,5.23
One-Step dentin bonding system (bodm),3.84e-07,0.14,3,17,0,3.53
uptake (phsf),1.42e-74,0.18,68,255,2,86.13
Ligands (chem),1.09e-18,0.13,2,46,0,2.09
Leptin|HSD3B1 (aapp),3.34e-121,3303.6,696,66,24,72.26
"Tomography, Emission-Computed, Single-Photon (diap)",5.05e-13,0.44,66,271,2,82.07
Thrombus (dsyn),1.5e-23,1.07,102,1865,14,107.58
Chromosome Pairing (celf),4.76e-88,0.06,10,77,0,11.3
Pre-diabetic (fndg),1.17e-23,12.55,172,98,17,153.84
Aryl Hydrocarbon Receptor|AHR (aapp),5.14e-13,0.16,5,40,0,5.62
FNDC5 (gngm),3.44e-09,3.67,51,2,1,2.08
Sjogren's Syndrome (dsyn),3.93e-20,0.17,9,67,0,10.21
Asparagine (aapp),1.66e-07,0.16,4,19,1,4.84
"MAPK14 protein, human|MAPK14 (aapp)",2.12e-23,0.18,5,85,0,5.29
nigrostriatum (bpoc),1.98e-09,0.09,2,12,0,2.33
depolarization (patf),7.26e-44,0.07,1,55,0,1.02
Structure of arteriole (bpoc),1.79e-22,0.31,8,168,1,8.38
"Breast Feeding, Exclusive (inbe)",1.13e-09,5.15,33,52,0,53.94
peroxisome (celc),1.4e-19,0.05,1,15,0,1.07
"Interleukin 2 Receptor, Alpha|IL2RA|ISG20 (aapp)",2.07e-13,0.34,7,134,0,7.37
Racial group (popg),1.65e-260,5.94,737,1206,99,1187.39
Bicarbonates (inch),1.72e-08,0.41,30,134,7,36.72
Levodopa (aapp),2.7e-78,0.07,15,79,0,17.85
Chemotactic Factors (bacs),3.51e-16,0.32,8,127,0,8.5
Apolipoproteins B|APOB (aapp),3.5e-38,2.13,255,81,10,106.73
Detrusor (bpoc),1.46e-07,0.27,41,24,1,38.05
Pseudomonas aeruginosa (bact),3.32e-23,0.77,24,1088,6,24.53
Transforming Growth Factor alpha (aapp),2.83e-16,0.11,2,35,0,2.11
beta-2 Adrenergic Receptors (aapp),2.2e-06,0.36,17,72,0,21.01
Evaluable Disease (dsyn),2.93e-06,2.23,36,1293,2,37.0
Leg (blor),3.79e-07,1.24,124,207,3,198.28
Young adult (humn),3.31e-110,3.42,1467,2088,89,2497.69
Enhancer (nnon),3.41e-14,0.14,5,36,0,5.69
Functional Status (fndg),1.41e-56,4.35,152,718,31,184.18
Naloxone (orch),8.19e-57,0.1,6,106,0,6.34
Assessment procedure (hlca),1.06e-308,2.78,2180,4707,193,3189.65
Locally Advanced Malignant Neoplasm (neop),2.03e-08,1.91,23,1250,17,23.42
Thromboplastin (aapp),1.47e-25,0.34,29,255,2,32.3
Glycine max (plnt),4.71e-20,0.09,1,35,0,1.03
Country (geoa),5.36e-08,2.22,166,1452,24,184.98
Disease Outcome (fndg),9.95e-14,5.39,38,383,12,41.77
Platelet-Derived Growth Factor (aapp),6.81e-44,0.1,2,86,0,2.05
Carotid Body (bpoc),3.05e-11,0.12,4,21,0,4.76
Chronic Obstructive Airway Disease (dsyn),6.32e-202,2.21,1115,4537,393,1389.02
Sarcoidosis (dsyn),8.38e-44,0.26,24,280,1,26.06
Brothers (humn),3.25e-06,0.46,12,102,3,13.41
Calcineurin (aapp),1.03e-22,0.14,2,63,1,2.06
Iron (phsu),7.34e-17,0.55,364,1051,16,490.07
Cytomegalovirus Infections (dsyn),1.46e-29,0.84,10,772,3,10.13
"Nephrolithotomy, Percutaneous (topp)",1.07e-15,3.0,131,26,1,31.16
Small RNA (bacs),1.32e-14,0.32,6,134,0,6.27
Protein Biosynthesis (moft),1.93e-20,0.22,31,91,1,41.56
Chickens (bird),4.94e-18,1.04,4,467,0,4.03
Neurilemmoma (neop),2.75e-30,0.15,3,88,0,3.1
Dilution (lbpr),4.82e-07,0.96,141,120,4,222.13
Infiltration (patf),1.36e-37,1.03,91,2068,6,95.0
Sphingosine (bacs),2.16e-07,0.09,2,9,0,2.44
PTPRC gene|PTPRC (gngm),1.58e-09,0.29,5,65,2,5.38
General Population (popg),0.0,5.87,1919,4182,340,2799.57
gefitinib (orch),1e-16,0.76,3,554,0,3.02
Drug Delivery Systems (medd),7.75e-08,0.31,2,72,0,2.06
Drainage procedure (topp),1.17e-10,1.56,74,1850,18,76.96
Dutch Population (humn),1.95e-10,3.89,27,63,0,38.57
Muscle function (ortf),2.23e-28,1.3,216,95,13,136.78
Dopamine Receptor (aapp),8.05e-23,0.09,9,19,1,13.26
Caudal (blor),1.35e-24,0.24,13,136,0,14.24
Recombinant Interferon-gamma|CALR (aapp),1.54e-09,71.43,7,50,0,7.98
Tyrosine (aapp),6.38e-27,0.16,26,68,0,35.94
Bone structure of ischium (bpoc),2.91e-40,2.39,1188,758,32,1241.64
Somatomedins|BP3 (horm),7.92e-10,39.33,23,15,0,24.78
Trans-Activation (Genetics) (genf),1.33e-14,0.14,4,38,0,4.42
Invagination (anab),6.83e-10,0.12,3,19,0,3.47
QT interval feature (fndg),7.21e-07,2.27,39,166,7,48.16
Endopeptidases|ERVK-10 (phsu),1.17e-49,0.12,6,111,0,6.32
Vascular function (clna),2.69e-07,5.92,103,82,4,147.28
Bromodeoxyuridine (phsu),2.69e-14,0.12,4,29,0,4.55
smooth muscle contraction (ortf),4.41e-09,0.16,4,27,0,4.59
Granulation Tissue (tisu),3.11e-07,0.24,1,35,0,1.03
Monoclonal Antibody HuM291 (gngm),6.09e-07,0.15,2,19,0,2.21
Pulse Pressure (orgf),5.71e-70,7.04,193,279,30,326.51
Betamethasone (horm),1.78e-06,0.36,3,79,1,3.11
VIP gene|VIP (aapp),3e-07,0.11,2,13,0,2.31
Cerebellum (bpoc),5.87e-120,0.22,33,584,0,34.86
Parasitemia (dsyn),4.58e-12,1.14,6,402,0,6.09
Myogenesis (ortf),3.32e-06,0.12,2,12,0,2.33
Morphogenesis (orgf),2.18e-30,0.18,4,116,0,4.14
Frozen Sections (tisu),7.97e-16,0.27,6,97,0,6.37
Attention deficit hyperactivity disorder (mobd),1.03e-33,0.24,171,67,1,93.25
Trehalose (bacs),4.65e-10,0.12,2,21,0,2.19
Tetracycline (antb),6.31e-25,0.17,2,87,0,2.05
Ear structure (bpoc),2.29e-19,0.18,7,71,1,7.69
sex (orga),1.52e-74,6.77,506,487,57,955.71
MYH14 (gngm),1.04e-22,0.06,4,20,0,4.8
Ionomycin (lipd),3.39e-14,0.06,3,10,0,3.9
Ontario (geoa),1.65e-07,4.36,31,270,3,34.56
"Receptors, Metabotropic Glutamate (aapp)",5.58e-16,0.03,1,7,0,1.14
Melphalan (aapp),4.22e-16,1.3,4,581,2,4.03
Cerebral hemisphere hemorrhage (patf),3.6e-08,2.32,36,1752,13,36.74
Chronic prostatitis (dsyn),1.15e-06,0.05,1,3,0,1.33
Microscope (medd),3.76e-19,0.12,2,45,0,2.09
Anabolism (biof),1.75e-09,0.25,20,43,2,29.3
UVRAG|TP63|CKAP4 (gngm),4.95e-06,0.31,1,74,0,1.01
Spermatogenesis (celf),5.73e-18,0.12,13,23,0,20.35
Urinary Calculi (fndg),5.83e-12,1.48,70,31,0,44.73
Stroma (bpoc),3.12e-40,0.4,42,1016,3,43.74
silybin (orch),7.12e-07,0.22,3,31,0,3.29
Common wart (dsyn),1.07e-08,0.11,1,15,1,1.07
"Lichen Planus, Oral (dsyn)",5.56e-10,0.05,1,8,0,1.12
Dietary protein intake (fndg),1.07e-06,11.08,33,21,7,34.36
Moving (orgf),5.3e-15,0.2,7,61,0,7.8
Locomotion (orgf),9.54e-14,0.17,13,38,0,17.45
Body Weight Changes (fndg),2.22e-14,20.4,501,70,64,79.78
Somatostatin|SST (aapp),2.52e-17,0.25,20,99,0,24.04
Tissue membrane (tisu),5.1e-176,0.09,28,246,3,31.19
Wound Infection (patf),2.72e-41,3.37,134,581,34,164.91
Malignant neoplasm of brain (neop),4.06e-08,1.31,2,264,0,2.02
Octreotide|PLXNA2 (aapp),1.38e-18,90.88,13,122,1,14.39
MICE gene|MICE (gngm),4.14e-07,0.09,1,10,0,1.1
Neural Development (orgf),6.89e-33,0.14,14,83,0,16.36
Youth (humn),2.57e-90,3.23,1527,462,21,601.78
Bupivacaine (orch),1.68e-06,0.32,46,47,2,91.02
African race (humn),1.06e-49,2.71,407,855,50,600.74
"Recipient, Transplant (humn)",2.49e-27,2.51,449,5013,146,489.22
Danazol (phsu),1.13e-09,0.14,6,18,1,8.0
GPI gene|GPI (aapp),5.02e-26,0.19,12,101,1,13.43
CATALASE (aapp),2.38e-22,0.27,25,155,0,29.03
MSC gene|MSC (gngm),1.84e-13,0.25,5,77,0,5.32
Insemination (ortf),1.69e-06,0.18,2,23,0,2.17
CUX1|HCLS1|TNFRSF1B|PSIP1|SIGLEC7 (aapp),6.29e-09,0.12,1,19,0,1.05
Breast Cancer Treatment (topp),2.34e-06,3.4,21,85,1,26.19
Neural Stem Cell (cell),6.93e-20,0.11,1,42,0,1.02
Pyruvate Kinase (aapp),2.12e-11,0.12,1,24,1,1.04
Vaccines (imft),9.85e-90,0.76,33,3420,6,33.32
Gastric Bypass (topp),1.21e-66,17.48,456,159,122,214.44
T-Cell Activation (celf),1.18e-12,0.34,9,112,1,9.72
Hirsutism (fndg),1.67e-38,2.63,140,5,1,5.18
Parotid Gland (bpoc),1.41e-16,0.33,7,181,0,7.27
Acute leukemia (neop),5.64e-32,1.03,14,1049,7,14.19
Biopsy (diap),4.79e-14,1.3,1293,4275,51,1684.08
Curcumin (phsu),1.6e-50,0.17,14,176,1,15.11
Fluorescein (irda),6.46e-09,0.08,1,12,0,1.08
caspase-3 (aapp),4.15e-20,0.36,11,368,0,11.33
Hypoalbuminemia (fndg),9.6e-22,5.41,32,295,30,35.47
Ureterolithiasis (dsyn),9.61e-08,1.27,52,11,0,13.33
Grains (plnt),2.07e-11,0.18,1,40,1,1.03
Selenium and Vitamin E Efficacy Trial (resa),4.16e-06,2.14,77,500,8,88.86
Neutrophil Infiltration (phsf),1.04e-08,1.23,2,264,0,2.02
Mitosis (celf),3.97e-32,0.19,10,123,3,10.81
Hydroxyproline (aapp),4.5e-10,0.26,8,60,0,9.07
Polysaccharides (carb),6.65e-115,0.15,19,333,1,20.08
Aorta (bpoc),1.38e-29,0.85,306,3793,60,330.69
"Kidney Failure, Chronic (dsyn)",1.35e-193,2.75,1102,6664,305,1284.23
Entire substantia nigra (bpoc),1.1e-66,0.05,2,68,0,2.06
Benzene (hops),2.64e-12,0.14,7,25,0,8.96
WARS (gngm),2.61e-06,2.59,36,7,0,8.36
Glucosephosphate Dehydrogenase (aapp),8.37e-12,0.11,1,24,0,1.04
Dancer (humn),2.93e-09,1.66,38,2,0,2.11
Immunosuppressive Agents (phsu),5.23e-11,1.02,33,710,10,34.53
Gymnasts (humn),3.99e-13,2.78,46,1,0,1.02
Natives (popg),6.16e-28,3.51,82,210,6,114.02
Cryopreservation (lbpr),2.89e-12,0.21,4,55,0,4.29
Bone structure of lumbar vertebra (bpoc),2.02e-11,1.75,51,17,0,22.67
American (humn),3.51e-60,2.87,227,670,31,303.91
corporation (orgt),3.69e-09,7.52,13,23,8,20.35
Mesenteric Arteries (bpoc),8.29e-22,0.14,2,61,0,2.07
structural equation model (resa),5.99e-08,1.92,33,8,1,9.94
Labyrinth (bpoc),4.58e-36,0.08,5,51,0,5.49
vitamin therapy (topp),3.12e-08,3.09,27,76,1,36.59
"Purpura, Thrombocytopenic, Idiopathic (dsyn)",1.96e-16,0.29,4,121,1,4.13
Chloroform (hops),4.65e-11,0.16,1,35,0,1.03
adipocyte differentiation (celf),2.32e-11,1.43,64,14,0,17.06
"1,2-diacylglycerol (bacs)",8.83e-12,0.15,17,12,0,20.47
Medical center (hcro),1.9e-75,4.02,196,694,38,251.35
Membrane Transport Proteins (aapp),2.33e-61,0.2,48,256,3,57.0
beta-Lactams (antb),1.92e-09,0.81,3,242,0,3.04
"Staplers, Surgical, Circular (medd)",1.25e-09,5.0,17,38,5,24.61
"Mice, Inbred NOD (mamm)",1.19e-19,0.17,2,66,0,2.06
Experimental Autoimmune Encephalomyelitis (emod),2.01e-20,0.11,2,41,0,2.1
Titanium (elii),2.54e-09,0.08,3,8,0,4.12
PTPN11 gene|PTPN11 (gngm),2.42e-13,0.26,6,79,0,6.46
Death (finding) (fndg),3.24e-30,7.55,76,10915,319,76.53
postnatal development (orgf),7.35e-07,0.22,3,32,0,3.28
Ring device (medd),3.16e-38,0.12,10,84,0,11.19
Excitability (sosy),1.7e-38,0.1,10,65,0,11.54
Cell Growth (celf),3.29e-81,0.29,25,623,1,26.0
Albuminuria (fndg),3.55e-58,4.66,207,363,23,325.04
"DNA, Complementary (nnon)",2.12e-53,0.12,4,117,2,4.14
Entire olfactory bulb (bpoc),1.42e-24,0.05,2,18,0,2.22
Platinum (elii),3.3e-14,0.98,1,337,2,1.0
Orthomyxoviridae (virs),1.75e-24,1.03,3,620,2,3.01
Low risk pregnancy (orgf),1.96e-07,5.39,13,35,1,17.83
Thyrotropin (aapp),1.49e-23,1.3,204,127,1,206.06
Anesthesiologist (prog),6.83e-09,2.78,39,217,11,46.01
Geriatric Assessment (hlca),1.07e-06,6.5,15,203,6,16.11
leukemia (neop),9.21e-37,0.75,42,2003,12,42.88
ABCG2 gene|ABCG2 (gngm),1.46e-06,0.34,9,60,0,10.35
Prosencephalon (bpoc),9.97e-57,0.07,4,74,0,4.22
Flavonoids (orch),5.78e-25,0.3,34,205,2,39.64
Substance P (aapp),4.12e-84,0.04,7,51,0,7.96
Mutagens (hops),2.73e-40,0.09,2,67,2,2.06
Lithium (elii),1.86e-33,0.23,29,174,3,33.83
Risk Assessment (hlca),2.27e-26,4.18,88,609,21,100.72
CDK2 gene|CDK2 (gngm),5.62e-12,0.18,1,43,0,1.02
Puerto Ricans (humn),7.25e-07,3.09,22,55,0,30.8
Kininogenase (aapp),2.65e-08,0.13,1,20,0,1.05
Entire gastrocnemius (bpoc),1.61e-06,0.31,43,39,2,74.37
"Surgical Procedures, Laparoscopic (topp)",3.07e-229,5.1,389,968,117,545.32
Biosensors (medd),2.4e-21,0.08,2,30,0,2.13
Xeroderma Pigmentosum (neop),5.54e-10,0.13,1,26,0,1.04
Revascularization - action (topp),9.01e-10,3.47,42,4289,46,42.41
Lysosomal (blor),2.52e-18,0.19,6,69,1,6.52
DNA Fragmentation (moft),2.99e-07,0.15,2,20,0,2.2
"DNA, Mitochondrial (bacs)",2.24e-09,0.38,45,130,1,60.58
Isomerism (npop),2.25e-07,0.21,7,29,0,8.69
Bulimia (mobd),3.4e-27,3.71,347,61,11,71.72
Short stature (fndg),1.77e-17,2.6,193,62,14,81.92
New Zealand white rabbit (mamm),3.9e-09,0.23,2,44,0,2.09
Index (inpr),2.85e-11,5.29,14,40,8,18.9
Virus Diseases (dsyn),4.87e-48,1.01,182,3204,10,192.34
Microelectrodes (medd),5.02e-13,0.04,1,6,0,1.17
Radical hysterectomy (topp),9.33e-10,2.81,53,348,13,61.07
Dialysis procedure (topp),6.05e-23,3.22,166,2499,109,177.03
Panic Disorder (mobd),1.65e-14,0.2,21,44,2,31.02
imiquimod (phsu),5.81e-10,0.14,1,28,0,1.04
Cell division (celf),1.01e-27,0.18,6,103,0,6.35
"Antiretroviral Therapy, Highly Active (topp)",1.63e-11,2.9,94,849,21,104.41
Cell Nucleus (celc),1.08e-14,0.27,1,118,0,1.01
Cyclosporine|RIT2 (aapp),6.28e-49,892.46,23,141,2,26.75
wave (npop),1.47e-08,0.45,84,211,5,117.44
Fibronectins (aapp),3.16e-95,0.08,14,137,0,15.43
Uveitis (dsyn),1.7e-35,0.08,6,49,0,6.73
Vaccinated (fndg),5.23e-07,1.37,9,422,3,9.19
Primary Carcinoma (neop),1.06e-27,1.02,10,805,2,10.12
Doxycycline (antb),6.47e-10,0.35,4,174,0,4.09
disease characteristic (patf),1.3e-15,7.01,25,108,5,30.79
Isoflurane (orch),1.12e-26,0.19,11,104,1,12.16
Glucosamine (carb),2.23e-07,0.15,6,13,1,8.77
Rough endoplasmic reticulum (celc),1.14e-07,0.11,4,10,0,5.6
Vestibule (bsoj),2.75e-06,0.17,5,17,0,6.47
4-methoxyamphetamine (hops),3.3e-38,0.04,1,23,1,1.04
Mazes (mnob),1.31e-09,0.21,2,41,0,2.1
Thoracotomy (topp),1.82e-09,2.29,10,1092,9,10.09
Glutathione Reductase|GSR (aapp),3.04e-08,0.24,12,40,0,15.6
Paclitaxel (phsu),2.03e-73,0.88,20,1759,6,20.23
Gastrin|GAST (gngm),1.18e-17,0.11,8,27,0,10.37
Interleukin-2 (gngm),1.37e-77,0.27,26,502,0,27.35
Nicardipine (orch),9.69e-15,0.12,1,35,0,1.03
CARDIAC EVENT (dsyn),1.6e-13,4.58,68,1508,50,71.07
Prognosis bad (fndg),4.52e-11,6.61,95,5836,112,96.55
Cachexia (sosy),4.51e-60,5.53,143,264,51,220.46
Carboxylic Acids (orch),1.95e-09,0.07,2,8,0,2.5
Marsupialia (mamm),1.16e-06,0.13,2,14,0,2.29
Structure of retinal pigment epithelium (bpoc),1e-36,0.05,6,17,0,8.12
Dyssomnias (dsyn),8.44e-17,1.75,72,21,4,27.12
Pericytes (cell),1.27e-12,0.11,2,25,0,2.16
RABBIT SERUM (orch),4.11e-07,0.09,1,11,0,1.09
Early Intervention (Education) (topp),7.45e-12,4.41,27,68,1,37.72
External Ear (bpoc),7.68e-11,0.24,1,56,0,1.02
T-Lymphocyte (cell),0.0,0.24,43,1782,3,44.04
Niacinamide (orch),3.89e-13,0.17,3,45,0,3.2
"APEX1 protein, human|APEX1 (aapp)",7.01e-18,0.38,27,212,0,30.44
Helicobacter Infections (dsyn),1.69e-06,1.03,132,160,0,240.9
Entire lumbar spine (blor),5.6e-61,4.87,1042,142,16,161.35
Urban Population (popg),1.13e-14,7.08,254,160,24,260.79
Cyclooxygenase Inhibitors (phsu),4.62e-09,0.38,13,103,0,14.64
"Electrophoresis, Capillary (lbpr)",1.21e-06,0.14,2,16,0,2.25
Meetings (hlca),8.56e-11,2.99,40,99,7,56.16
Medulla (bpoc),1.28e-52,0.12,3,123,0,3.07
Retinal Diseases (dsyn),8.42e-12,1.28,205,326,11,333.91
free radical oxygen (bacs),1.32e-09,0.23,2,46,0,2.09
MEDITERRANEAN (fndg),3.15e-08,5.91,64,63,3,125.02
Structure of paraventricular nucleus (bpoc),3.24e-06,0.06,1,5,0,1.2
lipid raft (celc),4.59e-11,0.13,1,28,0,1.04
Severe malnutrition (dsyn),1.21e-40,6.64,56,224,24,70.0
Nucleocapsid Proteins (aapp),4.34e-07,0.18,1,26,0,1.04
neuroblastoma cell (cell),4.69e-15,0.23,1,71,0,1.01
"Microscopy, Fluorescence (lbpr)",2.31e-11,0.13,1,28,0,1.04
Nucleus solitarius (bpoc),1.25e-19,0.09,3,28,0,3.32
Elements (elii),1.11e-22,0.37,71,299,8,87.86
Polycystic Ovary Syndrome (dsyn),1.42e-320,4.8,2497,89,25,92.17
"Lens, Crystalline (bpoc)",2.13e-72,0.06,14,47,2,18.17
LDL Cholesterol Lipoproteins (bacs),2.43e-24,6.0,779,496,52,811.81
Oral contraception (topp),4.62e-06,1.97,32,11,0,14.78
Right hemicolectomy (topp),2.9e-15,4.81,30,172,13,35.23
Swimmer (humn),3.78e-10,1.48,50,3,0,3.18
Diarrhea (sosy),4.66e-21,1.17,80,1785,16,83.59
Silver (bacs),6.51e-10,0.29,3,65,0,3.14
myometrium (bpoc),1.56e-17,0.19,14,61,1,17.21
Health Surveys (resa),8.02e-17,5.96,110,116,15,214.31
Serine Protease (aapp),9.67e-25,0.26,11,148,0,11.82
penis (bpoc),3.98e-13,0.43,35,214,2,40.72
Oligonucleotides (nnon),9.49e-25,0.08,1,38,0,1.03
Specific antibody (aapp),8.2e-33,0.32,9,372,2,9.22
Cultured Cells (cell),3.19e-69,0.11,7,145,0,7.34
Nodulus cerebelli (bpoc),1.79e-19,0.19,6,79,0,6.46
"Ductus Arteriosus, Patent (cgab)",3.39e-10,1.16,3,304,0,3.03
Bone structure of carpus (bpoc),8.15e-07,0.1,4,6,0,6.67
Cyclosporine|CIC (aapp),1.74e-27,1396.85,14,174,0,15.13
Interleukin-8 (aapp),1.16e-11,0.56,106,479,6,129.46
Otitis Media (dsyn),1.39e-14,0.3,9,110,0,9.74
Risperidone (orch),2.96e-12,1.06,152,77,4,116.01
sphingosine 1-phosphate (orch),1.3e-08,0.25,5,47,0,5.53
Immunophenotyping (lbpr),5.96e-07,0.92,1,143,0,1.01
Acetate (phsu),2.79e-24,0.25,26,142,2,30.76
"Hemoglobin, Glycosylated (aapp)",1.3e-09,10.19,222,92,15,130.13
COLLAGENASE (aapp),4.06e-26,0.1,12,34,0,16.24
Neocortex (bpoc),3.98e-32,0.04,1,25,0,1.04
Cholinergic Receptors (aapp),1.67e-20,0.1,6,31,0,7.16
Chrysanthemum x morifolium (plnt),2.9e-14,0.21,12,64,0,14.25
public health program (hlca),2.09e-08,6.96,13,29,0,18.83
Helicobacter pylori (bact),2.61e-11,0.34,69,122,1,108.02
"Atmosphere, planetary (npop)",7.77e-08,0.14,2,20,0,2.2
Ablation (topp),9.76e-23,1.17,87,1904,13,90.98
Longitudinal Studies (resa),0.0,4.19,1341,5229,159,1684.91
Nasal cavity (bsoj),2.34e-07,0.92,5,207,0,5.12
Acetaminophen (phsu),6.02e-17,0.43,49,295,1,57.14
follow-up (hlca),9.02e-303,5.45,782,5977,217,884.31
"Hydrogen, Homeopathic preparation (inch)",4.04e-09,0.15,7,19,0,9.58
"Dermatitis, Atopic (dsyn)",1.02e-44,0.14,55,43,0,76.62
peptide hormone (aapp),6.36e-13,1.52,75,45,5,72.0
inpatient (humn),6.68e-69,3.02,388,2392,67,450.94
"PLA2G4A protein, human|PLA2G4A (aapp)",3.69e-08,0.06,1,7,0,1.14
"Rats, Sprague-Dawley (mamm)",4.2e-22,0.39,21,455,0,21.97
Estrogen Receptor alpha (aapp),1.43e-08,0.45,56,196,3,72.0
Histamine (nsba),1.15e-100,0.04,4,58,2,4.28
Neutropenia (dsyn),2.73e-36,1.76,18,2007,2,18.16
Eosinophilic cellulitis (dsyn),7.76e-07,0.26,6,40,0,6.9
Leptin|CDH11|LEP (aapp),1.42e-08,112.89,125,13,4,14.35
Transient ischemia (dsyn),1.94e-13,0.24,1,70,0,1.01
Traumatic Rupture (inpo),1.96e-06,1.02,30,462,2,31.95
Ketanserin (phsu),5.85e-11,0.06,2,7,0,2.57
Myoglobin|MB (aapp),1.35e-09,0.18,2,34,0,2.12
microsomal enzymes (aapp),6.71e-09,0.03,1,2,0,1.5
Management procedure (hlca),3.37e-09,2.45,626,8639,107,671.36
Splenectomy (topp),3.27e-08,1.26,20,741,19,20.54
"Condoms, Male (medd)",1.72e-08,0.51,46,229,0,55.24
Low density lipoprotein cholesterol measurement (lbpr),1.42e-14,6.02,26,52,3,39.0
23s (bpoc),6.59e-11,0.08,1,16,0,1.06
"Muscle, Smooth, Vascular (tisu)",2.19e-24,0.2,6,105,2,6.34
Entire fetus (anst),1e-12,0.36,22,144,0,25.36
Migration Inhibitory Factor (aapp),9.33e-11,0.33,9,93,1,9.87
Alteplase|IV (phsu),2.02e-23,939.52,13,566,1,13.3
Arginine|AR (phsu),1.77e-31,220.09,18,59,0,23.49
TRH gene|TRH (gngm),1.09e-22,0.03,1,10,0,1.1
Axon (celc),5.79e-120,0.07,3,164,0,3.05
Nitric Oxide (bacs),3.35e-157,0.33,246,1554,23,284.94
Mutant (comd),8.17e-53,0.15,4,155,0,4.1
Fibril (celc),1.24e-17,0.09,2,29,0,2.14
Histone H3 (aapp),3.63e-09,0.19,2,35,0,2.11
Antibody Formation (celf),1.94e-37,0.31,11,319,4,11.38
Beclomethasone Dipropionate (phsu),2.14e-07,0.08,2,7,0,2.57
Chlorpromazine (phsu),1.66e-18,0.11,3,34,1,3.26
Entire soleus (bpoc),1.71e-11,0.24,57,16,0,20.49
Sleep disturbances (dsyn),2.13e-15,2.01,178,102,11,160.45
Carcinomatosis (neop),1.32e-17,1.63,4,919,7,4.02
Coronary Arteriosclerosis (dsyn),4.53e-298,2.64,1527,6690,312,1875.54
"Genes, rRNA (gngm)",2.08e-40,0.22,15,198,0,16.14
Tendon structure (bpoc),7.26e-07,0.21,15,15,1,30.0
osteosarcoma (neop),1.03e-14,0.67,9,1167,4,9.07
Medulla Oblongata (bpoc),2.21e-11,0.37,7,138,2,7.36
HSPD1 (gngm),2.13e-06,0.18,5,19,0,6.32
"Supranuclear Palsy, Progressive (dsyn)",6.94e-10,0.18,3,37,0,3.24
Histamine H2 Receptors (aapp),2.26e-07,0.17,4,22,0,4.73
Middle Aged (aggp),1.76e-35,5.78,624,479,67,846.69
Oxidoreductase (aapp),4.58e-33,0.29,71,263,6,90.17
Dystrophin|DMD (aapp),2.24e-13,0.13,1,34,0,1.03
ESTERASE (aapp),5.44e-13,0.15,4,36,0,4.44
Body Weight (orga),2.06e-09,15.66,2000,300,114,345.0
retinoic acid receptor alpha (aapp),1.96e-06,0.21,3,27,0,3.33
Chromosome abnormality (comd),6.57e-09,0.73,24,679,0,24.85
Hypersensitivity (patf),1.2e-32,0.34,116,364,4,152.97
Laparoscopy (diap),1.8e-38,2.42,174,542,36,229.86
Somatomedins (aapp),1.11e-14,1.12,216,244,18,407.21
Canada (geoa),2.59e-11,3.42,72,570,5,81.09
Stimulation procedure (topp),4.14e-66,0.34,410,756,2,632.35
Etanercept (aapp),1.33e-08,0.42,36,151,2,44.58
cofactor (bacs),6.57e-16,0.27,23,107,0,27.94
mitogen-activated protein kinase p38 (aapp),1.18e-09,0.17,1,34,0,1.03
Retinal Detachment (dsyn),3.27e-23,0.05,2,19,0,2.21
ETS1 gene|ETS1 (gngm),1.05e-07,0.19,1,30,0,1.03
Nifedipine (orch),2.41e-51,0.13,11,120,2,12.01
Ceramides (bacs),1.59e-09,0.29,37,65,1,58.06
Anti-Arrhythmia Agents (phsu),5.16e-21,1.12,26,958,2,26.71
Porphyrins (bacs),8.95e-17,0.1,1,31,0,1.03
dimer (chvs),4.19e-07,0.06,1,5,0,1.2
Callithrix (mamm),2.69e-12,0.11,1,26,0,1.04
Leak NOS (patf),1.81e-25,2.56,141,849,51,164.42
pathologic fistula (anab),1.45e-11,1.07,50,945,13,52.65
Tumor necrosis factor receptor 11b (aapp),3.25e-10,1.27,113,149,6,198.7
Candidiasis (dsyn),4.73e-13,1.15,9,514,2,9.16
Cardiac rehabilitation (topp),3.38e-08,10.13,10,35,1,12.86
Neural Cell Adhesion Molecules (aapp),4.65e-13,0.08,1,18,0,1.06
Oligosaccharides (carb),2.17e-28,0.12,10,57,0,11.75
Solid tumor (neop),4.54e-43,1.14,41,1891,7,41.89
intraocular lens implantation procedure (topp),1.84e-08,0.04,1,3,0,1.33
Mitochondria (celc),5.36e-144,0.11,28,286,1,30.74
inhibin B (aapp),4.84e-14,1.88,52,4,0,4.31
Abdomen (blor),4.26e-133,2.58,693,2359,53,896.58
Forearm (blor),3.13e-39,1.53,222,86,9,119.32
Implants (medd),9.19e-18,0.54,144,677,11,174.63
basiliximab|SI (phsu),3.05e-15,597.44,6,64,2,6.56
Extraction (topp),3.46e-25,0.42,129,492,8,162.82
Surgical fistula (fndg),1.97e-09,1.11,15,466,2,15.48
Hip surgery (topp),3.34e-12,5.72,24,180,9,27.2
Ankylosis (acab),1.32e-10,0.26,33,53,1,53.55
Multiple lesions (fndg),1.88e-06,1.19,10,329,1,10.3
Malignant Childhood Neoplasm (neop),1.92e-12,2.85,80,651,24,89.83
Ammonium (inch),8.79e-08,0.15,5,18,0,6.39
Roux-en-Y Gastric Bypass (topp),1.24e-89,24.92,730,158,177,192.2
Vital capacity (ortf),2.43e-20,4.79,243,253,21,476.4
Immunotherapy (topp),2.1e-58,0.9,11,1300,1,11.09
Hip region structure (blor),1.01e-11,1.39,76,34,2,49.21
Brefeldin A (antb),5.59e-08,0.03,1,2,0,1.5
prednisolone (phsu),4.29e-10,0.54,46,484,4,50.37
Electromagnetic Energy (npop),1.22e-15,0.41,20,208,0,21.92
homocysteine (aapp),1.38e-25,1.74,457,414,20,789.05
Drug eluting stent (medd),9.89e-10,2.77,15,1590,11,15.14
Viral Tumor Antigens (aapp),2.57e-12,0.09,2,19,0,2.21
Neurotensin|NTS (aapp),1.91e-14,0.03,1,6,0,1.17
Vascular constriction (function) (ortf),5.06e-33,0.22,21,156,2,23.83
Myopathy (dsyn),1.24e-10,0.51,33,342,3,36.18
Epididymis (bpoc),5.46e-39,0.11,25,48,0,38.02
Regression Analysis (qnco),1.97e-16,4.97,32,72,3,46.22
gemcitabine (nnon),1.51e-53,1.49,4,1829,2,4.01
Voluntary Workers (prog),1.21e-87,1.25,770,333,12,477.01
Federal Government (orgt),1.52e-263,4.53,595,1354,50,856.47
Flavin-Adenine Dinucleotide (bacs),1.14e-07,0.07,2,6,0,2.67
Y Chromosome (celc),1.85e-09,0.09,2,13,0,2.31
Complex procedure (hlca),1.89e-07,6.44,11,51,3,13.37
Cytoskeletal Modeling (celf),2.05e-07,0.14,1,19,0,1.05
Myoglobin (aapp),6.46e-09,0.24,3,46,1,3.2
Buffaloes (mamm),8.59e-11,0.27,3,67,1,3.13
Peptidoglycan (bacs),4.48e-22,0.1,1,42,0,1.02
Meningoencephalitis (dsyn),1.58e-11,1.19,1,299,0,1.0
Relative Risk (qlco),2.06e-24,6.26,37,104,9,50.16
harpin (aapp),6.53e-10,0.12,2,22,0,2.18
Intestinal Mucosa (tisu),1.04e-15,0.28,6,105,1,6.34
Primary Prevention (topp),1.13e-24,4.74,89,900,25,97.8
Phacoemulsification (topp),1.46e-14,0.04,1,6,1,1.17
Gelatinase A (aapp),6.03e-08,0.49,25,360,1,26.74
Long-Term Survivors (podg),3.72e-13,3.76,67,748,23,73.0
Major Histocompatibility Complex (gngm),2.93e-28,0.11,3,57,0,3.16
Aflatoxins (bacs),7.08e-07,0.24,3,34,0,3.26
Cancer Survivor (podg),5.06e-33,4.63,80,423,22,95.13
diagnostic procedure (diap),1.59e-07,0.99,23,427,2,24.24
angiogram (diap),2.77e-07,1.19,146,1718,17,158.41
Eating Disorders (mobd),1.78e-26,5.47,883,147,31,171.47
Lactones (orch),3.98e-10,0.12,1,23,0,1.04
Membrane Lipids (lipd),2.2e-09,0.06,1,8,0,1.12
Urolithiasis (dsyn),1.19e-10,1.25,87,43,1,64.25
Septicemia (dsyn),9.28e-81,2.87,60,11246,77,60.32
Government hospital (hcro),1.95e-07,5.32,11,26,3,15.65
Rickets (dsyn),5.08e-15,1.89,125,65,4,98.8
methyl group (orch),3.67e-08,0.07,1,8,0,1.12
G-Protein-Coupled Receptors (aapp),9.52e-27,0.18,15,96,0,17.34
Entire caudate nucleus (bpoc),6.9e-11,0.16,9,27,0,12.0
HIV-1 (virs),1.54e-64,0.23,22,329,4,23.47
Nitrendipine (orch),2.02e-06,0.25,2,32,3,2.12
Nutritional status (orga),7.74e-136,14.24,1173,512,198,735.48
Protamines (phsu),1.32e-09,0.15,2,28,0,2.14
alpha 2-Glucoproteins (aapp),4.96e-08,0.12,6,9,0,10.0
PREDICTED (clna),8.21e-61,4.12,153,522,28,197.84
Colonic mucous membrane (bpoc),4.77e-13,0.26,10,82,0,11.22
Myelin (tisu),7.17e-23,0.1,1,42,0,1.02
Zonal (orch),2.19e-113,0.2,58,485,4,64.94
altretamine/cisplatin/cyclophosphamide protocol (topp),6.9e-11,4.59,24,115,6,29.01
brain cell (cell),4.49e-06,0.23,2,29,0,2.14
Serum urate measurement (lbpr),2.14e-19,12.0,71,61,6,113.41
"Leishmaniasis, Cutaneous (dsyn)",1.25e-09,0.12,4,18,0,4.89
Neurotransmitters (nsba),8.86e-33,0.21,36,142,3,45.13
Catecholamines (nsba),3.06e-27,0.35,47,305,4,54.24
"Fasciitis, Plantar (dsyn)",6.99e-12,2.47,37,1,0,1.03
Excision of left hemicolon NOS (topp),2.24e-09,5.8,11,45,7,13.69
Vibrissae (bpoc),1.15e-06,0.05,1,4,0,1.25
Proteolysis (moft),5.7e-12,0.15,3,35,0,3.26
Cataract (dsyn),4.02e-15,0.32,52,125,12,73.63
Prosthesis (medd),3.91e-13,0.94,92,1194,24,99.09
Radioimmunotherapy (topp),3.48e-06,0.91,1,129,0,1.01
Ethnic group (humn),8.57e-183,6.15,1444,1439,115,2873.02
Endocrine therapy (topp),1.77e-50,2.73,290,1231,15,358.32
Counseling (hlca),1.81e-22,3.24,109,226,5,161.57
Gastrointestinal Hemorrhage (patf),3.47e-11,1.7,11,789,4,11.15
Slinging procedure (topp),1.7e-11,1.62,52,8,0,9.23
Renin|REN (aapp),1.96e-10,0.21,13,39,0,17.33
vinorelbine (phsu),5.3e-12,1.22,1,346,1,1.0
Scaffold (mnob),9.19e-17,0.12,2,38,1,2.11
Mesenchymal Stem Cells (cell),8.59e-64,0.14,15,176,0,16.28
Pyelonephritis (dsyn),3.87e-06,0.39,7,67,1,7.73
Cricetinae (mamm),4.6e-88,0.11,8,195,0,8.33
Mucins (aapp),3.5e-17,0.3,3,202,0,3.04
Glial (blor),3.42e-10,0.23,2,49,0,2.08
Primary open angle glaucoma (dsyn),4.93e-11,0.16,19,9,0,13.26
Heel (blor),6.51e-07,1.92,53,27,1,40.75
Phosphatidylethanolamines (bacs),7.24e-22,0.07,8,14,0,12.57
Carbon (elii),6.9e-30,0.31,38,250,4,43.78
concomitant disease (patf),2.32e-08,3.67,30,196,6,34.59
Insulin Resistance (patf),2.98e-28,8.28,6278,1132,181,1336.11
caspase-8 (aapp),2.67e-10,0.29,5,70,0,5.36
Candidate Disease Gene (gngm),6.82e-18,1.27,190,2920,12,202.36
Cerebrovascular Circulation (ortf),3.47e-21,0.33,29,205,0,33.1
Purinoceptor (aapp),5.43e-10,0.11,1,20,0,1.05
Inferior vena cava structure (bpoc),2.26e-09,1.0,15,399,1,15.56
Bone Screws (medd),2.78e-10,0.43,45,186,0,55.89
6-minute walk test (diap),3.52e-09,8.82,33,34,2,65.03
perforin (aapp),3.85e-09,0.3,2,81,0,2.05
irinotecan (orch),1.7e-20,1.67,5,915,1,5.03
Peritoneal Dialysis (topp),4.97e-29,3.61,101,960,60,111.63
"Animals, Laboratory (anim)",1.03e-14,0.36,25,162,1,28.86
Soil (sbst),1.85e-08,0.17,1,28,0,1.04
UCP3 (gngm),6.99e-08,2.07,28,4,0,4.57
Pacific Islander Americans (humn),3.89e-13,4.11,31,71,4,44.54
"Kidney Failure, Acute (dsyn)",5.94e-30,1.43,21,1726,16,21.26
Dysplasia (neop),4.69e-09,0.53,45,507,2,48.99
Ureter (bpoc),7.77e-08,0.53,50,246,5,60.16
Chest (blor),6.2e-08,1.32,188,2402,16,202.71
Biliopancreatic Diversion (topp),7.95e-08,15.03,131,31,25,38.34
Antigen-Antibody Complex (aapp),6.04e-42,0.1,5,81,0,5.31
Lactic acid (phsu),4.47e-10,0.3,7,73,1,7.67
caveolin 1 (aapp),1.22e-11,0.31,4,104,0,4.15
Xanthine Oxidase (aapp),3.27e-15,0.17,3,51,2,3.18
alpha 1-Antitrypsin (phsu),2.21e-15,0.2,10,63,1,11.59
Intervention Trial (resa),5.01e-17,4.87,34,79,3,48.63
Urinary Incontinence (dsyn),3.13e-70,2.04,359,92,7,115.58
"Angiotensin II Receptor, Type 2|AGTR2 (aapp)",5.83e-07,0.12,1,15,0,1.07
macromolecule (chvs),2.16e-08,0.12,2,18,0,2.22
Factor IX (aapp),1.67e-10,0.1,2,17,0,2.24
Smoking (inbe),8.53e-109,3.87,1845,2155,232,3424.59
Cataract Extraction (topp),9.85e-14,0.17,8,35,3,9.83
Ketoconazole (phsu),1.36e-21,0.16,5,70,0,5.36
Maxilla (bpoc),5.37e-44,0.19,26,171,1,29.95
Omeprazole (phsu),8.85e-19,0.19,12,72,1,14.0
Entire hippocampus (bpoc),1.16e-240,0.09,29,382,0,31.2
Flagellin (aapp),2.86e-08,0.24,2,43,0,2.09
[D]Electrocardiogram (ECG) abnormal (fndg),1.73e-06,3.01,27,181,8,31.03
Cell Adhesion Molecules (aapp),1.22e-12,0.53,96,436,1,117.14
Local Therapy (topp),1.91e-07,1.72,3,351,0,3.03
Health Status (qlco),4e-12,4.86,20,55,6,27.27
Nitric Oxide Synthase Type I (aapp),5.48e-16,0.11,1,33,0,1.03
Cloning (resa),9.89e-17,0.06,2,14,0,2.29
Glycoconjugates (carb),2.89e-14,0.1,1,26,0,1.04
Protein-Serine-Threonine Kinases (aapp),3.28e-14,0.29,4,100,0,4.16
copolymer 1 (phsu),2.67e-06,0.13,3,11,0,3.82
N-terminal pro-B-type natriuretic peptide|PREP|AP3B1 (horm),5.31e-89,1626.14,33,256,11,37.25
Alkaloids (orch),1.03e-38,0.19,5,151,1,5.17
Uterus - Cervix (MMHCC) (tisu),1.36e-08,0.76,9,396,1,9.2
Motility (orgf),9.65e-27,0.3,38,224,0,44.45
cohort (humn),0.0,7.21,5983,17202,967,8063.94
transduction (orgf),2.04e-27,0.13,1,68,0,1.01
Donor person (humn),2.97e-17,2.1,282,2248,74,317.38
Triticum aestivum (plnt),6.02e-22,0.1,2,40,0,2.1
Phagocytes (cell),1.05e-20,0.27,3,148,0,3.06
Leptocyte (cell),6.82e-41,0.15,2,124,0,2.03
Sodium (bacs),1.02e-08,0.61,125,535,17,154.21
Renal epithelial cell (cell),8.35e-07,0.14,1,18,0,1.06
"Clinical Trials, Randomized (resa)",1.15e-24,3.73,97,490,6,116.2
Parathyroid gland (bpoc),2.07e-06,0.35,5,56,0,5.45
Glycosides (carb),3.71e-11,0.13,5,23,0,6.09
"Myeloid Leukemia, Chronic (neop)",7.32e-07,0.63,21,1104,0,21.4
Cell Culture Techniques (lbpr),5.82e-47,0.14,19,112,0,22.22
Neuronal Plasticity (ortf),4.58e-09,0.15,4,24,0,4.67
Reporter (prog),8.41e-10,0.3,28,79,0,37.92
Chemokine (C-C Motif) Receptor 5|CCR5 (aapp),2.93e-16,0.19,4,66,0,4.24
Radiofrequency ablation (topp),4.28e-14,1.59,34,1318,6,34.88
Sustained ventricular tachycardia (dsyn),2.99e-07,0.95,1,154,0,1.01
Interferons (aapp),6.43e-87,0.36,79,922,2,85.77
CD86 (gngm),3.41e-13,0.21,1,58,0,1.02
Creatinine increased (fndg),1.42e-22,7.65,36,199,9,42.51
Bone structure of cranium (bpoc),9.29e-38,0.32,19,306,0,20.18
DELETION (comd),1.73e-07,0.51,32,448,1,34.29
Total cholesterol (strd),1.04e-09,7.07,1260,474,124,652.31
Mannitol (carb),1.05e-15,0.29,3,132,0,3.07
Pressors (phsu),8.45e-09,0.29,4,60,0,4.27
Chlorides (inch),9.44e-35,0.15,10,97,1,11.03
Oxytocin (aapp),7.98e-31,0.26,61,182,1,81.45
Motor Neurons (cell),1.78e-69,0.11,4,157,0,4.1
acidification (celf),6.46e-30,0.13,2,80,0,2.05
Thymidine (bacs),2.13e-18,0.08,2,25,0,2.16
Facial paralysis (dsyn),5.06e-09,0.25,1,51,0,1.02
Dystonia (sosy),1.99e-21,0.12,6,47,0,6.77
Bone necrosis (patf),5.05e-08,0.41,50,143,1,67.48
Pancreatic Fistula (dsyn),5.71e-12,5.23,23,371,24,24.43
Antiviral Agents (phsu),2.77e-07,1.54,16,596,2,16.43
Estrogen Antagonists (phsu),3.43e-10,0.37,19,118,0,22.06
Flatfoot (anab),1.06e-06,1.49,30,1,0,1.03
Fatigue (sosy),6.74e-08,1.47,364,575,14,594.43
Glucose Control (medd),1.76e-64,5.07,137,369,12,187.86
Type 2 (clas),3.76e-11,2.58,76,173,8,109.39
Febrile neutropenia (dsyn),1.23e-06,2.65,8,765,2,8.08
Insulin|INS (horm),4.14e-68,2.9,2092,997,75,1472.15
Abscisic Acid (bacs),9.01e-27,0.02,1,5,0,1.2
Myasthenia Gravis (dsyn),4.1e-26,0.36,19,275,0,20.31
Syringomyelia (dsyn),7.78e-08,0.16,1,25,0,1.04
Patient counseled (hlca),2.32e-06,5.63,10,22,1,14.55
Bone Density (lbtr),2.75e-232,3.53,1887,212,43,235.82
Corticosterone (horm),3.84e-48,0.13,23,100,0,28.29
Liver neoplasms (neop),2.56e-21,0.93,7,555,2,7.09
Vanadates (inch),1.65e-10,0.04,2,1,0,1.5
Spinal Cord Diseases (dsyn),1.2e-08,0.38,18,107,1,21.03
Ulcerative Colitis (dsyn),8.12e-17,0.51,177,608,9,228.53
Papio (mamm),2.06e-24,0.14,4,67,0,4.24
Neodymium-YAG laser (medd),6.87e-17,0.12,3,36,0,3.25
CYP2B6 (gngm),5.1e-19,0.07,2,23,0,2.17
Urine albumin:creatinine ratio,2.53e-07,10.45,2,23,0,2.17
Sodium Dodecyl Sulfate (lipd),1.72e-25,0.04,3,12,0,3.75
Exercise stress test (diap),2.3e-95,3.36,349,815,71,498.45
Estrogen Receptors (aapp),1.55e-07,0.44,27,138,4,32.28
Medical History (fndg),1.16e-36,3.63,105,305,12,141.15
NPPB (gngm),2.32e-11,2.48,78,431,12,92.12
Advice (hlca),7.84e-14,1.88,137,523,12,172.89
"Microscopy, Confocal (lbpr)",6.28e-08,0.21,8,33,0,9.94
Lasers (mnob),1.89e-07,0.22,13,26,0,19.5
Intracranial Hemorrhages (patf),1.06e-06,2.74,11,936,3,11.13
Laminin (aapp),2.21e-40,0.07,1,54,0,1.02
Cardiopulmonary Bypass (topp),4.21e-07,1.89,18,1093,19,18.3
NES gene|NES (gngm),4.52e-07,0.28,1,52,0,1.02
Fluimucil|XK|NLRP1 (aapp),2.17e-15,0.24,6,83,0,6.43
cyclooxygenase 2 (aapp),1.29e-50,0.34,27,579,2,28.26
Rod Photoreceptors (cell),7.87e-13,0.09,3,16,0,3.56
Rectum (bpoc),9.26e-11,1.07,44,902,17,46.15
Medical Imaging (diap),6.72e-30,0.49,593,1308,34,861.84
Entire hindlimb (bpoc),2.72e-21,0.23,5,108,0,5.23
IL8 gene|CXCL8 (gngm),1.58e-06,0.25,5,37,0,5.68
mineral metabolism (orgf),1.22e-13,3.95,39,163,5,48.33
Femur (bpoc),7.29e-70,2.15,1519,1031,41,1730.78
Protein-tyrosine kinase inhibitor (phsu),4.28e-24,1.22,7,819,2,7.06
athlete (prog),6.06e-99,1.46,656,306,5,448.74
Friedreich Ataxia (dsyn),2.14e-07,0.11,2,12,0,2.33
Ito cell (cell),7.28e-15,0.16,7,45,0,8.09
Developmental Process (ortf),2.64e-08,0.24,7,45,0,8.09
Neoplasm progression (neop),1.51e-32,1.72,53,3160,29,53.89
Eosinophilia (dsyn),1.65e-06,0.43,10,188,0,10.53
Frailty (fndg),1e-134,10.31,146,747,68,174.54
Insulin-Like Growth Factor Binding Protein 3 (aapp),2.83e-14,1.78,126,78,4,126.29
Smoking Status (clna),4.22e-23,8.75,137,113,14,206.2
Purines (orch),9.94e-12,0.18,7,40,0,8.22
Glycosaminoglycans (bacs),2.51e-34,0.12,13,70,0,15.41
Multiple Sclerosis (dsyn),2.8e-107,0.2,156,399,2,216.99
adduct (chvs),2.87e-08,0.11,2,14,0,2.29
Freund's Adjuvant (imft),1.23e-10,0.18,3,39,0,3.23
Thapsigargin (orch),2.09e-12,0.06,3,6,0,4.5
"Embolization, Therapeutic (topp)",4.12e-46,1.17,26,1795,7,26.38
"Scoliosis, unspecified (anab)",1.55e-08,1.11,104,76,2,131.54
Genistein (bacs),4.57e-27,0.16,28,62,0,40.65
Sorbitol (carb),4.93e-09,0.12,5,13,0,6.92
"Tomography, Optical Coherence (diap)",2.55e-09,0.28,34,54,0,55.41
c-myc Genes|MYC (gngm),4.58e-49,0.19,1,192,0,1.01
Taurine|ELANE (aapp),1.84e-08,57.56,5,25,1,6.0
Acute Erythroblastic Leukemia (neop),1.21e-18,0.14,1,53,0,1.02
Laparoscopic (spco),6.58e-13,7.88,18,48,2,24.75
Hybrids (orgm),3.24e-37,0.11,1,81,0,1.01
DNA chemical synthesis (lbpr),3.92e-08,0.12,1,19,0,1.05
cell activation (celf),1.69e-06,0.34,9,62,1,10.31
Bronchoconstriction (ortf),3.61e-08,0.2,13,25,0,19.76
Entire face (bpoc),2.23e-08,0.29,14,61,0,17.21
Pericarditis (dsyn),3.99e-08,0.94,2,187,0,2.02
Cancer of Rectum (neop),2.83e-09,2.75,167,2565,75,177.87
Buprenorphine (phsu),4.48e-20,0.27,5,122,0,5.2
Hospital admission (hlca),3.88e-08,4.56,59,1374,32,61.53
GTP-Binding Proteins (aapp),3.57e-30,0.16,25,74,0,33.45
Histidine (aapp),1.42e-12,0.16,13,23,1,20.35
medulloblastoma (neop),2.44e-16,0.81,3,419,0,3.02
Somatic mutation (comd),2.04e-08,1.03,2,230,1,2.02
Gonadal structure (bpoc),4.72e-14,0.19,9,54,0,10.5
Chronic Childhood Arthritis (dsyn),2.09e-07,0.34,51,71,1,87.63
Sediment (bdsu),8.66e-07,0.22,1,31,0,1.03
target group (humn),2.68e-07,3.39,19,59,3,25.12
Ligase (aapp),5.25e-25,0.11,4,53,0,4.3
Ergometers (medd),2.7e-08,3.56,92,16,4,18.78
Ptosis (dsyn),4.17e-06,1.25,148,267,1,230.04
Enalapril|SSB (phsu),3.02e-06,658.58,3,24,0,3.38
Diffuse hemorrhage (patf),2.43e-06,1.42,1,207,0,1.0
leukemia inhibitory factor|LIF (aapp),1.94e-14,0.07,2,14,0,2.29
CD28 gene|CD28 (gngm),8.51e-10,0.26,6,58,2,6.62
"Risk factor, cardiovascular (dsyn)",0.0,15.07,2676,2020,418,3544.81
Phospholipase A2 (aapp),9.93e-14,0.26,32,79,0,44.96
rosiglitazone (phsu),5.69e-14,1.17,166,155,7,299.73
Intoxication (fndg),2.19e-12,0.97,3,315,1,3.03
Biliary Atresia (cgab),2.97e-06,0.98,9,275,4,9.29
Insurance Coverage (idcn),5.3e-14,2.59,62,196,6,81.61
ERBB2 gene|ERBB2 (aapp),1.03e-16,1.37,12,799,2,12.18
research study (resa),1.06e-79,0.35,79,799,5,86.81
CDKN1A gene|CDKN1A (gngm),7.84e-08,0.28,1,60,0,1.02
Indicators (irda),3.24e-23,3.53,155,263,9,246.35
Helper-Inducer T-Lymphocyte (cell),2.33e-09,0.22,4,45,0,4.36
Sensitization (menp),7.86e-12,0.11,4,21,0,4.76
BULIMIC (clna),4.09e-13,3.55,59,1,0,1.02
NFKB1 (gngm),2.56e-08,0.31,6,63,0,6.57
Sensors (medd),5.88e-12,0.32,67,101,2,111.45
Obesity Hypoventilation Syndrome (dsyn),1.01e-08,8.61,57,39,14,65.68
IgG1 (aapp),3.01e-32,0.18,2,118,0,2.03
CD8-Positive T-Lymphocytes (cell),5.17e-07,0.37,4,68,2,4.24
Abnormal breathing (sosy),5.9e-21,4.3,49,134,5,66.92
Rifampin (antb),1.9e-16,0.41,18,265,2,19.22
Agaricales (fngs),2.38e-10,0.25,4,57,0,4.28
Tinnitus (sosy),1.86e-13,0.14,12,20,0,19.2
Neuromuscular Junction (bsoj),3.1e-07,0.16,1,22,0,1.05
Pneumonia (dsyn),7.21e-76,1.92,99,7987,77,100.23
Dissociation (mobd),1.99e-37,0.14,25,82,0,32.62
Encounter due to puberty (fndg),3.99e-14,8.12,338,23,3,24.57
Knee Injuries (inpo),2.59e-08,2.27,36,6,0,7.0
colonoscopy (diap),1.26e-21,2.14,165,577,5,212.18
Ranitidine (phsu),3.41e-15,0.12,5,31,0,5.81
Granulocyte Colony-Stimulating Factor|LAMC2 (aapp),2.16e-07,1.12,4,239,0,4.07
Formalin (hops),1.15e-06,0.29,2,43,0,2.09
beta catenin (gngm),8.63e-23,0.37,13,543,1,13.31
Hydrocortisone (horm),2.67e-37,1.08,614,560,11,1070.75
Postoperative wound complication (inpo),2.87e-09,14.94,15,17,3,28.24
Heat-Shock Response (orgf),2.89e-18,0.17,2,64,0,2.06
reactive hyperemia (patf),2.6e-06,2.22,41,13,2,17.12
Strawberry nevus of skin (neop),3.28e-06,0.18,2,21,0,2.19
DNA biosynthesis (genf),5.74e-52,0.09,6,81,1,6.44
Gene Expression (genf),1.54e-44,0.46,144,899,4,167.07
Carcinoma of larynx (neop),5.92e-07,1.18,2,205,0,2.02
School (environment) (orgt),1.54e-25,3.48,324,71,1,86.56
Blood Coagulation Disorders (dsyn),4.77e-09,2.23,21,1219,5,21.36
Entire bile duct (bpoc),2.24e-08,1.18,21,577,6,21.76
Mammography (diap),4.8e-09,1.75,96,328,5,124.1
Cesarean section (finding) (fndg),9.12e-59,5.53,210,321,20,347.38
Leucovorin (orch),9.98e-17,1.41,7,720,2,7.07
Generalized osteoarthritis (dsyn),6.97e-08,3.48,96,20,3,24.17
Tumor Angiogenesis (neop),1.51e-12,0.82,1,278,0,1.0
Thyrotropin|TH (horm),7.48e-23,46.78,51,33,1,54.35
lymphocyte proliferation (celf),3.87e-12,0.12,1,27,0,1.04
Emergency cesarean section (topp),6.24e-09,4.06,24,84,1,30.86
Deoxycorticosterone (horm),1.92e-08,0.07,1,10,0,1.1
Gases (chvs),3.19e-11,0.4,12,189,1,12.76
Progesterone (horm),2.49e-32,0.33,161,350,4,235.06
Nitric Oxide Donors (phsu),1.15e-09,0.28,6,65,2,6.55
FK-506 (orch),1.75e-24,0.16,4,77,1,4.21
Cefotaxime (antb),1.86e-06,0.36,4,90,0,4.18
Thromboxane A2 (eico),3.7e-16,0.08,1,24,0,1.04
tomography (diap),2.13e-07,1.23,708,3282,77,860.73
Aspiration-action (topp),8.9e-07,1.07,36,565,4,38.29
Case Series (resa),2.88e-16,3.15,88,535,9,102.47
Pregnancy (orgf),1.32e-138,2.73,2415,4046,117,3856.48
Cyclic AMP-Responsive DNA-Binding Protein (aapp),2.4e-13,0.09,1,22,0,1.05
External auditory canal structure (bpoc),1.93e-08,0.3,2,69,0,2.06
Stents (medd),1.55e-46,1.49,79,3744,30,80.67
Ovulation Induction (topp),3.65e-14,1.66,64,14,1,17.06
"Angioplasty, Transluminal, Percutaneous Coronary (topp)",1.92e-11,0.8,8,390,1,8.16
Acetone (orch),1.66e-17,0.16,3,58,0,3.16
Bariatric Surgery (topp),5.24e-161,19.41,1333,437,250,580.26
Topical form corticosteroids (phsu),3.81e-10,0.15,1,30,0,1.03
"TGFB1 protein, human|TGFB1 (aapp)",2.5e-58,0.25,59,346,1,69.06
oxidized low density lipoprotein (aapp),4.07e-12,1.11,152,121,10,217.32
college student (popg),2.15e-62,2.29,294,47,4,54.51
Intracranial (blor),6.27e-27,1.28,21,1196,1,21.37
Menarche (orgf),4.41e-09,9.58,319,16,11,16.8
Diarrheal disorder (dsyn),3.19e-06,1.63,2,262,0,2.02
Non-smoker (fndg),3.77e-07,3.69,173,184,25,335.66
Premature Birth (patf),5.62e-86,3.45,326,1464,43,398.59
Lymphatic Diseases (dsyn),2.37e-10,0.81,2,305,4,2.01
Brucellosis (dsyn),4.4e-20,0.19,2,81,0,2.05
Dipyridamole (orch),9.24e-11,0.32,13,93,1,14.82
Ligation (topp),1.3e-38,1.07,20,1348,7,20.3
Hyperglycemia (dsyn),6.25e-178,3.01,859,1960,71,1235.47
Fabry Disease (dsyn),2.1e-06,0.48,12,112,3,13.29
Vaccination (topp),1.5e-79,0.98,42,2457,7,42.72
Probenecid (phsu),1.45e-06,0.12,3,11,0,3.82
Vehicle accident NOS (inpo),1.2e-06,5.25,15,215,10,16.05
Mammals (mamm),8.74e-53,0.27,63,372,1,73.67
"Complication, infection (dsyn)",2.11e-09,4.45,43,862,30,45.15
Agar (phsu),2.82e-43,0.17,4,150,0,4.11
Praziquantel (phsu),4.83e-10,0.3,4,70,0,4.23
Veins (bpoc),1.63e-10,0.6,86,788,9,95.39
Subcutaneous Fat (tisu),6.03e-17,7.47,527,46,15,50.02
Hearing normal (fndg),8.89e-10,0.07,4,2,0,3.0
Polypeptides (aapp),1.49e-80,0.08,20,79,1,25.06
Podocytes (cell),1.24e-13,0.18,9,48,0,10.69
Division (procedure) (topp),5.81e-29,0.43,44,670,4,46.89
Proliferating Cell Nuclear Antigen (aapp),2.34e-29,0.22,3,136,0,3.07
year (tmco),2.14e-07,4.43,15,56,3,19.02
Fatty Acid-Binding Proteins (aapp),1.8e-12,1.42,78,35,1,50.71
Astigmatism (dsyn),2.31e-15,0.05,5,2,0,2.8
Congenital adrenal hyperplasia (cgab),7.66e-15,1.64,76,35,3,51.12
Methimazole (horm),1.75e-07,0.18,6,23,0,7.57
beta-Globin (aapp),8.1e-12,0.09,1,19,0,1.05
adalimumab|ADAL (phsu),4.05e-29,1506.73,13,24,1,20.04
Radical prostatectomy (topp),4.04e-93,3.45,324,1356,54,401.42
pol genes|ERVW-4 (gngm),1.18e-06,0.14,2,16,0,2.25
Allodynia (fndg),1.32e-10,0.04,1,6,0,1.17
Cocaine (phsu),3.16e-79,0.13,24,180,1,27.2
Probucol (orch),1.89e-08,0.13,3,19,0,3.47
Prostaglandin-Endoperoxide Synthase (aapp),7.41e-37,0.17,14,127,0,15.54
parent (famg),2.45e-66,1.54,907,905,24,1808.0
Ligaments (tisu),8.4e-07,0.25,19,29,1,31.45
Household income (fndg),1.16e-12,8.84,85,66,5,117.25
Plexus (bpoc),6.41e-08,0.23,7,36,1,8.36
Tertiary care hospital (hcro),1.54e-27,5.38,93,794,11,103.89
Aboriginals (humn),1.2e-18,3.33,87,178,6,129.52
Sexually Transmitted Diseases (dsyn),3.11e-15,0.25,12,87,0,13.66
Encephalopathies (dsyn),1.4e-21,1.08,8,691,3,8.09
Isosorbide Dinitrate (carb),1.07e-06,0.3,3,47,0,3.19
cell motility (celf),5.25e-18,0.36,3,597,0,3.02
pars compacta (bpoc),1.81e-21,0.05,2,15,0,2.27
Peripheral Vascular Diseases (dsyn),9.07e-45,2.59,275,1756,91,318.07
Triamcinolone Acetonide (phsu),1.8e-08,0.09,5,4,0,7.2
Excitatory Amino Acids (aapp),1.31e-09,0.11,2,18,0,2.22
initial segment (celc),8.64e-07,0.03,1,1,0,2.0
Serine (aapp),1.29e-27,0.13,12,60,1,14.4
Sensorineural Hearing Loss (dsyn),1.87e-13,0.2,13,52,0,16.25
"Mice, Inbred DBA (mamm)",2.37e-09,0.21,1,40,0,1.03
Sheep (mamm),7.1e-168,0.13,8,422,0,8.15
Insertion of pack (topp),3.58e-06,0.93,2,156,1,2.03
"Child, Preschool (humn)",5.25e-47,3.28,493,98,7,117.48
"Ether, Ethyl (phsu)",3.77e-17,0.1,4,30,0,4.53
trastuzumab (aapp),5.01e-22,0.96,19,757,3,19.48
CCAAT-Enhancer-Binding Protein-beta (aapp),2.83e-06,0.17,4,17,0,4.94
AIDS related complex (dsyn),6.41e-16,0.19,7,63,1,7.78
Malignant neoplasm of larynx (neop),3.06e-07,1.54,6,398,1,6.09
Eminence (bpoc),3.65e-08,0.04,1,4,0,1.25
White Matter (tisu),5.26e-18,0.39,34,240,1,38.82
Deoxyribonuclease I (aapp),3.87e-14,0.1,1,26,0,1.04
Interleukin-1 alpha (aapp),1.29e-32,0.24,36,180,2,43.2
African American (popg),8.66e-257,5.29,1158,1656,122,1967.76
Capra hircus (mamm),1.13e-27,0.23,7,142,0,7.35
medical complication (patf),2.82e-19,5.92,39,237,10,45.42
Cell Communication (celf),3.08e-26,0.21,4,115,0,4.14
Neuromyelitis Optica (dsyn),6.81e-10,0.15,3,28,0,3.32
fibrosarcoma (neop),3.44e-17,0.22,2,81,0,2.05
Glutamates (aapp),2.06e-11,0.12,2,25,0,2.16
3-Iodobenzylguanidine (phsu),2.65e-06,0.45,10,143,1,10.7
Zidovudine (nnon),1.37e-24,0.22,18,117,3,20.77
Rural Population (humn),9.18e-16,6.51,241,176,14,304.53
Lipid Metabolism (moft),4.03e-14,2.1,181,103,3,161.61
Diet good (topp),3.16e-10,14.23,111,47,8,66.9
Citrate (orch),2.34e-06,0.37,20,77,0,25.19
Endurance (fndg),9.29e-15,2.59,179,65,8,88.6
Cyclic GMP (bacs),1.17e-61,0.08,13,70,0,15.41
Dysmyelopoietic Syndromes (neop),1.06e-60,1.17,11,1756,1,11.07
Hydroxyindoleacetic Acid (bacs),1.2e-11,0.12,3,23,0,3.39
"Shock, Toxic (dsyn)",1.23e-06,1.11,1,168,0,1.01
Oxidation-Reduction (npop),1.36e-18,0.29,15,138,1,16.63
Antihypertensive Agents (phsu),1.58e-51,2.38,264,858,41,345.23
ADRBK1 gene|ADRBK1 (gngm),3.83e-18,0.33,53,189,0,67.86
reference group (humn),1.79e-11,5.06,65,81,15,117.16
Rural Communities (popg),1.82e-10,3.09,117,188,9,189.81
Dactinomycin (antb),3.88e-29,0.15,1,86,0,1.01
Dipeptides (aapp),2.83e-08,0.17,3,26,0,3.35
Gastroesophageal reflux disease (dsyn),1.61e-64,1.51,514,402,21,716.4
Low Birth Weights (fndg),3.66e-137,4.06,370,1088,33,495.83
Urticaria (dsyn),2.11e-09,0.3,7,69,0,7.71
Cardiac function (ortf),1.59e-18,2.23,189,1075,23,222.23
Digestion (orgf),7.42e-09,0.3,24,68,0,32.47
Endocrine Disruptors (hops),2.38e-06,1.46,35,20,1,31.43
Adiponectin (aapp),2.94e-93,5.97,2539,297,102,331.74
Metals (inch),3.78e-38,0.3,64,317,2,76.92
Fragile X Syndrome (dsyn),2.08e-12,0.07,4,6,0,6.67
Encounter due to tobacco use (fndg),4.43e-19,2.54,81,231,11,109.4
Amines (orch),3.58e-33,0.04,3,17,1,3.53
Adrenalectomy (topp),1.4e-10,2.03,66,209,11,86.84
Stanolone (phsu),5.76e-09,0.29,44,52,1,81.23
"Microscopes, Electron, Scanning (medd)",2.46e-07,0.34,19,74,2,23.88
Extracellular Matrix (tisu),8.18e-56,0.26,30,349,2,32.58
Superoxide Dismutase (aapp),8.27e-40,0.36,116,493,4,143.29
Postoperative Hemorrhage (patf),2.64e-06,2.95,39,380,14,43.0
Rumen (bpoc),7.08e-21,0.08,3,25,0,3.36
Transforming Growth Factor beta (aapp),3.15e-106,0.23,34,544,1,36.12
Glycosylated hemoglobin A (aapp),5.92e-11,10.11,326,126,22,174.7
Increase in blood pressure (fndg),5.86e-30,7.4,401,274,32,461.22
CXCR4 gene|CXCR4 (gngm),6.45e-07,0.37,2,234,0,2.02
Diphosphates (inch),3.46e-10,0.14,2,26,0,2.15
Oocytes (cell),2.19e-109,0.07,42,56,0,73.5
Fetal brain (emst),7.04e-11,0.12,1,25,0,1.04
Mixture (sbst),7.27e-19,0.2,3,79,0,3.11
Keratoconus (dsyn),2.63e-12,0.08,7,3,0,4.29
Menstruation Disturbances (patf),8.02e-10,3.23,74,11,1,12.64
mature animal (anim),5.41e-08,0.17,1,27,0,1.04
Phentolamine (phsu),1.4e-12,0.12,7,18,0,9.72
Neoplasm Metastasis (neop),4.13e-89,1.84,168,9224,48,171.06
Hyperalgesia (fndg),2.27e-12,0.08,6,7,0,11.14
RANTES|CCL5 (aapp),7.21e-08,0.32,10,66,0,11.52
Former smoker (humn),1.38e-34,6.54,116,159,14,200.63
Denervation (topp),6.34e-07,0.39,18,92,1,21.52
Question of pregnancy (fndg),8.92e-29,2.33,224,992,14,274.58
Pyrimidine (orch),1.6e-06,0.17,2,21,0,2.19
Hyaluronidase (aapp),1.57e-15,0.07,3,16,0,3.56
"1,4-dioxin (orch)",1.64e-12,0.2,8,49,1,9.31
Chambers (medd),4.67e-08,0.27,5,51,0,5.49
Stomach Carcinoma (neop),3.86e-17,1.25,12,928,15,12.16
High Density Lipoproteins (aapp),1.68e-28,2.37,485,250,24,378.87
Glycogen (bacs),9.77e-23,0.22,42,92,1,61.17
Sleep (orgf),1.15e-66,2.21,814,395,27,586.68
Nevus (neop),3.29e-10,0.24,2,51,0,2.08
C-Peptide (aapp),8.26e-27,4.19,371,54,11,61.86
Availability of (ftcn),4.19e-11,1.68,147,605,21,182.72
Liver function (ortf),1.51e-07,2.58,82,728,16,91.24
"Ganglia, Spinal (bpoc)",1.26e-77,0.03,1,43,0,1.02
Elastases (aapp),7.37e-08,0.31,16,65,2,19.94
Metabolic Rates (phsf),7.41e-31,1.98,201,75,6,102.99
Protein Tyrosine Phosphatase (aapp),1.35e-09,0.14,5,22,0,6.14
Heart Diseases (dsyn),6.89e-36,2.74,354,3272,92,392.3
Surgical Patients (humn),5.4e-48,3.9,200,2114,89,218.92
Leptospirosis (dsyn),1.62e-13,0.97,1,285,0,1.0
Hydrolysis (npop),2.24e-40,0.08,11,32,2,14.78
Fluorides (inch),2.69e-32,0.1,20,24,0,36.67
Mental Retardation (mobd),1.66e-12,0.33,29,125,1,35.73
Order Coleoptera (invt),7.33e-07,0.96,3,179,0,3.05
BAG3 (gngm),2.19e-09,0.25,19,46,2,26.85
IgG2 (aapp),2.14e-06,0.17,4,18,0,4.89
Thromboembolism (patf),5.29e-30,2.45,322,2451,67,364.3
Gap Junctions (bsoj),6.57e-11,0.07,1,12,0,1.08
Secondary malignant neoplasm of lymph node (neop),1.01e-20,2.36,56,3239,11,56.97
Peripheral blood mononuclear cell (cell),5.94e-30,0.36,126,379,5,167.89
Nutritional Support (topp),2.67e-63,4.37,134,490,43,170.64
leflunomide (phsu),4.28e-07,0.26,5,42,0,5.6
Entire corpus cavernosum (bpoc),3.83e-10,0.04,1,5,0,1.2
Blood Glucose (carb),1.95e-09,2.99,548,638,37,1018.7
Ultrasonography (diap),1.61e-23,1.37,998,1717,38,1578.08
Disorder characterized by fever (dsyn),2.91e-06,1.31,3,250,1,3.04
Entire dentate gyrus (bpoc),8.63e-48,0.04,1,34,0,1.03
C-reactive protein|CRP (aapp),2.16e-33,4.38,253,338,24,442.38
Ototoxicity (dsyn),3.65e-06,0.25,3,33,0,3.27
Primary biliary cirrhosis (dsyn),9.68e-14,0.43,32,226,3,36.53
Natural Killer Cells (cell),7.05e-41,0.32,14,489,0,14.4
Abdominal pressure (clna),4e-15,5.88,27,70,2,37.41
Megakaryocytes (cell),1.91e-14,0.14,1,41,0,1.02
Vasoactive Intestinal Peptide (aapp),1.19e-45,0.06,8,30,0,10.13
human old age (65+) (aggp),2.5e-07,2.62,46,286,8,53.4
Cancer pain (sosy),1.19e-07,0.26,7,46,0,8.07
Pan troglodytes (mamm),1.19e-11,0.21,2,51,1,2.08
Chronic heart failure (dsyn),3.49e-08,2.55,159,2753,113,168.18
CD4 gene|CD4 (gngm),5.92e-18,0.5,68,1172,16,71.95
"Wounds, Penetrating (inpo)",2.27e-10,1.43,2,408,2,2.01
Type 1 (clas),2.02e-36,4.38,193,298,13,318.0
"Oils, Volatile (phsu)",2.41e-11,0.37,6,288,1,6.12
Chronic low back pain (fndg),9.45e-08,0.92,106,9,2,9.76
Brain Edema (dsyn),5.59e-13,1.1,3,357,0,3.03
Phenols (orch),2.06e-20,0.08,3,29,0,3.31
Sleeves (medd),4.44e-110,10.75,1039,496,266,732.78
Glaucoma (dsyn),9.97e-29,0.22,92,64,1,108.52
Multiple polyps (neop),8.98e-10,0.27,4,60,0,4.27
Sulfonamides (phsu),3.96e-14,0.17,2,48,0,2.08
Pseudoaneurysm (anab),4.1e-24,1.01,9,691,1,9.12
Primary Lesion (dsyn),3.3e-09,1.39,3,363,1,3.02
FPR1 gene|FPR1 (gngm),9.59e-10,0.1,1,16,1,1.06
Disc degeneration (dsyn),2.91e-14,2.11,52,7,0,7.94
21-hydroxylase deficiency (dsyn),2.13e-06,1.76,27,9,0,12.0
"Pregnancy, Multiple (orgf)",7.05e-11,3.88,33,184,7,38.92
sperm cell (cell),7.32e-85,0.03,6,29,0,7.24
Esophagogastroduodenoscopy (diap),7.02e-09,2.21,67,170,2,93.41
Hematologic Neoplasms (neop),3.68e-14,2.37,50,2530,8,50.99
Palatine Tonsil (bpoc),4.73e-10,0.28,15,71,0,18.17
Tenascin (aapp),8.16e-16,0.11,2,31,0,2.13
"CRK protein, human|CRK (aapp)",9.37e-46,0.16,1,147,0,1.01
Multiple Organ Failure (patf),8.66e-07,4.31,7,1975,16,7.02
Knee (blor),3.83e-194,1.83,837,186,11,227.33
Organic solvent product (orch),1.71e-11,0.04,1,7,0,1.14
Female infertility (patf),5.31e-06,1.98,19,2,0,2.21
Thrombosis (patf),4.07e-28,1.38,113,3143,35,117.06
Bone age (fndg),2.21e-06,4.5,50,2,2,2.08
Lipofuscin (bacs),3.38e-06,0.13,1,14,0,1.07
Fluvoxamine (orch),4.15e-11,0.07,2,10,0,2.4
Vascular resistance (phsf),5.32e-07,0.33,39,62,3,63.53
Repair of hip (topp),1.58e-06,2.38,34,89,1,46.99
EDNRB (gngm),7.43e-08,0.21,1,34,0,1.03
Entire large artery (bpoc),6.14e-07,2.4,51,259,3,61.04
Cesarean section (topp),9.06e-34,2.26,231,835,15,294.91
"Swine, Miniature (mamm)",7.76e-08,0.13,1,20,0,1.05
Thyroid Diseases (dsyn),2.18e-06,1.19,95,158,5,152.12
Glucocorticoid Receptor (aapp),2.16e-19,0.2,28,66,1,39.88
Lovastatin (orch),1.13e-17,0.15,2,52,1,2.08
"Discharge, Body Substance (bdsu)",2.87e-07,0.95,50,650,13,53.85
cell invasion (celf),2.99e-07,0.73,1,256,0,1.0
K562 Cells (cell),3.37e-20,0.05,1,16,0,1.06
"N,N-dimethylarginine|ARHGEF12 (aapp)",1.01e-60,672.1,20,83,11,24.82
Pancreaticoduodenectomy (topp),4.36e-09,4.71,48,1664,58,49.38
QUINTILE (clna),6.54e-47,14.04,118,114,17,224.14
CD80 Antigens (aapp),6.81e-11,0.26,1,76,0,1.01
Sermorelin|GH1|GGH (aapp),9.11e-10,2.01,33,4,0,4.48
Bell Palsy (dsyn),2.49e-06,0.1,1,11,0,1.09
Cytochrome P-450 CYP1A1 (aapp),1.35e-10,0.13,1,26,0,1.04
Adenosine Triphosphate (bacs),1.88e-21,0.21,12,93,1,13.55
Thyroglobulin|TG (aapp),2.19e-15,0.13,3,37,0,3.24
Lamella (bpoc),6.63e-15,0.12,1,35,0,1.03
Asians (popg),2.24e-52,4.43,519,620,76,953.45
Health center (hcro),1.18e-31,3.64,114,243,7,167.48
Movement (orgf),2.85e-30,0.32,118,288,2,166.35
Papilloma (neop),3.19e-15,0.13,1,39,0,1.03
Receptor Protein-Tyrosine Kinases (aapp),4.23e-08,0.36,1,263,0,1.0
Reticulum (bpoc),3.23e-06,0.15,1,17,0,1.06
HISTORY OF SYMPTOMS & DISEASES:FINDING:POINT IN TIME:KIDNEY:NOMINAL,5.54e-22,2.27,1,17,0,1.06
Metoclopramide (orch),1.09e-12,0.14,8,27,0,10.37
Adrenergic beta-Agonists (phsu),2.62e-07,0.29,11,53,0,13.28
Nonpenetrating Wounds (inpo),2.6e-08,2.25,3,651,4,3.01
Ion Channel (aapp),1.23e-32,0.19,1,123,0,1.01
Reagents (irda),6.21e-16,0.16,7,45,1,8.09
glucose uptake (ortf),2.26e-11,1.03,151,68,2,98.62
Climate (npop),4.14e-08,1.0,16,378,1,16.68
Esophagectomy (topp),1.27e-06,4.62,44,1807,58,45.07
Dehiscence (inpo),2.64e-06,1.87,57,252,10,69.89
Gastritis (dsyn),5.97e-08,0.33,24,78,1,31.38
X Chromosome (celc),8.26e-09,0.22,11,34,2,14.56
Hemorrhoids (dsyn),4.91e-06,0.25,6,32,0,7.12
Obsessive-Compulsive Disorder (mobd),3.35e-27,0.12,27,23,0,42.59
Malignant neoplasm of endometrium (neop),8.2e-86,3.46,454,879,81,688.49
Epidemiologic Studies (resa),3.01e-35,3.21,107,312,20,143.7
Growth Factor (bacs),2.27e-75,0.29,85,598,8,97.08
Meniere's Disease (dsyn),1.47e-12,0.06,4,4,0,8.0
Adenine Nucleotides (bacs),9.72e-11,0.06,1,10,0,1.1
Activins (aapp),6.07e-12,0.21,13,45,2,16.76
montelukast (orch),6.09e-10,0.12,4,18,0,4.89
Glyceraldehyde-3-Phosphate Dehydrogenases (aapp),1.41e-12,0.08,1,18,0,1.06
Shock (patf),1.64e-23,1.41,108,2813,23,112.15
Silk (aapp),1.35e-12,0.16,1,41,0,1.02
Streptomycin (antb),3.12e-22,0.12,1,52,0,1.02
Medullary (bpoc),6.11e-33,0.27,15,211,0,16.07
Inverse (qlco),8.19e-70,5.51,818,755,99,1451.85
Neostriatum (bpoc),5.01e-181,0.08,36,194,1,42.68
Tumorigenesis (neop),1.55e-41,0.77,26,1677,6,26.4
Sarcopenia (fndg),6.59e-148,20.54,378,258,105,434.1
Alzheimer's Disease (dsyn),1.64e-66,0.35,269,809,22,358.44
TNFRSF6B gene|TNFRSF6B (gngm),2.17e-09,1.39,9,515,3,9.16
World Health Organization (hcro),4.32e-06,3.66,16,71,3,19.61
Antilipemic Agents (phsu),5.69e-32,3.21,95,259,17,129.85
Diffusion (npop),1.69e-14,0.27,13,94,4,14.8
defense response (orgf),8.42e-07,0.14,1,18,0,1.06
Fracture (inpo),1.25e-11,1.03,859,2327,67,1176.1
Aortic calcification (dsyn),1.15e-14,3.13,40,125,12,52.8
Carrier Proteins (aapp),1.43e-07,0.29,16,52,0,20.92
Sphingomyelins (bacs),1.88e-06,0.22,14,21,0,23.33
Hindlimb (bpoc),1.47e-06,0.29,3,43,0,3.21
Human serum albumin (aapp),2.15e-25,0.07,2,31,0,2.13
Metabolic syndrome (dsyn),3.83e-21,8.62,5489,1618,368,2094.94
Lactates (orch),4.19e-07,0.15,2,19,0,2.21
Epoxide hydrolase (gngm),6.08e-07,0.14,2,18,0,2.22
Lipids abnormal (fndg),1.1e-11,5.24,57,76,3,99.75
Solutions (sbst),2.33e-35,0.14,2,103,0,2.04
MONONUCLEAR CELLS (cell),8.27e-22,0.33,53,220,1,65.77
Hay fever (dsyn),6.94e-07,0.23,26,15,0,23.65
Entire trabecular meshwork (bpoc),1.57e-13,0.04,2,6,0,2.67
Triamcinolone (phsu),5.11e-08,0.08,3,6,0,4.5
Intracranial Aneurysm (dsyn),1.49e-09,1.57,5,470,1,5.05
trophoblast (emst),7.86e-12,0.25,11,69,0,12.75
HSPA5 (gngm),1.29e-09,0.17,2,33,0,2.12
"DNA, Ribosomal (bacs)",2.4e-06,0.13,1,15,0,1.07
Aneurysm (anab),2.83e-97,1.09,30,2926,5,30.31
Cyst (anab),8.33e-49,0.33,25,542,1,26.15
deceased (fndg),1.07e-13,6.43,45,1438,43,46.41
Oncogene Proteins (gngm),2.18e-06,0.37,2,160,1,2.02
Interleukin-12 (aapp),5.95e-22,0.38,19,368,1,19.98
"Fatty Acids, Saturated (bacs)",6.67e-11,1.8,79,42,3,64.33
Ribosomal RNA (bacs),9.45e-56,0.11,9,113,2,9.72
liraglutide|IDE (phsu),2.04e-23,505.08,48,18,1,24.75
End Point (resa),1.94e-27,4.61,145,2298,58,154.15
Modeling (resa),5.64e-31,2.06,229,813,28,293.5
Human Age Group (humn),1.67e-220,3.8,649,1981,58,861.62
insulin secretion (celf),2.44e-76,1.57,403,81,7,97.28
tau Proteins|MAPT (aapp),5.41e-08,0.19,1,30,0,1.03
Entire aortic arch (bpoc),7.8e-10,1.6,6,579,4,6.06
mating (orgf),1.7e-10,0.33,5,103,0,5.24
Childbirth (orgf),1.17e-17,3.19,63,179,1,85.17
"Epilepsy, Temporal Lobe (dsyn)",2.08e-36,0.14,2,98,2,2.04
Nicotine (phsu),3.93e-42,0.22,53,200,3,67.05
Combination Drug Therapy (topp),2.06e-29,1.26,8,997,1,8.06
Dyspnea (sosy),5.82e-19,2.54,192,1469,34,217.09
in vitro Model (resa),3e-07,0.17,2,23,0,2.17
"Chromatography, Gel (lbpr)",8.16e-24,0.02,1,8,0,1.12
Structure of papillary muscle (bpoc),1.31e-09,0.14,2,26,0,2.15
Hemangioma (neop),5.71e-42,0.19,3,166,0,3.05
Opioid Receptor (aapp),3.33e-22,0.08,5,25,0,6.0
Retinoblastoma Protein|RB1 (aapp),1.88e-15,0.25,2,85,0,2.05
BRAZILIAN (fndg),3.87e-08,5.14,466,303,20,500.02
Thromboxane B2 (eico),1.31e-08,0.15,8,12,1,13.33
Anura (amph),3.86e-62,0.11,3,130,0,3.07
Lipoid nephrosis (dsyn),8.23e-08,0.25,8,43,0,9.49
MMP (gngm),9.96e-08,0.36,5,98,0,5.26
Traumatic Brain Injury (inpo),8.24e-40,1.45,44,2372,6,44.82
Thyroid Gland (bpoc),1.3e-21,0.33,20,196,1,22.04
Face (blor),1.5e-16,0.5,50,373,4,56.7
Fibroblast Growth Factor (aapp),7.48e-21,0.21,13,94,1,14.8
Vero Cells (cell),8.41e-07,0.28,1,55,0,1.02
Disease Progression (patf),2.85e-09,2.86,237,3345,45,253.79
Underweight (fndg),7.74e-157,25.29,1212,242,334,290.32
Snoring (sosy),9.59e-14,7.24,384,33,11,35.84
Group C (clas),3.06e-06,2.15,34,122,5,43.48
Epiphysis of bone (bpoc),2.18e-07,0.09,1,12,0,1.08
Pre-existing disease (sosy),1.48e-06,4.26,23,345,14,24.53
I Kappa B-Alpha (bacs),1.33e-17,0.27,6,112,1,6.32
Hypoglycaemic episode (dsyn),3.6e-06,4.01,34,52,2,56.23
Cervix carcinoma (neop),9.34e-10,0.96,13,406,5,13.42
Muramidase (aapp),6.82e-19,0.11,3,37,0,3.24
Energy Metabolism (phsf),8.51e-56,3.43,969,256,34,323.63
Collagen (aapp),2.29e-100,0.22,89,482,1,105.43
Epithelium (tisu),1.13e-187,0.25,32,1048,2,32.98
TRANSCRIPTION FACTOR (aapp),1.96e-115,0.29,78,870,1,84.99
Small cell carcinoma of lung (neop),1.37e-62,0.97,7,1537,8,7.03
Thalamic structure (bpoc),3.04e-23,0.27,20,152,0,22.63
Motion (npop),2.8e-22,0.18,27,63,0,38.57
"Laser Therapy, Low-Level (topp)",5.11e-09,0.32,9,77,0,10.05
Nuclear Proteins (aapp),2.98e-27,0.19,2,106,0,2.04
Laparoscopic Colectomy (topp),6.54e-42,6.57,49,164,29,63.64
Excessive weight loss (fndg),2.72e-09,38.58,140,12,22,13.03
Suicide (inpo),5.83e-14,1.83,37,1851,20,37.74
Papillary thyroid carcinoma (neop),1.47e-06,0.99,42,531,1,45.32
TUBULAR CELLS (cell),1.09e-16,0.27,5,102,1,5.25
Metyrapone (phsu),2.38e-06,0.15,1,18,0,1.06
Baclofen (aapp),3.97e-17,0.11,6,30,0,7.2
Annexins (aapp),1.2e-11,0.14,1,33,0,1.03
IGA Glomerulonephritis (dsyn),1.79e-08,0.44,27,148,5,31.93
Connective Tissue Diseases (dsyn),1.22e-08,1.0,17,411,2,17.7
tat Genes|TAT (gngm),8.9e-14,0.15,9,32,0,11.53
11-beta-Hydroxysteroid Dehydrogenase Type 1 (aapp),5.3e-07,2.56,46,10,2,12.17
Hospitalized Patients (humn),1.38e-52,4.06,284,3673,109,305.96
Entire head (bpoc),1.39e-08,0.53,39,444,2,42.43
Topoisomerase (aapp),2.23e-15,0.2,1,62,0,1.02
health disparity (hlca),6.16e-10,4.41,24,67,0,32.6
Janus kinase 2|JAK2 (aapp),4.84e-10,0.24,1,49,0,1.02
Granulocyte Colony-Stimulating Factor (aapp),4.43e-08,0.71,14,564,0,14.35
server (popg),1.55e-07,0.1,2,11,0,2.36
Billroth I Procedure (topp),2.39e-25,3.3,69,230,21,89.7
Pancreatic Ductal Adenocarcinoma (neop),4.71e-06,2.31,10,858,9,10.12
"Ventricular Function, Left (ortf)",6.47e-35,2.61,239,1255,26,284.51
Mesothelioma (neop),1.78e-14,1.1,3,427,2,3.02
Kidney operations NOS (topp),3.74e-06,3.24,16,52,3,20.92
Glutathione Disulfide (aapp),3.52e-06,0.27,12,36,0,16.0
Gunshot wound (inpo),4.97e-09,1.41,1,335,2,1.0
CDKN1A|TCEAL1|NSG1|H3F3AP6 (gngm),4.42e-37,0.27,3,305,1,3.03
Ornithine Decarboxylase (aapp),7.9e-23,0.05,1,18,0,1.06
bone morphogenetic protein 2 (aapp),9.06e-11,0.13,3,26,0,3.35
Berberine (orch),1.97e-14,0.15,2,42,0,2.1
ENOLASE (aapp),7.23e-08,0.14,1,21,0,1.05
Tissue Extracts (bacs),6.26e-07,0.19,2,27,0,2.15
Ca(2+)-Transporting ATPase (aapp),4.52e-06,0.14,2,14,0,2.29
"Antigens, Differentiation (imft)",1.17e-07,0.18,2,28,0,2.14
EGF gene|EGF (gngm),8.58e-22,0.16,2,69,1,2.06
FASTK Gene (aapp),1.19e-14,0.23,8,76,0,8.84
Factor Xa (gngm),5.45e-07,0.38,5,78,1,5.32
Apomorphine (phsu),5.21e-26,0.02,1,6,0,1.17
Growth Inhibitors (bacs),1.47e-16,0.23,2,80,0,2.05
rituximab (phsu),4.12e-68,0.92,8,1555,6,8.04
Pulmonary Fibrosis (dsyn),6.75e-11,1.03,13,513,9,13.33
PATIENT PROFILE (hlca),3.91e-06,4.72,12,48,2,15.0
Hepatitis B reactivation (dsyn),3.25e-06,1.01,1,141,0,1.01
Coronary angiography (diap),2.33e-95,3.39,325,1148,41,417.01
Pituitary cell (cell),4.33e-18,0.03,3,3,0,6.0
Atrioventricular Block (dsyn),5.94e-07,1.02,4,221,1,4.07
sevoflurane (orch),2.35e-08,0.35,32,95,0,42.78
Propofol (orch),1.61e-10,0.45,106,279,4,146.27
"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse (neop)",3.73e-12,1.41,2,406,0,2.01
Levonorgestrel (phsu),3.42e-06,1.14,48,9,1,10.69
Transfection (mbrt),8.66e-45,0.14,3,122,0,3.07
Fingerprints (mnob),1.81e-08,0.09,1,14,0,1.07
Brain natriuretic peptide (aapp),7.74e-29,2.83,167,1167,51,190.9
Clone (tisu),1.2e-54,0.26,3,433,0,3.02
"Lupus Erythematosus, Systemic (dsyn)",5.54e-44,0.56,216,1672,11,243.9
Alcohols (orch),2.09e-14,0.17,7,45,0,8.09
Chlamydia trachomatis (rich),2.18e-11,0.09,4,11,0,5.45
Outpatients (podg),4.21e-73,2.5,851,1757,95,1263.18
Ocular Hypertension (dsyn),1.67e-06,0.15,10,4,0,5.6
Osteoblasts (cell),2.01e-37,0.16,31,100,0,40.61
Heart Valves (bpoc),2.09e-06,1.76,95,2303,34,98.92
Older Population (popg),7.85e-112,6.47,180,435,28,254.48
"Echocardiography, Transesophageal (diap)",1.25e-07,1.01,16,375,2,16.68
Underserved Population (popg),4.65e-06,3.47,17,48,0,23.02
Allergens (imft),3.95e-33,0.09,11,40,0,14.03
Androgen therapy (topp),1.81e-10,2.98,65,532,17,72.94
neutrophil (cell),7.13e-197,0.26,69,1181,4,73.03
Entire flexor tendon (bpoc),1.66e-06,0.08,2,6,0,2.67
water channel (aapp),5.27e-13,0.19,3,52,0,3.17
Cigarette Smoking (dora),4.16e-29,3.94,161,267,28,258.08
Macular Holes (dsyn),6.57e-13,0.03,1,3,0,1.33
Atherosclerosis (dsyn),1.29e-226,2.92,1756,3500,192,2637.01
Lymph node excision (topp),6.67e-11,3.87,93,1308,20,99.61
Zona Pellucida (celc),1.27e-08,0.05,1,5,0,1.2
"Genes, Reporter (gngm)",1.92e-10,0.09,1,17,0,1.06
Vaginal delivery procedure (topp),5.32e-34,3.51,102,276,8,139.7
film (photographic) (mnob),4.43e-10,0.15,4,26,0,4.62
SMALL SIZE (fndg),1.06e-30,3.48,84,219,13,116.22
Malignant mesothelioma (neop),4.18e-09,0.83,4,233,0,4.07
Diltiazem (phsu),2.58e-32,0.1,1,64,0,1.02
"Leukemia, Lymphocytic, Acute (neop)",6.26e-13,1.32,105,2035,27,110.42
Schizoaffective Disorder (mobd),9.89e-08,2.24,91,43,13,63.32
Ampicillin (antb),3.49e-08,0.36,3,175,0,3.05
QTC INTERVAL (orga),3.88e-09,4.4,21,92,4,25.79
Sulfuric Acid Esters (orch),3.7e-09,0.25,25,40,1,40.62
Central incisor (bpoc),4.41e-09,0.07,4,2,0,3.0
Histone Deacetylase (aapp),3.9e-12,0.29,5,82,0,5.3
functional disability (fndg),1.96e-06,2.98,49,89,2,75.98
Patient Selection (resa),2.53e-12,4.53,52,681,19,55.97
Molecular Chaperones (aapp),1.76e-31,0.16,10,98,1,11.02
Females (popg),2.76e-40,5.36,777,647,29,1185.75
Cranial Nerves (bpoc),8.18e-07,0.97,2,163,0,2.02
CA3 (gngm),3.73e-07,0.16,3,20,0,3.45
TNF-related apoptosis-inducing ligand|TNFSF10 (aapp),6.01e-20,0.19,4,76,1,4.21
Microsomes (celc),3.3e-90,0.03,7,29,0,8.69
"Component, LOINC Axis 1 (clas)",1.05e-12,3.0,153,249,11,247.01
Peripheral Stem Cell Transplantation (topp),7.23e-08,2.18,3,472,0,3.02
Dental Implants (medd),1.23e-14,0.1,3,25,0,3.36
Upper gastrointestinal hemorrhage (dsyn),2.88e-09,2.3,7,718,0,7.07
Somatotropin (aapp),1.36e-10,0.84,366,262,18,449.55
Nation (orgt),3.15e-09,9.01,141,78,5,121.15
Optic Disk (bpoc),3.41e-07,0.2,17,13,0,22.94
Glutamate-Ammonia Ligase (aapp),1.31e-16,0.06,1,19,0,1.05
Orthologous Gene (gngm),3.82e-38,0.12,4,88,0,4.18
Facilitation (ortf),5.66e-16,0.14,6,40,0,6.9
Angiotensin II (aapp),6.23e-97,0.22,75,473,2,86.89
Erosive esophagitis (dsyn),1.22e-08,3.75,71,8,1,8.9
Dopamine (nsba),1.64e-181,0.12,71,341,2,85.78
Aortic diameter (fndg),3.98e-08,4.58,22,142,4,25.41
Cartilage damage (inpo),1.23e-09,2.66,39,3,0,3.23
NELFCD (gngm),9.68e-14,0.33,12,122,0,13.18
Protein Kinase C|DYT10|PRRT2 (aapp),4.66e-23,0.07,2,28,0,2.14
Lymphocyte (cell),1.23e-201,0.2,87,899,4,95.42
"EP300 protein, human|EP300 (aapp)",4.43e-11,0.1,3,18,0,3.5
Gamma globulin (aapp),9.41e-11,0.12,1,25,0,1.04
Paget's Disease (neop),2.12e-07,0.83,1,168,1,1.01
Pelvic prolapse (dsyn),1.5e-44,1.75,199,34,0,39.81
Kidney Diseases (dsyn),5.21e-50,2.01,581,2938,77,695.89
Invasive Carcinoma (neop),4.95e-11,1.04,8,368,0,8.17
Argipressin (phsu),9.2e-57,0.28,25,378,1,26.65
Infectious Mononucleosis (dsyn),9.9e-10,0.19,2,39,0,2.1
Dominant-Negative Mutation (comd),1.47e-08,0.22,2,40,0,2.1
Substance P Receptor (aapp),3.81e-10,0.08,1,14,0,1.07
Aortic valve replacement NOS (topp),3.54e-07,4.57,53,2641,88,54.06
Calcium (bacs),7.93e-30,0.48,560,1170,41,828.03
Decidua (bpoc),1.35e-12,0.11,2,24,0,2.17
Botulinum Toxins (hops),1.36e-16,0.2,23,55,1,32.62
RNA Interference (genf),8.36e-07,0.36,2,172,0,2.02
Magnetism (npop),7.53e-16,0.04,1,11,0,1.09
Zebrafish (fish),3.74e-18,0.37,10,424,1,10.24
beta-Endorphin (aapp),3.06e-20,0.1,18,6,0,8.0
Natriuretic Peptides (aapp),6.86e-12,2.58,70,427,19,81.48
Ambulatory Care Facilities (hcro),4.3e-33,2.93,818,1162,61,1393.84
Vagotomy (topp),2.87e-06,0.23,4,31,0,4.52
Somatosensory Cortex (bpoc),6.71e-13,0.03,2,2,0,4.0
Knee pain (sosy),1.1e-23,4.73,185,8,1,8.35
"Tissue, Paraffin (tisu)",1.67e-10,1.14,2,286,0,2.01
Unrelated (fndg),3.39e-13,1.93,203,1069,11,241.55
Glucose Transporter (aapp),4.68e-10,0.18,9,31,0,11.61
cell body (neuron) (celc),8.29e-13,0.41,58,215,9,73.65
Pneumocystis (fngs),3.11e-06,1.43,2,226,0,2.02
terbinafine (orch),2.61e-08,0.12,1,18,0,1.06
BRAF gene|BRAF|SNRPE (gngm),6.07e-13,1.08,7,445,2,7.11
Preventive Intervention (hlca),3.16e-14,4.61,29,78,4,39.78
Alcohol dehydrogenase (aapp),8.3e-18,0.08,3,23,0,3.39
Carbohydrates (carb),1.01e-53,1.3,430,197,12,287.25
Light Sources (medd),1.64e-06,0.08,1,8,0,1.12
Tumor Suppressor Genes (gngm),1.7e-34,0.76,13,1344,5,13.13
Microbial Biofilms (bact),1.31e-13,0.31,4,135,0,4.12
MYOD1 (gngm),9.82e-07,0.13,3,12,0,3.75
Dexamethasone (phsu),1.51e-129,0.32,95,1124,1,103.03
"Blood Pressure Monitoring, Ambulatory (diap)",3.49e-13,5.58,94,101,10,181.49
Basal Ganglia (bpoc),6.55e-24,0.31,15,191,0,16.18
"Leukemia, Myelocytic, Acute (neop)",1.19e-122,1.29,22,4438,24,22.11
Optic Nerve (bpoc),7.56e-29,0.16,8,92,0,8.7
undergraduate student (popg),3.53e-08,2.3,36,6,0,7.0
Galectin 1 (aapp),2.7e-08,0.23,1,39,0,1.03
Nitrate (inch),3.9e-18,0.26,21,115,0,24.83
anti-IgM|CD40LG (aapp),5.11e-08,0.19,1,31,0,1.03
Multiple tumors (neop),8.45e-08,1.29,4,292,0,4.05
Xenon (phsu),1.16e-06,0.12,1,15,0,1.07
Interleukin-7 (aapp),3.58e-09,0.25,3,49,0,3.18
Lipoproteins (aapp),4.73e-56,1.22,568,386,24,648.32
SP1 gene|SP1 (gngm),3.34e-18,0.13,4,44,0,4.36
CD14 gene|CD14 (gngm),1.58e-07,0.48,21,151,5,23.92
P-Glycoprotein (aapp),2.22e-62,0.15,12,187,0,12.77
Column Chromatography (lbpr),3.71e-09,0.06,2,6,0,2.67
Glycolipids (bacs),3.15e-19,0.07,1,26,0,1.04
Cell Wall (celc),3.63e-66,0.13,4,167,1,4.1
N-terminal pro-B-type natriuretic peptide (aapp),3.94e-44,4.81,97,504,32,115.67
Nerve Fibers (celc),7.58e-11,0.16,13,20,0,21.45
Phenolics (orch),5.37e-13,0.22,15,58,0,18.88
Heart Arrest (patf),1.77e-19,3.2,17,3432,26,17.08
Primary Neoplasm (neop),3.07e-58,1.73,20,3247,15,20.12
Workers (humn),1.31e-31,1.17,640,1107,16,1010.01
RAC1 (gngm),5.03e-19,0.14,2,54,0,2.07
Interferon-beta (aapp),7.64e-29,0.18,11,111,0,12.09
S-Adenosylmethionine (aapp),7.44e-12,0.15,7,28,1,8.75
Camels (mamm),3.63e-08,0.18,1,29,0,1.03
Epiphysial cartilage (tisu),2.77e-13,0.14,16,15,0,29.06
CATHEPSIN D|CTSD (aapp),3.36e-15,0.16,2,48,0,2.08
Lymphoproliferative Disorders (neop),1.12e-24,0.98,2,556,1,2.01
Reserpine (phsu),6.74e-17,0.03,1,8,0,1.12
Lower respiratory tract infection (dsyn),2.19e-07,1.36,6,425,6,6.08
Chlamydia (rich),8.07e-12,0.15,3,33,1,3.27
Health care facility (hcro),2.59e-94,4.27,412,3804,92,456.62
Two (qnco),3.46e-07,1.15,584,1566,41,801.79
Myofibrils (celc),2.24e-06,0.09,2,6,0,2.67
Offspring (famg),4.43e-33,2.05,983,802,27,1456.33
Movement Disorders (dsyn),1.96e-10,0.25,13,60,0,15.82
"STAT5A protein, human|STAT5A (aapp)",4.08e-16,0.19,1,62,0,1.02
IGHE (gngm),1.25e-51,0.14,42,87,1,62.28
Mitogen-Activated Protein Kinases (aapp),5.58e-102,0.18,11,392,1,11.31
Lipid A (imft),1.09e-09,0.14,1,26,0,1.04
Syncope (sosy),1.67e-11,0.89,21,457,1,21.96
Renal Blood Flow (ortf),6.1e-10,0.27,8,63,0,9.02
Screw (medd),7.5e-10,0.34,39,104,2,53.62
Platelet rich plasma (bdsu),6.1e-07,0.2,5,27,0,5.93
Water consumption (orgf),5.85e-17,1.66,160,117,7,202.56
ALPHA-AMYLASE (aapp),4.94e-14,0.08,4,13,0,5.23
"Mice, Transgenic (mamm)",5.25e-58,0.31,21,597,0,21.74
Metal stent (medd),7.38e-12,2.22,10,1123,6,10.09
Gelatin (aapp),8.77e-11,0.19,3,43,0,3.21
Microfilaments (celc),3.98e-24,0.06,1,28,0,1.04
Human Chorionic Gonadotropin|CTSG (aapp),3.43e-08,100.67,5,7,0,8.57
Methylene blue (phsu),1.28e-13,0.26,8,85,1,8.75
chemokine (aapp),7.05e-07,0.6,89,940,5,97.43
Echocardiography (diap),1.59e-46,2.66,355,2322,61,409.27
"Endarterectomy, Carotid (topp)",4.87e-10,2.2,9,974,6,9.08
Demography (ocdi),5.55e-101,8.85,135,339,20,188.76
"Medical record, device (mnob)",3.24e-19,3.81,64,315,9,77.0
Spinal Fractures (inpo),2.16e-13,2.85,204,329,13,330.49
Plasmodium falciparum infection (dsyn),3.33e-08,0.76,3,269,0,3.03
poor health (fndg),1.75e-67,5.84,182,305,35,290.6
Saline (clnd),4.96e-17,0.31,7,127,0,7.39
Zinc (bacs),1.09e-08,0.52,242,496,5,360.07
Secretin (aapp),2.68e-07,0.08,3,4,0,5.25
Population Group (humn),0.0,35.36,681,1521,85,985.91
Midazolam (orch),2.07e-13,0.37,33,168,2,39.48
Seminal fluid (bdsu),8e-07,0.14,6,11,0,9.27
Enalapril (aapp),2.49e-13,0.42,19,186,3,20.94
Neck Dissection (topp),1.61e-07,2.18,7,587,0,7.08
Transfer factor - respiratory measure (fndg),3.79e-17,4.87,37,160,8,45.56
Dystrophy (patf),1.44e-06,0.19,6,21,0,7.71
Hyaluronic Acid (bacs),7.71e-14,0.24,29,64,0,42.14
Lack of sensation (sosy),1.16e-08,0.58,102,433,7,126.03
Behavior (inbe),2.08e-42,2.11,1635,1380,73,2544.77
radioligand (irda),1.03e-06,0.12,3,12,0,3.75
Delirium (mobd),3.84e-09,1.75,17,966,11,17.3
Chemical-Induced Change (resa),6.29e-07,0.14,1,18,0,1.06
Ranibizumab (aapp),2.79e-21,0.06,1,21,0,1.05
"Lymphoma, Large-Cell, Diffuse (neop)",8.07e-09,2.59,12,1410,14,12.1
Dopa (phsu),3.45e-17,0.04,2,8,0,2.5
Laparotomy (topp),2.51e-17,2.89,173,1615,30,191.53
Caffeine (orch),1.99e-12,0.32,77,108,2,131.9
Congenital heart disease (dsyn),1.62e-11,1.65,72,1981,16,74.62
Biopsy sample (tisu),1.02e-07,0.67,95,615,3,109.67
Abnormal renal function (patf),1.1e-17,3.36,130,1461,38,141.57
Adsorbents (phsu),1.65e-10,0.15,1,30,1,1.03
"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human|COX8A|COX5A (aapp)",3.79e-17,0.26,4,98,0,4.16
HLA-E (gngm),1.49e-22,0.14,1,65,0,1.02
Delusions (mobd),2.02e-06,0.26,4,37,0,4.43
Salicylic Acid (phsu),1.23e-21,0.1,2,39,1,2.1
Diclofenac (orch),1.81e-13,0.24,13,72,0,15.35
1-Phosphatidylinositol 4-Kinase (aapp),1.98e-14,0.15,2,44,0,2.09
Periodontal Diseases (dsyn),9.71e-21,1.3,177,116,3,192.02
Brain natriuretic peptide|NPPB (horm),5.16e-94,242.54,39,438,19,42.47
resistin|RETN (horm),6.99e-32,4.4,371,36,13,39.49
Pheromone (bacs),1.18e-09,0.09,1,16,0,1.06
Oxytocin|HCRT (aapp),7.33e-11,35.13,9,13,0,15.23
Gonorrhea (dsyn),6.08e-20,0.07,2,22,0,2.18
Clinical act of insertion (hlca),4.86e-06,2.97,35,305,10,39.02
"Chromosomes, Human, Pair 21 (celc)",4.38e-06,0.18,2,20,0,2.2
NBL1 gene|NBL1 (gngm),1.36e-06,0.15,3,16,0,3.56
melanoma (neop),1.11e-97,0.77,56,3855,12,56.81
Cardiac Tamponade (dsyn),1.09e-06,1.56,3,334,2,3.03
fibroblast growth factor 21|FGF21 (aapp),3.5e-10,2.02,49,13,1,16.45
Platelet Activating Factor (imft),9.74e-50,0.06,1,56,0,1.02
Human Cell Line (cell),2.43e-177,0.17,18,620,1,18.52
Phenobarbital (orch),6.38e-40,0.12,3,97,0,3.09
"Receptors, Progesterone|PGR (gngm)",3.69e-10,0.28,15,71,0,18.17
Operation on abdominal region (topp),7.3e-22,3.69,60,308,22,71.69
TP53 gene|TP53 (gngm),6.92e-42,0.41,36,2281,10,36.57
Twin Multiple Birth (humn),3.51e-21,2.63,249,472,7,380.36
Hormones (horm),7.32e-25,1.08,370,303,11,551.13
mast cell (cell),4.27e-87,0.07,6,102,0,6.35
Cell Proliferation (celf),1.36e-33,0.43,55,1677,7,56.8
Vibration - physical agent (npop),1.93e-14,0.05,2,8,0,2.5
"Infections, Hospital (dsyn)",6.09e-10,2.48,13,1432,13,13.12
Serum albumin measurement (lbpr),7.9e-10,12.24,13,19,3,21.89
Fibrinogen (aapp),8.56e-11,1.57,316,414,28,557.2
Bone structure of calcaneum (bpoc),9.79e-10,1.05,102,22,0,26.75
nitric oxide receptor (aapp),2.35e-13,0.13,1,34,0,1.03
3/4 (fndg),1.78e-23,5.46,46,171,8,58.37
C-reactive protein level (lbtr),4.06e-31,7.02,48,97,6,71.75
Small-for-dates unspecified (patf),1.25e-09,7.35,98,73,6,127.38
AROMATICS (orch),4.28e-18,0.05,2,14,0,2.29
"Liver Failure, Acute (dsyn)",7.77e-22,1.82,7,1293,7,7.04
"Urinary Incontinence, Stress (dsyn)",1.4e-53,1.45,306,22,0,23.58
Structure of parenchyma of lung (bpoc),1.86e-17,0.72,12,905,1,12.16
Hematopoiesis (ortf),5.85e-15,0.33,14,135,1,15.45
Isoproterenol (orch),5.54e-55,0.14,34,113,0,44.23
Immune Sera (gngm),3.61e-153,0.06,3,190,0,3.05
Prostaglandin Production (phsf),6.45e-09,0.09,1,14,0,1.07
Colectomy (topp),1.09e-11,3.6,45,470,24,49.31
Proto-Oncogenes (gngm),4.2e-20,0.24,3,103,0,3.09
Nucleus pulposus (bpoc),1.76e-07,0.11,5,7,0,8.57
Collimator (medd),1.57e-06,0.15,3,14,1,3.64
Amyloid (aapp),2.37e-16,0.34,44,180,2,54.76
Progesterone Receptor Status (clna),1.33e-06,5.28,11,25,1,15.84
Prostate-Specific Antigen (aapp),8.64e-10,1.59,172,539,9,226.89
inhibitors (chvf),8.17e-09,0.91,34,518,5,36.23
Microbicides (phsu),2.07e-80,1.3,37,3292,10,37.42
Electrolytes (inch),8.98e-16,0.28,19,111,1,22.25
Intervention Studies (resa),8.97e-17,4.31,37,91,4,52.04
Mucous Membrane (tisu),2.13e-54,0.44,101,1561,5,107.53
Virulence (biof),1.05e-36,0.83,2,825,0,2.0
Lymphedema (dsyn),9.57e-20,1.36,153,120,10,214.12
Deoxyglucose (carb),1.64e-09,0.18,6,31,1,7.16
Epithelial Cells (cell),2.65e-299,0.18,31,1126,4,31.85
Body Weight decreased (fndg),4.62e-181,15.26,4033,1111,477,1417.06
Medication use (fndg),1.23e-18,4.07,86,148,10,135.97
Left Ventricle Remodeling (ortf),1.27e-07,3.09,46,327,5,52.47
Syphilis (dsyn),6.8e-22,0.24,2,110,0,2.04
osteoblast differentiation (celf),2.61e-07,0.2,9,25,0,12.24
Immunoglobulins|WDR20 (aapp),1.31e-06,73.89,5,57,0,5.44
"Transplantation, Homologous (topp)",4.85e-06,3.18,5,707,1,5.04
Cleft Lip (cgab),1.51e-07,0.23,8,35,0,9.83
Calcitonin Gene-Related Peptide (aapp),1.35e-47,0.03,3,19,0,3.47
Antipsychotic Medications (hlca),1.91e-08,4.48,51,69,8,88.7
Amyloid beta-Protein Precursor (aapp),7.69e-32,0.09,3,56,0,3.16
Binding Protein (aapp),7.69e-35,0.24,49,187,3,61.84
S Phase (genf),4.11e-12,0.16,1,39,0,1.03
Malignant neoplasm of lung (neop),6.17e-38,1.66,175,6560,109,179.67
Sedentary (fndg),5.17e-07,7.78,1187,407,71,546.55
Minority Groups (popg),3.93e-31,4.42,78,215,3,106.3
Tumor Necrosis Factor-alpha (aapp),2.38e-10,0.7,474,1745,25,602.75
SMAD2 gene|SMAD2 (gngm),4.17e-06,0.3,2,44,0,2.09
Ventricular arrhythmia (patf),2.54e-12,1.4,20,892,8,20.45
Exertion (orgf),2.12e-10,1.69,263,1435,20,311.2
Hypopituitarism (dsyn),4.79e-06,2.44,68,141,15,100.79
Chondroitin Sulfates (bacs),1.58e-11,0.09,2,13,1,2.31
Female (orga),1.9e-143,2.82,3797,5624,260,6360.52
Flagella (celc),1.63e-09,0.08,1,13,0,1.08
Encounter due to cardiac rehabilitation (fndg),3.29e-58,6.53,102,201,20,153.76
Transglutaminases (aapp),6.87e-15,0.05,1,11,0,1.09
Antigen-Presenting Cells (cell),7.24e-22,0.21,1,96,0,1.01
Prostaglandins (bacs),3.66e-101,0.15,22,305,0,23.59
Entire tendon (bpoc),5.67e-16,0.2,48,21,0,30.19
Cell surface (celc),8.54e-144,0.12,18,347,0,18.93
Citric Acid (bacs),7.1e-08,0.1,3,9,0,4.0
Bone plates (medd),2.74e-23,0.28,68,155,0,97.83
Isotretinoin (orch),1.03e-15,0.2,9,66,0,10.23
Gonadorelin (aapp),3.85e-14,0.28,67,69,3,132.06
Levetiracetam (orch),9.33e-09,0.31,9,71,0,10.14
Aspergillus (fngs),5.15e-09,1.38,2,305,0,2.01
Human cells (lbtr),2.28e-63,0.15,9,199,0,9.41
Extracellular (celc),1.97e-98,0.26,158,638,14,197.13
Gonadotropins|HSD3B1 (phsu),9.43e-08,1042.37,40,6,0,6.9
Autophagy (celf),1.63e-70,0.25,12,384,0,12.38
abciximab (aapp),8.78e-08,1.33,2,315,3,2.01
"Recombination, Genetic (genf)",1.45e-40,0.07,3,47,0,3.19
bevacizumab|COX5A (phsu),1.18e-20,9800.24,7,499,3,7.1
Respiratory distress (sosy),4.45e-06,1.9,6,482,3,6.07
Secretin|SCT (aapp),4.53e-07,0.07,2,4,0,3.0
Cancer Promoting Genes (gngm),1.98e-06,0.89,2,156,1,2.03
Cardiopulmonary (blor),3.76e-103,4.71,222,625,34,300.85
RNA (bacs),2.6e-208,0.21,113,977,9,126.07
Entire sciatic nerve (bpoc),2.5e-26,0.08,7,25,0,8.96
Elastin|ELN (aapp),1.18e-09,0.14,3,23,1,3.39
C-reactive protein measurement (lbpr),4.15e-13,11.89,94,55,9,87.18
Primary Care Physicians (prog),1.46e-07,1.99,52,156,5,69.33
"Sleep Apnea, Central (dsyn)",6.14e-16,3.36,47,117,4,65.88
South Asian (humn),7.6e-58,6.89,192,256,25,336.0
Radiopharmaceuticals (irda),6.32e-07,0.27,2,41,0,2.1
Tumor Antigens (imft),1.32e-08,0.33,1,152,0,1.01
Dichlorodiphenyl Dichloroethylene (orch),7.52e-07,2.14,45,16,1,21.69
Ammonia (bacs),3.28e-26,0.24,10,145,1,10.69
Immunomodulators (imft),3.08e-11,0.8,31,648,1,32.48
Lipolysis (orgf),1.46e-41,1.56,218,41,4,48.71
multilevel analysis (resa),3.15e-09,3.5,25,68,2,34.19
Normal renal function (fndg),2.19e-17,3.18,78,465,16,91.08
"Infant, Premature (humn)",2.5e-36,1.22,72,2198,2,74.36
Structure of interstitial cell of Leydig (cell),1.66e-25,0.02,1,6,0,1.17
6/5 (fndg),2.08e-28,5.63,53,145,6,72.37
Gonadorelin|ZBTB7A|CREBRF (aapp),1.38e-07,13.31,31,23,1,40.06
Memantine (orch),1.63e-09,0.26,4,55,0,4.29
Bone Morphogenetic Proteins (aapp),4.7e-23,0.15,8,65,0,8.98
Sequence Analysis (lbpr),1.69e-06,0.4,13,83,0,15.04
Socioeconomic Status (qlco),4.53e-09,10.87,11,18,3,17.72
Albuterol (orch),9.96e-17,0.22,13,79,0,15.14
HLA Antigens (aapp),1.15e-06,0.4,7,140,0,7.35
Pyotraumatic dermatitis (dsyn),9.19e-08,0.31,3,60,0,3.15
Immunoglobulin A (aapp),1.07e-06,0.22,4,30,0,4.53
Respiratory complication (patf),1.28e-17,5.53,34,247,15,38.68
"Hypertension, Renovascular (dsyn)",3.43e-08,0.28,5,53,0,5.47
FAVOR (orch),5.48e-41,2.11,411,1976,44,496.49
Complications of Diabetes Mellitus (patf),1.44e-33,4.59,88,180,9,131.02
Hallucinations (mobd),6.63e-07,0.33,4,56,0,4.29
Duct (organ) structure (bpoc),7.41e-13,0.24,4,66,0,4.24
Entire entorhinal cortex (bpoc),1.59e-11,0.05,2,6,0,2.67
Toluene (orch),3.91e-14,0.05,2,10,0,2.4
Durapatite (phsu),4.16e-26,0.06,4,20,0,4.8
Pyruvate Dehydrogenase Complex (aapp),2.32e-06,0.08,1,8,0,1.12
Immunoglobulin G (aapp),5.96e-22,0.28,24,155,1,27.72
recombinant FVIIa (aapp),3.36e-06,1.21,1,171,0,1.01
Silence (mobd),7.17e-08,0.4,6,339,0,6.11
Dextroamphetamine (orch),5.98e-11,0.04,2,3,0,3.33
Left ventricular systolic dysfunction (patf),3.23e-08,4.56,42,644,14,44.74
Heartburn (sosy),6.72e-16,2.21,88,22,0,27.5
Micronucleus (celc),5.43e-07,0.23,7,33,0,8.48
Contact Dermatitis (dsyn),1.39e-10,0.03,1,4,0,1.25
Neurofibrillary Tangles (acab),1.68e-10,0.16,2,32,0,2.12
insulin sensitivity (patf),2.38e-38,8.15,2139,252,42,281.69
Energy Balance (orgf),2.32e-09,4.78,340,77,14,94.44
"Neoplasm, Residual (neop)",8.36e-11,1.65,1,428,1,1.0
Breast adenocarcinoma (neop),2.96e-07,0.22,1,32,0,1.03
PROTECTION (fndg),1.37e-40,0.97,104,2218,16,108.88
Cytomegalovirus (virs),1.23e-49,0.85,13,1150,0,13.15
Gel (bodm),6.37e-09,0.1,1,15,0,1.07
Cohort Studies (qnco),1.06e-94,13.53,97,234,18,137.21
Dysmenorrhea (patf),4.66e-12,1.49,63,10,0,11.59
Risk Reduction (topp),3.4e-69,5.99,143,639,21,175.0
Silicon Dioxide (bodm),2.44e-23,0.19,2,90,0,2.04
Complex (qlco),5.31e-20,3.27,160,275,21,253.09
"RNA, Messenger (bacs)",2.3e-131,0.23,79,715,1,87.73
parathyroid hormone-related protein (aapp),8.24e-21,0.15,1,64,0,1.02
Respiratory Burst (celf),1.46e-19,0.23,4,96,0,4.17
Methylene Chloride (phsu),3.61e-08,0.09,1,12,0,1.08
"Contraceptives, Oral (phsu)",1.59e-38,1.51,225,82,4,111.88
lymphoblastoid cell line (cell),4.71e-06,0.13,1,14,0,1.07
Amenorrhea (dsyn),1.65e-12,2.53,128,44,4,59.12
Anogenital venereal warts (dsyn),9.32e-13,0.18,1,47,0,1.02
Mental disorders (mobd),1.07e-06,1.03,479,1379,62,645.38
Diabetic Retinopathy (dsyn),2.39e-07,0.92,201,203,9,400.02
Signaling Molecule (bacs),6.04e-16,0.36,17,163,0,18.77
IDO1 (gngm),8.61e-07,0.38,5,73,1,5.34
Extensor (blor),2.2e-13,1.07,130,9,0,9.62
Poor glycemic control (patf),1.9e-18,9.24,168,112,10,186.67
Fabaceae (plnt),1.14e-07,0.14,4,17,0,4.94
abnormal glucose tolerance test (fndg),4.66e-06,9.94,1027,283,38,360.98
Reflex action (ortf),4.03e-13,0.21,4,58,0,4.28
Sulindac (phsu),1.05e-06,0.25,3,36,0,3.25
Dioxygenases (aapp),1.48e-06,0.36,5,62,1,5.4
Malignant Glioma (neop),1.43e-24,1.01,2,548,0,2.01
Hamartoma (neop),8.54e-19,0.17,1,66,0,1.02
Primordium (ortf),5.75e-13,0.1,3,19,1,3.47
Onychomycosis (dsyn),1.58e-13,0.04,1,8,0,1.12
Membrane Proteins (aapp),3.84e-89,0.13,6,236,1,6.15
Vancomycin (antb),2.04e-11,0.98,43,723,3,45.56
Tooth structure (bpoc),3.59e-34,0.2,60,88,6,100.91
Diastolic dysfunction (patf),4.89e-59,4.09,140,370,22,192.97
Scopolamine (phsu),1.47e-13,0.08,4,12,0,5.33
Ureteral obstruction (dsyn),1.18e-08,0.3,3,59,1,3.15
Hepatocyte (cell),1.23e-241,0.16,67,785,1,72.72
release of sequestered calcium ion into cytoplasm (celf),3.71e-10,0.13,5,18,0,6.39
Monozygotic twins (humn),1.85e-06,1.25,63,69,2,120.52
ATP-Binding Cassette Transporters|ATP8A2 (aapp),1.67e-06,0.23,2,31,0,2.13
Eicosapentaenoic Acid (bacs),3.59e-07,1.13,104,137,9,182.95
Vascular Permeability (ortf),1.12e-06,0.4,6,127,1,6.28
"Receptors, Nuclear (aapp)",1.59e-07,0.37,28,97,1,36.08
Retroviridae (virs),4.09e-39,0.1,1,75,0,1.01
Spastic syndrome (dsyn),3.42e-19,0.2,10,78,3,11.28
peginterferon alfa-2b|IFNA1 (phsu),1.46e-08,19.67,8,20,0,11.2
Infantile spasms (dsyn),3.31e-09,0.2,1,38,0,1.03
Societies (orgt),2.03e-06,2.4,59,412,9,67.45
Female Breast Carcinoma (neop),7.95e-14,4.82,31,176,9,36.46
Calcitonin (aapp),4.26e-23,0.18,20,77,0,25.19
Gram-Negative Bacteria (bact),1.81e-22,0.8,4,643,2,4.02
Carcinoma of Nasopharynx (neop),2.01e-33,0.93,12,962,8,12.15
Visual Acuity (clna),3.53e-20,0.19,11,74,2,12.64
Light microscopy (lbpr),1.89e-13,0.31,4,124,0,4.13
Neuronal Transmission (celf),1.13e-17,0.15,14,42,0,18.67
Indirect Immunofluorescence (lbpr),3.11e-06,0.18,2,22,0,2.18
Yohimbe Preparation (orch),8.86e-16,0.06,2,15,0,2.27
Metric (orch),8.54e-21,2.55,89,314,20,114.23
Myocardial Ischemia (dsyn),2.18e-12,1.94,324,3018,118,358.78
lenalidomide (orch),1.22e-10,1.3,3,355,0,3.03
beta-Tubulin (aapp),6.56e-08,0.24,1,40,0,1.03
Arteriovenous malformation (neop),3.21e-07,0.32,2,81,0,2.05
"Evoked Potentials, Motor (diap)",3.71e-06,0.16,6,12,0,9.0
Cardiac cachexia (fndg),9.06e-08,7.83,7,16,6,10.06
Testis (bpoc),2.53e-124,0.12,19,273,0,20.32
Laparoscopic adrenalectomy (topp),9.05e-14,3.09,45,118,15,62.16
Revision procedure (topp),7.34e-45,3.6,174,368,32,256.27
Cities (geoa),2.69e-08,3.76,35,64,0,54.14
Waist circumference (fndg),2.67e-15,38.68,2910,101,193,104.51
Back Pain (sosy),2.04e-11,1.51,131,128,1,253.07
Atropine (phsu),4.91e-35,0.17,11,117,1,12.03
Estriol (horm),3.11e-06,0.09,2,7,0,2.57
Solvents (irda),8.64e-27,0.07,1,36,0,1.03
Budesonide (phsu),2.6e-09,0.27,16,57,1,20.49
Lambda (blor),2.84e-12,0.15,1,38,0,1.03
Colorectal resection (topp),1.82e-34,8.28,39,311,29,43.89
GB virus C (virs),1.98e-08,0.22,1,38,0,1.03
Vegetation (anab),1.67e-09,1.21,1,257,0,1.0
HSPB1 gene|HSPB1 (gngm),1.52e-06,0.32,5,51,0,5.49
Entire papillary muscle (bpoc),4.71e-10,0.23,1,49,0,1.02
Lipids (lipd),1e-161,1.24,1545,964,70,1565.49
Tramadol (phsu),4.02e-09,0.22,6,40,1,6.9
Receptor Gene (gngm),1.31e-23,1.73,188,112,3,178.72
Radical gastrectomy (topp),7.96e-09,6.9,16,174,7,17.47
HEART STUDY (diap),1.06e-13,10.94,34,35,9,67.03
Hamman-Rich syndrome (dsyn),8.29e-11,1.43,18,963,19,18.34
"APP protein, human|APP (aapp)",2.28e-07,0.18,5,20,1,6.25
Nicotinamide adenine dinucleotide (NAD) (bacs),7.71e-24,0.11,10,36,0,12.78
Magnetic Resonance Spectroscopy (diap),7.17e-26,1.3,207,99,4,146.35
"Mice, Nude (mamm)",8.2e-25,0.34,4,527,0,4.03
Science (ocdi),2.21e-06,0.37,6,65,0,6.55
Sleeplessness (sosy),8.09e-16,1.25,153,134,9,251.36
Cadmium (elii),3.54e-14,0.36,80,181,7,115.36
Telomerase (aapp),5.47e-22,0.24,2,118,0,2.03
Diagnosis (hlca),2.01e-26,1.92,1122,9443,165,1255.31
Mucous body substance (bdsu),2.25e-08,0.32,2,116,0,2.03
Thromboembolic event (patf),1.18e-11,3.73,61,651,18,66.72
Cholangiocarcinoma (neop),8.01e-21,1.48,4,842,3,4.02
p65|RELA|SYT1|GORASP1|WNK1 (gngm),4.38e-06,0.41,5,126,2,5.2
Adenosine (phsu),2.86e-76,0.16,37,226,0,43.06
Ifosfamide (phsu),5.07e-13,0.9,5,319,0,5.08
Does squat (fndg),9.39e-07,3.17,32,2,0,2.12
beta-2 Microglobulin (aapp),6.58e-09,0.38,6,94,4,6.38
PROTEIN KINASE (aapp),2.59e-67,0.14,22,166,2,24.92
Endostatins (phsu),8.55e-10,0.34,6,84,1,6.43
Nucleosides (nnon),7.31e-09,0.15,3,24,0,3.38
Acetylcholine (nsba),2.68e-78,0.11,41,107,1,56.71
Fasting (fndg),1.88e-23,5.15,584,96,12,111.78
Aminolevulinic Acid (aapp),3.83e-16,0.1,1,32,0,1.03
Proline (aapp),8.54e-20,0.13,10,40,0,12.5
Priapism (dsyn),2.43e-06,0.15,1,18,0,1.06
Entire renal tubule (bpoc),9.88e-09,0.32,3,69,1,3.13
Heat-Shock Proteins 70 (aapp),5.2e-06,0.46,11,111,0,12.09
Structure of locus ceruleus (bpoc),3.98e-22,0.04,4,6,0,6.67
Icterus (patf),1.34e-18,1.09,9,622,2,9.13
Untranslated Regions (bacs),1.2e-07,0.29,7,54,0,7.91
"Genome, Human (gngm)",4.65e-07,0.26,11,42,0,13.88
Methylprednisolone (horm),2.56e-06,0.45,13,391,0,13.43
trait (orga),6.58e-15,2.55,330,174,6,265.75
Proteinuria (dsyn),7.85e-29,1.8,289,1036,38,369.62
Entire scalp (bpoc),1.94e-13,0.49,35,275,4,39.45
Thyroxine|ELANE (aapp),5.28e-41,121.01,41,38,1,73.22
Copper (bacs),2.67e-30,0.3,86,251,2,115.47
Warfarin (hops),5.38e-16,0.81,71,1234,9,75.09
CD69 (gngm),1.57e-07,0.25,1,40,0,1.03
Adolescent idiopathic scoliosis (anab),3.26e-15,1.59,71,11,3,12.7
drospirenone (orch),1.51e-06,2.97,32,3,0,3.28
Gonadorelin|RHCE|RHD (aapp),1.06e-08,51.24,6,9,0,10.0
"Hysterectomy, Vaginal (topp)",3.84e-06,1.83,37,17,1,24.81
Phospholipase (aapp),1.74e-10,0.25,15,55,1,19.09
Interleukin-2|IL2 (aapp),4.65e-25,0.17,5,85,0,5.29
Isoenzymes (aapp),1.81e-08,0.16,8,17,0,11.76
Aminophylline (orch),1.93e-08,0.21,3,36,0,3.25
Somatotropin|GH1|GGH (horm),9.5e-10,287.7,3,9,2,4.0
Rare Diseases (dsyn),3.97e-15,1.15,42,1004,3,43.76
Lewy Body Disease (dsyn),4.5e-07,0.23,2,35,0,2.11
Prenatal care (hlca),5.9e-37,4.75,101,436,7,124.4
Cervical Intraepithelial Neoplasia (neop),8.1e-12,0.35,8,124,0,8.52
Leukocytes (cell),7.55e-32,0.49,178,878,12,214.09
Plasmin (aapp),6.14e-20,0.13,5,46,0,5.54
Hepatolenticular Degeneration (dsyn),5.78e-07,0.37,3,100,2,3.09
Gland structure (bpoc),6.04e-27,0.2,18,107,3,21.03
Gene Family (gngm),2.01e-21,0.15,6,62,0,6.58
Calpain (aapp),2.18e-22,0.13,1,57,0,1.02
bacteriocin (aapp),1.09e-09,0.07,1,11,0,1.09
Fibrosis (patf),5.7e-19,1.72,755,5125,96,866.22
"Hepatitis C, Chronic (dsyn)",6.02e-27,1.25,457,720,8,747.07
Suppressor T Lymphocyte (cell),4.71e-07,0.27,1,48,0,1.02
Tight Junctions (bsoj),2.52e-08,0.27,1,58,0,1.02
Candida (fngs),5.24e-08,1.27,2,273,1,2.01
APP gene|APP (aapp),7.21e-24,0.37,16,342,3,16.75
cancer recurrence (neop),5.6e-07,5.07,10,271,20,10.37
Cytokinesis (celf),9.3e-11,0.1,1,19,0,1.05
Epidermal Growth Factor|EGF (aapp),1.98e-90,0.08,12,121,1,13.19
Epidermal Growth Factor Receptor|EGFR (aapp),2.13e-18,0.69,11,1226,4,11.1
Esophageal Varices (dsyn),1.14e-07,1.16,7,317,1,7.15
Uracil (bacs),7.47e-08,0.17,1,27,0,1.04
Isoelectric Focusing (lbpr),1.43e-07,0.09,3,7,0,4.29
Calcitriol (horm),9.34e-08,0.49,19,154,5,21.34
Lymphoma (neop),9.89e-77,0.8,38,2569,10,38.56
Girls (popg),1.19e-101,3.25,3236,1337,39,1889.4
Pleural effusion disorder (patf),3.84e-11,1.16,21,641,4,21.69
Mollusca (invt),5.15e-10,0.27,1,74,0,1.01
Cimetidine (orch),2.95e-42,0.03,1,26,0,1.04
Tail (bpoc),2.33e-23,0.45,43,591,4,46.13
Entire thumb (bpoc),5.82e-07,0.2,11,16,2,18.56
Grade (clas),9.8e-84,3.98,356,660,15,548.02
Bone Regeneration (ortf),4.71e-06,0.11,1,11,0,1.09
Observational Study (resa),1.2e-85,7.45,160,1104,39,183.19
Oryza sativa (plnt),1.82e-26,0.15,14,67,1,16.93
"Lymphoma, Non-Hodgkin's (neop)",1.52e-19,1.26,52,1505,11,53.8
Smooth muscle (tissue) (tisu),1.02e-112,0.19,32,456,1,34.25
Muscarinic Acetylcholine Receptor (aapp),8.24e-40,0.04,4,21,0,4.76
Contraceptive methods (topp),2.69e-07,1.37,114,153,2,198.94
Plasma Exchange (topp),1.02e-19,0.97,1,405,0,1.0
Western society (humn),2.55e-29,5.31,62,173,3,84.22
"2,2,6,6-tetramethyl-4-piperidinol-N-oxyl (orch)",2.05e-07,0.2,1,29,0,1.03
Trochanter (bpoc),1.03e-07,2.72,106,40,3,55.09
M NOS (aapp),1.03e-06,0.22,2,30,1,2.13
Naproxen (phsu),5.68e-08,0.19,9,24,0,12.38
Chemokine (C-C Motif) Ligand 4|CCL4 (aapp),8.81e-11,0.24,3,55,0,3.16
Androstenedione (horm),6.06e-30,1.69,132,10,4,10.76
Acid Phosphatase (aapp),3.77e-23,0.07,3,24,0,3.38
Primary Health Care (hlca),9.16e-22,2.75,158,335,16,232.52
Ventilator-associated lung injury (inpo),2.39e-10,3.22,6,1205,3,6.03
Ruminants (mamm),3.93e-10,0.35,6,122,0,6.3
ethyl acetate (orch),7.61e-07,0.26,1,39,0,1.03
Ouabain (carb),1.26e-39,0.04,2,27,0,2.15
Acute graft-versus-host disease (patf),3.46e-06,3.86,3,1041,6,3.01
Phencyclidine (orch),1.45e-07,0.03,1,1,0,2.0
Tannic Acid (orch),5.5e-12,0.16,1,37,0,1.03
basiliximab|BAS (imft),3.02e-06,694.6,1,24,2,1.04
"Hospitals, University (hcro)",2.32e-201,5.29,438,1607,60,557.38
Immobilization (topp),7.59e-08,0.43,27,135,0,32.4
Color (npop),3.8e-17,0.15,9,45,0,10.8
Myosin Light Chains (aapp),2.99e-07,0.09,1,11,0,1.09
Methionine (aapp),5.97e-25,0.21,28,109,1,35.19
Myocardial Infarction (dsyn),3.04e-19,2.73,656,11063,265,694.9
connective tissue growth factor (aapp),3.04e-17,0.14,1,48,0,1.02
Antiphospholipid Antibodies (aapp),2.59e-07,0.41,9,91,0,9.89
Protein Kinase C Inhibitor (phsu),9.92e-10,0.08,2,11,0,2.36
gastric inhibitory polypeptide receptor (aapp),4.13e-06,2.64,27,3,0,3.33
Transcription Coactivator (aapp),6.89e-10,0.16,3,31,0,3.29
Chemotaxis (celf),1.01e-44,0.11,6,96,0,6.38
Alteplase|CALCA|PCYT1A (phsu),9.1e-26,1590.53,13,470,1,13.36
arginine methyl ester (aapp),9e-15,0.17,4,50,0,4.32
"Vaccines, Inactivated (imft)",7.33e-07,0.86,3,162,0,3.06
Bone Wires (medd),1.41e-07,0.46,18,131,2,20.47
Amblyopia (dsyn),6e-11,0.06,4,3,0,5.25
Intravenous therapy (topp),2.22e-08,1.08,18,453,2,18.72
leptin receptor|LEPR (aapp),1.1e-11,3.96,127,17,3,19.28
Systolic hypertension (dsyn),1.96e-20,5.52,61,99,11,98.59
Bronchopulmonary Dysplasia (dsyn),6.81e-12,1.2,7,436,0,7.11
"Pneumonitis, Interstitial (dsyn)",1.82e-08,1.22,2,310,3,2.01
establishment and maintenance of substrate location (biof),1.37e-47,0.28,27,324,2,29.25
Form of muscle (fndg),7.54e-21,10.88,635,190,102,246.85
young adulthood (humn),2.94e-07,7.85,388,151,42,209.77
"Pneumocyte, type 2 (cell)",2.83e-11,0.24,1,58,0,1.02
Institutionalized (fndg),1.97e-07,3.34,105,143,19,182.1
biological adaptation to stress (phsf),1.56e-11,0.47,45,242,1,53.37
Immunity (phsf),3.49e-38,0.88,58,1444,4,60.33
Massive hemorrhage (patf),4.68e-08,1.82,4,455,1,4.04
Gastrointestinal Stromal Tumors (neop),3.41e-27,1.0,9,749,1,9.11
Resuscitation (topp),6.92e-11,2.87,8,1613,14,8.04
N-Methylaspartate (phsu),3.21e-60,0.05,1,53,0,1.02
Entire long bone (bpoc),4.87e-09,0.43,14,130,1,15.51
Dehydroepiandrosterone Sulfate (bacs),5.06e-21,2.52,156,39,3,48.75
cell injury (comd),3.01e-06,0.55,28,244,1,31.21
Lipid Peroxidation (moft),1.39e-09,0.35,27,106,1,33.88
Dyskinetic syndrome (dsyn),3.24e-13,0.2,9,54,0,10.5
Ice (inch),1.09e-09,0.26,5,58,1,5.43
Tetrodotoxin (bacs),4.3e-22,0.03,2,9,0,2.44
"Insulin, Glargine, Human (aapp)",3.79e-06,3.08,141,58,3,81.86
Poisoning (inpo),4.92e-21,1.43,6,869,3,6.04
Duodenum (bpoc),6.12e-16,0.51,59,683,6,64.1
Blood Cells (cell),6.25e-07,0.51,51,210,3,63.39
Guanylate Cyclase (aapp),1.49e-16,0.08,2,21,0,2.19
Dependence (mobd),2.64e-18,0.5,70,446,12,80.99
Entire iris (bpoc),2.46e-29,0.11,3,64,0,3.14
Activated Lymphocyte (cell),2.32e-06,0.21,1,27,0,1.04
isoniazid (orch),1.05e-16,0.32,8,141,0,8.45
Nursing Homes (hcro),9.19e-09,1.91,62,202,12,81.03
Androgen Receptor|AR (aapp),8.66e-21,0.25,15,120,1,16.88
Hedgehog signaling complex location (celc),1.72e-06,0.19,1,24,0,1.04
Drug resistance (biof),9.82e-25,0.83,5,582,0,5.04
disease stage (diap),3.03e-08,5.38,18,118,4,20.75
Metastatic Carcinoma (neop),1.31e-20,0.99,4,499,0,4.03
Pulmonary Edema (dsyn),3.13e-14,1.25,13,693,4,13.24
"[M]Adenocarcinoma, metastatic, NOS (neop)",1.45e-07,1.33,1,224,0,1.0
Carcinosarcoma (neop),3.18e-07,0.97,3,204,1,3.04
Entire vas deferens (bpoc),4.23e-28,0.04,5,10,0,7.5
Chamber (bpoc),4.27e-13,0.45,84,298,5,107.68
Cyclosporine|POR (aapp),1.03e-08,215.93,5,39,0,5.64
Platelet volume (fndg),1.52e-17,3.72,72,141,10,108.77
insulinoma (neop),1.4e-06,0.41,14,88,0,16.23
Promoter (Genetics) (bacs),5.19e-14,0.21,11,59,0,13.05
Hemoperfusion (topp),8.11e-08,0.9,1,173,1,1.01
PLAT gene|PLAT (gngm),2.45e-29,0.11,6,58,1,6.62
Cations (chvs),3.37e-25,0.06,2,26,0,2.15
Married (fndg),3.93e-33,2.72,136,434,20,178.62
capecitabine (phsu),1.96e-18,1.53,3,672,0,3.01
Learning Disabilities (mobd),3.89e-12,0.15,8,29,0,10.21
School child (aggp),2.79e-63,4.53,901,119,14,134.72
celecoxib (phsu),4.48e-18,0.33,16,163,0,17.57
"Rats, Zucker (mamm)",7.6e-15,0.16,9,41,1,10.98
Cerebral Palsy (dsyn),6.66e-10,0.48,111,318,0,149.75
Cell-Free System (celc),1.68e-13,0.03,1,4,0,1.25
calreticulin|CALR (aapp),1.69e-06,0.15,1,19,0,1.05
Sucrose (bacs),2.75e-06,0.33,61,42,0,70.92
Meperidine (phsu),4.48e-06,0.16,6,10,1,9.6
CA1|S100A10 (gngm),1.26e-18,0.09,1,33,0,1.03
Gout (dsyn),6.37e-12,1.59,150,140,4,270.67
cardiac arrhythmia (patf),1.95e-09,1.57,71,1769,20,73.85
Chronic Disease (dsyn),5.78e-170,2.9,962,2172,145,1388.08
Primary bacterial peritonitis (dsyn),2.06e-07,1.9,1,317,0,1.0
Obstructed labor (patf),8.63e-12,2.59,92,201,11,134.11
DMD|BEST1 (gngm),8.18e-32,3.09,252,41,4,47.67
outer membrane (celc),1.94e-42,0.13,1,110,0,1.01
Blood Transfusion (topp),4.59e-16,3.4,108,1338,44,116.72
"Hypertension, Pulmonary (dsyn)",2.79e-11,1.49,94,2171,30,98.07
Peptidylprolyl Isomerase (aapp),2.58e-09,0.11,2,18,0,2.22
Repeat Surgery (topp),1.41e-56,4.41,208,2492,102,225.36
NGF (gngm),3.11e-08,0.09,4,5,0,7.2
erlotinib (phsu),1.78e-23,1.07,2,580,1,2.01
Succinate Dehydrogenase (aapp),1.38e-09,0.13,2,24,0,2.17
Ovarian Follicle (bpoc),2.78e-33,0.13,38,34,0,64.42
Tretinoin (phsu),1.54e-122,0.13,9,314,6,9.26
Insulin measurement (lbpr),4.83e-06,7.34,163,18,0,19.99
EXERCISE INTOLERANCE (sosy),1.19e-08,3.29,28,65,1,40.06
Secondary prevention (topp),4.27e-09,4.28,60,1065,25,63.38
End stage liver disease (dsyn),2.56e-10,6.23,51,1848,43,52.41
Antidepressive Agents (phsu),1.36e-12,0.54,204,641,14,268.92
Leptin|LEP (aapp),0.0,3.9,2983,247,88,267.45
"Sleep Apnea, Obstructive (dsyn)",7.42e-33,5.34,2872,720,152,900.5
Entire midbrain (bpoc),1.53e-29,0.14,9,80,0,10.01
Immunoglobulin D (aapp),3.24e-06,0.1,1,10,0,1.1
Narcolepsy (dsyn),4.05e-06,1.01,64,12,1,14.25
CDC2 Protein Kinase|CDK1 (gngm),9.63e-09,0.09,1,14,0,1.07
Physical function (fndg),7.98e-27,7.09,392,272,25,460.73
Skin Specimen (bpoc),1.11e-06,0.32,4,52,0,4.31
Operation on stomach (topp),1.12e-29,11.43,197,124,24,202.05
growth hormone secretion (celf),1.04e-14,1.39,86,12,1,13.67
Bronchi (bpoc),5.04e-09,0.36,3,175,1,3.05
adenylate cyclase activity (moft),7.79e-12,0.02,1,1,0,2.0
Muscle Cells (cell),4.48e-59,0.22,32,287,1,35.57
stage IIIA breast cancer (neop),7.72e-09,14.23,10,14,4,17.14
middle ear (bsoj),3.16e-11,0.17,2,39,0,2.1
Losartan (orch),1.03e-06,0.58,57,280,7,68.6
Lysosomes (celc),2.43e-36,0.1,2,73,0,2.05
6/4 (fndg),7.53e-15,6.06,28,118,4,34.64
particle (chvs),1.11e-15,0.43,43,264,3,50.0
Observation parameter (fndg),4.65e-65,3.02,2819,3495,183,5092.75
"Cell Transformation, Neoplastic (neop)",5.55e-10,0.22,1,45,0,1.02
Etiology aspects (ftcn),1.18e-08,3.1,59,464,7,66.5
Protein Synthesis Inhibitors (phsu),6.87e-09,0.09,1,14,0,1.07
"Neoplasms, Intracranial (neop)",5.87e-07,1.11,2,192,0,2.02
Organelles (celc),7.81e-34,0.1,2,62,0,2.06
Procaine (orch),1.6e-06,0.07,2,3,0,3.33
Entire facial nerve (bpoc),3.9e-14,0.24,1,75,0,1.01
Enalapril|HSD3B1 (aapp),2.38e-06,39.25,5,27,0,5.93
PARP1 (gngm),6.38e-09,0.22,1,40,0,1.03
Endothelial dysfunction (dsyn),2.38e-83,2.97,603,1200,62,906.01
Duodenal Ulcer (dsyn),3.92e-32,0.2,18,135,0,20.4
Health (idcn),0.0,3.17,1288,3060,141,1830.14
PD 98059 (phsu),1.3e-19,0.06,2,20,0,2.2
Embryo (emst),6.72e-214,0.19,29,843,1,30.0
Echocardiographs (medd),1.97e-06,2.84,26,95,1,33.12
Breast Feeding (orgf),4.26e-24,1.34,411,580,14,702.24
Superantigens (gngm),1.89e-10,0.27,1,77,0,1.01
Acids (chem),4.81e-49,0.19,48,173,3,61.32
Thiopental (orch),7.59e-09,0.23,7,45,0,8.09
Detectors (medd),6.12e-19,0.2,34,56,0,54.64
Molecular Modeling (inpr),1.4e-10,0.09,1,17,0,1.06
"Hypertrophy, Left Ventricular (patf)",5.16e-115,3.62,529,1043,111,797.3
Secondary malignant neoplasm of liver (neop),7.24e-37,2.1,19,3191,25,19.11
Domestic Sheep (mamm),5.5e-81,0.12,1,185,1,1.01
neuropeptide Y|NPY (aapp),3.99e-10,0.29,81,30,1,41.11
Clonidine (phsu),6.76e-43,0.09,10,64,0,11.56
Interleukin-4 (aapp),3.13e-78,0.21,49,370,1,55.49
Chorionic Gonadotropin (aapp),9.08e-09,0.03,1,2,0,1.5
Osteopenia (dsyn),2.62e-23,3.68,375,83,12,101.37
Low Back Pain (sosy),9.05e-36,1.25,288,80,3,102.22
Centenarians (humn),1.68e-07,2.98,26,85,2,33.95
Ascites (fndg),5.81e-07,1.63,29,873,5,29.96
Lysine (phsu),3.01e-27,0.2,27,98,3,34.44
Trace Elements (bacs),1.22e-08,1.21,122,191,7,199.93
Hour (tmco),2.61e-09,3.36,46,309,5,52.85
Crossbreeding (genf),3.6e-09,0.15,3,26,0,3.35
cholinergic system (bacs),1.58e-07,0.1,2,12,0,2.33
Laryngeal Squamous Cell Carcinoma (neop),1.6e-06,1.41,2,233,0,2.02
Cerebrospinal Fluid (bdsu),8.42e-28,0.36,65,333,0,77.69
Intestines (bpoc),6.6e-34,0.56,264,3231,27,285.57
Dietary Fats (food),8.71e-15,1.8,114,62,2,95.72
Allergic Reaction (patf),5.49e-12,0.32,5,104,0,5.24
Anisotropy (npop),6.16e-14,0.08,6,9,0,10.0
Immunoglobulins (aapp),2.83e-87,0.29,30,602,2,31.5
Vascular inflammations (dsyn),7.99e-08,2.86,57,111,3,86.27
Proto-Oncogene Proteins c-fos|FOS (aapp),1.07e-43,0.06,3,44,0,3.2
Peroxynitrite (bacs),6.98e-17,0.18,2,63,0,2.06
Streptococcus pneumoniae (bact),2.28e-63,1.16,2,1565,1,2.0
Matched Case-Control Studies (resa),6.85e-11,8.72,16,59,1,20.34
Virulence Factors (bacs),1e-06,0.72,12,457,1,12.32
Screening procedure (hlca),5.03e-248,2.76,1126,3817,117,1458.17
Subarachnoid Hemorrhage (dsyn),1.46e-21,1.37,34,1404,6,34.82
Autonomic dysfunction (patf),2.04e-16,2.91,59,212,12,75.42
Immunocompromised Host (fndg),4.89e-24,2.55,9,1839,2,9.04
Glucans (carb),6.36e-11,0.24,2,57,0,2.07
Caspase Inhibitor (phsu),1.15e-06,0.19,1,25,0,1.04
jejunum (bpoc),9.45e-30,0.37,19,394,5,19.92
Piroxicam (orch),7.31e-09,0.11,2,16,0,2.25
conjugation (celf),1.37e-13,0.16,5,41,0,5.61
Tissue Engineering (topp),5.52e-08,0.18,2,29,0,2.14
Lamina Propria (tisu),7.12e-18,0.16,5,57,0,5.44
Luteolin (orch),1.09e-09,0.11,1,19,0,1.05
genotoxicity (comd),3.01e-15,0.27,10,99,1,11.01
Population Study (resa),1.09e-19,6.46,37,67,15,57.43
Procedure on spinal cord (topp),5.44e-19,3.96,67,133,14,100.75
Participant (popg),5.48e-282,6.28,7916,5129,699,8452.22
ATRIAL FIBRILLATION RECURRENT (dsyn),1.96e-08,3.1,27,87,3,35.38
Alanine (aapp),3.69e-12,0.25,35,53,0,58.11
Ileal conduit procedure (topp),2.45e-07,3.12,22,87,5,27.56
Postoperative infection NOS (dsyn),5.56e-14,2.83,61,298,14,73.49
Introns (bacs),8.26e-09,0.17,10,19,1,15.26
Nitrogen (elii),1.83e-35,0.17,20,111,5,23.6
Endoplasmic Reticulum (celc),2.39e-68,0.08,5,105,0,5.24
Kainic Acid (orch),1.08e-15,0.18,1,58,0,1.02
Long-term oxygen therapy (topp),4.46e-08,3.91,4,68,20,4.24
Prospective Studies (resa),0.0,5.9,751,3384,136,917.67
CD40LG (gngm),7.37e-42,0.24,18,233,1,19.39
Hispanics (humn),2.56e-124,4.94,556,842,51,923.14
Endothelial Cells (cell),5.37e-226,0.2,66,952,4,70.58
"Angioplasty, Balloon (topp)",4.74e-19,1.09,11,672,2,11.18
Essential Tremor (dsyn),5.7e-10,0.12,5,13,1,6.92
CATALASE|CAT (aapp),2.4e-10,0.28,21,69,0,27.39
arsenite (inch),8.27e-12,0.07,1,13,0,1.08
Hyaluronan (bacs),3.82e-22,0.17,11,75,0,12.61
Oxidase (aapp),2.92e-23,0.17,5,78,0,5.32
trastuzumab|ERBB2 (aapp),6.79e-09,43.65,10,415,3,10.24
Body mass index (clna),7.02e-167,46.31,19749,254,1949,257.27
synaptogenesis (ortf),6.64e-09,0.05,1,6,0,1.17
"Transcranial Magnetic Stimulation, Repetitive (topp)",4.04e-09,0.11,6,10,0,9.6
Estrus (orgf),8.49e-15,0.09,3,20,0,3.45
"Epilepsies, Partial (dsyn)",8.69e-07,0.29,14,45,1,18.36
cancer surgery (topp),1.62e-16,6.41,35,258,8,39.75
Methane (orch),2.87e-12,0.07,3,10,0,3.9
Microtomy (lbpr),3.3e-06,0.06,1,5,0,1.2
T-Cell Proliferation (celf),1.64e-15,0.21,1,66,1,1.02
"Pain, Postoperative (sosy)",7.31e-09,1.16,113,125,5,215.15
Bucladesine (nnon),7.85e-08,0.03,1,1,0,2.0
Immunocytochemistry (lbpr),1.73e-17,0.15,2,54,0,2.07
Aggressive behavior (mobd),2.1e-16,0.87,67,1007,11,71.46
Apolipoprotein A-I (aapp),8.8e-21,1.36,154,87,6,136.15
Monoterpenes (orch),3.25e-06,0.22,1,27,0,1.04
cyclooxygenase 1 (gngm),1.84e-08,0.22,5,40,0,5.62
Macaca mulatta (mamm),8.39e-41,0.19,18,158,3,20.05
C5|C5AR1 (gngm),5.89e-07,0.32,4,54,1,4.3
Antihypertensive therapy (topp),2.97e-12,2.82,54,217,6,67.44
Achievement (inbe),2.57e-17,3.21,55,143,4,76.15
"Cell Line, Transformed (cell)",4.64e-06,0.1,1,10,0,1.1
Lipase (aapp),6.26e-16,0.3,40,122,4,53.11
Amoxicillin (antb),1.73e-12,0.37,10,142,0,10.7
Replacement therapy (topp),1.11e-06,1.7,142,390,12,193.7
Guanine (bacs),3.62e-09,0.09,3,10,0,3.9
Vitamin D (phsu),1.62e-17,3.74,1190,1065,65,2018.13
"VEGF protein, human|VEGFA (aapp)",2.4e-56,0.45,106,1307,4,114.6
Immunoglobulin Isotypes (aapp),1.41e-26,0.2,5,115,0,5.22
Ciliary Body (bpoc),4.27e-11,0.21,2,50,0,2.08
Paw (bpoc),1.13e-15,0.12,6,30,0,7.2
Malignant neoplasm of cervix uteri (neop),1.75e-16,1.51,81,2284,23,83.87
Delayed Hypersensitivity (patf),7.34e-20,0.16,4,65,0,4.25
Benzodiazepines (phsu),6.31e-15,0.47,33,349,1,36.12
Survivors (podg),1.05e-82,3.24,573,6827,265,621.09
Simian immunodeficiency virus (virs),1.93e-13,0.21,2,57,2,2.07
FGFR3 gene|FGFR3 (gngm),3.9e-09,0.19,3,30,3,3.3
Focal Adhesions (celc),9.56e-11,0.09,1,18,0,1.06
Pelvis (blor),2.21e-11,1.61,279,1351,19,336.62
derivatives (chvs),2.87e-07,0.18,3,26,0,3.35
Horns (bpoc),8.46e-10,0.39,17,122,0,19.37
beta-defensin-2 (aapp),7.81e-08,0.09,2,9,0,2.44
Endotoxins (lipd),4.51e-17,0.43,26,571,4,27.18
Hemangiosarcoma (neop),4.24e-18,1.0,2,409,0,2.01
Filters (medd),1.15e-40,0.27,17,262,4,18.1
Neurotrophic Tyrosine Kinase Receptor Type 2|NTRK2 (gngm),7.12e-08,0.12,3,15,0,3.6
"Obesity, Morbid (dsyn)",2.15e-122,19.5,1826,359,375,429.58
"Surgical Procedures, Elective (topp)",5.9e-34,4.94,95,750,28,107.03
Sulfur (elii),1.86e-24,0.07,2,28,0,2.14
high-risk group (humn),3.96e-53,5.02,144,858,25,168.17
Corticotropin|CALCA|PCYT1A (aapp),8.56e-29,405.65,27,22,0,39.93
Sex Hormone-Binding Globulin (aapp),9e-33,5.25,348,17,8,17.83
Cysteamine (phsu),6.29e-09,0.1,1,15,0,1.07
Elderly person (humn),3.82e-15,2.54,69,299,19,84.92
"Hemangioma, Cavernous (neop)",2.07e-16,0.23,1,86,0,1.01
"Receptors, Opioid, mu (aapp)",2.43e-19,0.08,5,21,0,6.19
Choroid (bpoc),1.72e-26,0.33,14,226,0,14.87
Peroxidase (aapp),6.01e-24,0.3,24,190,1,27.03
stellate cell (cell),2.35e-11,0.13,1,28,0,1.04
Toxic effect (inpo),2.03e-113,1.31,171,7091,37,175.12
Pineal gland (bpoc),9.59e-23,0.07,2,27,0,2.15
Uridine (bacs),8.08e-07,0.16,4,17,0,4.94
Menstrual cycle (orgf),2.95e-49,1.7,228,39,1,45.67
Leisure physical activity (dora),3.84e-09,12.7,109,39,21,52.95
Membrane Potentials (celf),5.76e-52,0.09,6,86,1,6.42
Vitronectin|VTN (gngm),3.3e-06,0.07,1,6,0,1.17
Sedentary lifestyle (fndg),1.63e-09,13.54,114,50,5,71.93
"Thoracic Surgery, Video-Assisted (topp)",7.34e-10,3.18,46,222,1,55.53
Elective cesarian delivery procedure (topp),3.33e-08,4.44,18,39,1,26.31
"Anemia, Pernicious (dsyn)",5.83e-07,0.08,1,9,0,1.11
Phosphotransferases (aapp),2.04e-184,0.18,35,714,2,36.72
Shortened (tmco),4.15e-37,4.17,129,1051,41,144.83
Keloid (acab),6.55e-10,0.05,2,5,0,2.8
Physical activity (dora),2.95e-30,10.51,2960,846,165,1087.8
Posture (orga),4.87e-10,1.32,64,15,1,18.52
tumor growth (neop),4.34e-36,0.75,32,1841,12,32.56
undiagnosed (fndg),1.88e-09,3.79,24,86,4,30.7
Vacuole (celc),6.7e-35,0.11,2,72,0,2.06
Obesity surgery (topp),1.86e-07,16.66,22,13,7,20.68
Plain x-ray (diap),6.05e-31,1.17,435,486,12,824.35
narcotic use (fndg),7.51e-07,3.1,20,56,2,27.14
High pressure liquid chromatography procedure (lbpr),7.03e-20,0.27,74,121,0,119.26
Nerve Growth Factors (aapp),1.52e-72,0.07,15,59,1,18.81
Chromaffin Cells (cell),2.63e-19,0.05,2,14,0,2.29
Oxygen (elii),1.63e-19,0.6,159,1504,28,175.81
Comorbidity (idcn),4.38e-31,7.93,52,458,20,57.9
DNA Sequence (nusq),7.36e-219,0.12,47,487,1,51.54
Papule (fndg),1.12e-09,0.22,1,43,0,1.02
Prefrontal Cortex (bpoc),1.58e-41,0.12,33,46,0,56.67
protein transport (celf),3.11e-06,0.1,2,8,0,2.5
Cell Therapy (topp),8.23e-11,1.08,2,277,0,2.01
Dopamine Agonists (phsu),1.72e-10,0.31,26,90,1,33.51
"Adenocarcinoma, Clear Cell (neop)",6.67e-07,0.98,7,242,1,7.2
Renal function (ortf),9.39e-108,2.76,554,2467,82,678.41
Membrane receptor (rcpt),4.19e-11,0.14,2,30,0,2.13
Embolism (patf),1.62e-14,1.38,11,800,7,11.15
Severe Acute Respiratory Syndrome (dsyn),8.08e-08,1.49,5,507,8,5.05
Carcinogenesis (neop),3.39e-09,0.86,206,1925,25,228.04
Heme Oxygenase (Decyclizing) (aapp),3.98e-09,0.21,6,39,0,6.92
Steroid Use (inbe),3.22e-10,6.69,16,40,1,22.4
Blood supply aspects (bpoc),4.62e-11,0.55,64,660,3,70.21
Lymphopenia (dsyn),1.06e-06,1.16,5,259,1,5.1
Edetic Acid (orch),4.71e-39,0.07,7,42,0,8.17
Myoblasts (cell),2.37e-17,0.08,3,21,0,3.43
Polyclonal antibody (aapp),2.9e-23,0.21,5,105,0,5.24
Adult Children (famg),4.68e-08,1.78,64,38,2,60.56
Respiratory Tract Infections (dsyn),1.24e-11,1.29,38,976,5,39.48
Total proctectomy (topp),6.25e-07,3.35,32,252,7,36.06
salicylate (phsu),3.93e-09,0.12,2,19,0,2.21
Entire pelvic floor (bpoc),1.41e-33,1.74,150,30,1,36.0
Vincristine (phsu),5.02e-30,0.87,3,669,5,3.01
Sulfasalazine (phsu),2.63e-11,0.18,7,38,1,8.29
Rotenone (hops),5.11e-08,0.2,1,32,0,1.03
mastitis (dsyn),2.04e-17,0.17,5,61,0,5.41
Retinoids (phsu),2.51e-30,0.2,11,126,1,11.96
Cardiac resynchronisation therapy (topp),1.26e-07,2.94,9,939,1,9.09
Breast Carcinoma (neop),7.98e-24,0.86,34,861,3,35.34
Mastectomy (topp),1.75e-23,2.59,156,700,5,190.77
Leukotriene C4 (eico),2.02e-12,0.02,1,1,0,2.0
Prednisone (horm),3.58e-12,0.95,64,925,12,68.43
Structure of sertoli cell (cell),8.96e-22,0.02,1,5,0,1.2
Pulmonary Surfactant-Associated Protein A (aapp),1.02e-08,0.2,3,37,0,3.24
Tetradecanoylphorbol Acetate (hops),4.97e-54,0.05,6,42,0,6.86
Structure of wisdom tooth (bpoc),1.88e-06,0.15,11,3,0,3.82
"Lymphohistiocytosis, Hemophagocytic (dsyn)",2.08e-11,1.87,1,510,1,1.0
Frontotemporal dementia (mobd),8.26e-07,0.36,4,65,1,4.25
Mumps (dsyn),5.24e-07,0.25,1,36,0,1.03
Collagen Type IV (aapp),3e-16,0.17,5,56,0,5.45
Health Care (hlca),4.28e-07,1.88,137,922,24,157.36
Insecticides (hops),1.38e-20,1.72,3,875,1,3.01
caspase-9 (gngm),1.24e-11,0.22,1,54,0,1.02
RNA Polymerase II (aapp),3.85e-12,0.06,1,12,0,1.08
Gender (orga),1.82e-189,7.02,1126,1143,82,2235.25
Fine needle aspiration biopsy (diap),8.36e-18,0.36,11,249,1,11.49
Hyperlipidemia (dsyn),6.37e-12,3.36,574,605,46,1118.59
Cycloheximide (antb),1.13e-43,0.02,1,15,0,1.07
Clenbuterol (phsu),4.42e-09,0.04,1,4,0,1.25
acetonitrile (orch),8.97e-17,0.03,1,5,0,1.2
Acetylcholinesterase (aapp),1.48e-45,0.16,9,143,0,9.57
Matrix Metalloproteinases (aapp),7.34e-18,0.46,40,513,1,43.12
FYN gene|FYN (gngm),3.62e-08,0.09,1,13,0,1.08
Mefloquine (phsu),3.79e-06,0.2,2,24,1,2.17
1/36 (fndg),1.15e-11,9.44,16,27,4,25.48
K-ras Oncogene|KRAS (gngm),2.73e-07,1.66,12,572,2,12.25
Spermine (nsba),2.54e-19,0.05,1,15,1,1.07
Gram-negative bacillus (bact),4.31e-07,1.53,2,325,2,2.01
CA2 (gngm),0.0,0.03,12,133,0,13.08
Mounts (medd),2.73e-09,0.22,3,44,0,3.2
Entire subthalamic nucleus (bpoc),9.96e-07,0.13,3,13,0,3.69
Lymphocyte Activation (celf),1.06e-18,0.12,2,44,0,2.09
Plasminogen|PLG (aapp),2.79e-14,0.2,11,59,0,13.05
"Carcinoma, Transitional Cell (neop)",3.91e-28,1.17,33,1586,24,33.69
Entire thoracic aorta (bpoc),3.69e-13,1.02,13,511,3,13.33
Adenine (bacs),5.15e-12,0.09,2,18,0,2.22
Thrombin (aapp),4.06e-53,0.27,57,372,5,65.73
Plague (dsyn),1.54e-17,1.46,1,548,0,1.0
Factor VIII|F8 (aapp),2.46e-07,8.67,11,41,0,13.95
S100B (gngm),2.69e-08,0.41,18,115,1,20.82
Recurrent tumor (neop),1.27e-07,1.7,3,409,2,3.02
Sister Chromatid Exchange (genf),7.68e-10,0.03,1,2,0,1.5
"Diabetes Mellitus, Insulin-Dependent (dsyn)",5.08e-139,1.65,1488,1167,59,2082.25
Peptide YY|PYY (gngm),3.41e-31,2.05,112,14,2,15.75
Fatty deposition (patf),4.03e-07,3.28,108,28,9,35.26
Bladder (bpoc),6.71e-11,0.62,200,2171,22,218.42
Logistic Models (inpr),6.78e-08,7.66,13,48,0,16.52
"Receptors, LH (aapp)",1.08e-06,0.1,5,2,0,2.8
Entire oral cavity (blor),1.12e-09,0.86,31,496,2,32.94
Membrane (celc),0.0,0.1,53,556,2,58.05
Hernia of abdominal cavity (dsyn),2.31e-16,3.83,35,97,10,47.63
Deuterium (elii),1.96e-11,2.61,82,19,1,23.4
E2F1 gene|E2F1|UBE2L3 (gngm),2.13e-07,0.31,3,54,0,3.17
Adverse event (fndg),4.16e-60,4.45,328,4324,95,352.88
Glutamate (aapp),3.05e-109,0.09,23,156,1,26.39
Somatomedins|BP1 (aapp),1.56e-16,191.88,17,14,0,25.53
Physicians (humn),1.03e-11,1.46,559,2933,52,665.54
Wound Healing (orgf),1.86e-17,1.4,221,3956,46,233.35
Isolated systolic hypertension (fndg),2.17e-15,3.38,41,138,11,53.18
research outcome (fndg),6.71e-22,3.77,66,147,7,95.63
Disability NOS (patf),1.01e-33,1.68,633,3106,98,762.0
Chromatin Structure (celc),1.52e-07,0.1,1,13,0,1.08
Cultured skin (bpoc),3.87e-09,0.14,2,25,0,2.16
Regional Blood Flow (ortf),2.85e-43,0.11,21,61,0,28.23
Glomerular Filtration Rate (ortf),1.43e-280,3.51,764,1979,137,1058.94
Mouse monoclonal antibody (phsu),5.88e-07,0.16,1,22,0,1.05
Smoking History (fndg),1.05e-36,7.55,56,160,7,75.6
Ovulation (ortf),2.57e-08,0.88,166,57,2,76.57
Neurodegenerative Disorders (dsyn),2.93e-50,0.32,48,439,3,53.25
Ca(2+)-Transporting ATPase|CA2 (aapp),1.11e-09,0.08,1,14,0,1.07
"Receptors, Histamine H1 (aapp)",4.1e-07,0.05,1,4,0,1.25
Mixed infectious disease (dsyn),4.5e-08,1.0,2,228,2,2.02
Entire temporomandibular joint (bpoc),3.63e-21,0.05,2,15,0,2.27
Endosomes (celc),1.19e-28,0.07,1,41,0,1.02
Organic acid (orch),1.01e-08,0.13,2,20,0,2.2
Nephrectomy (topp),3.44e-07,2.34,87,764,24,96.91
Recombinant Interferon-gamma (aapp),7.78e-116,0.27,47,748,4,49.95
MRSA - Methicillin resistant Staphylococcus aureus infection (dsyn),2.78e-27,0.98,13,849,5,13.2
Insulin-Like-Growth Factor I Receptor (aapp),9.22e-09,0.37,14,97,2,16.02
Insulin-Like Growth Factor-Binding Protein-9|NOV (aapp),4.19e-07,0.11,2,11,0,2.36
Theophylline (phsu),5.73e-42,0.11,5,83,0,5.3
Nutritional Study (resa),3.33e-09,5.56,177,133,18,232.94
GLUCOSE TOLERANCE (phsf),4.61e-24,7.0,856,97,22,107.99
Vitiligo (dsyn),3.69e-16,0.11,7,23,0,9.13
Enzyme Precursors (aapp),1.27e-08,0.16,1,26,0,1.04
regular physical activity (dora),2.29e-25,11.78,90,79,10,148.34
Epidermis (tisu),8.3e-66,0.08,6,93,1,6.39
Clomiphene Citrate (phsu),3.13e-09,1.15,74,9,0,10.09
glucose homeostasis (phsf),5.47e-10,3.52,259,88,4,117.9
"Mitochondria, Liver (celc)",1.8e-26,0.02,2,6,0,2.67
PROTEIN INTAKE (fndg),1.24e-08,10.71,190,69,23,94.06
Anti-Allergic Agents (phsu),8.45e-07,0.07,1,7,0,1.14
NAMPT (gngm),8.05e-11,3.58,109,17,3,19.65
Albers-Schonberg disease (dsyn),8.96e-07,0.22,1,31,0,1.03
Encounter due to counseling (fndg),1.72e-12,4.13,71,109,14,117.25
gamma-Aminobutyric Acid (aapp),7.66e-132,0.06,15,105,1,17.14
Vasospasm (patf),2.56e-10,0.73,7,495,1,7.1
Nitrous Oxide (inch),3.03e-12,0.15,10,26,0,13.85
High income (fndg),1.21e-20,5.78,142,156,5,271.26
Pregnancy Complications (dsyn),3.36e-49,3.99,126,294,10,180.0
resveratrol (orch),8.13e-36,0.22,23,175,0,26.02
Densitometry (lbpr),9.66e-09,1.46,51,33,4,54.35
Histocytochemistry (lbpr),5.5e-26,0.09,2,42,0,2.1
Dithiothreitol (carb),3.7e-16,0.03,1,6,0,1.17
{PROVIDER} (hlca),6.9e-14,2.64,88,434,6,105.84
Mixed Function Oxygenases (aapp),1.32e-26,0.14,9,69,0,10.17
Parietal Lobe (bpoc),1.84e-11,0.17,6,36,1,7.0
Cardiovascular morbidity (dsyn),3.62e-290,16.7,116,3685,346,119.65
Recombinant Growth Hormone|TH (horm),5.61e-38,100.44,48,35,5,60.52
device aspects (mnob),7.19e-08,0.59,46,286,2,53.4
Clonazepam (orch),7.85e-08,0.11,1,15,0,1.07
CARBONATE DEHYDRATASE (aapp),4.28e-18,0.06,3,16,0,3.56
Procedures (hlca),8.31e-77,2.1,946,5900,200,1097.68
Birth Weight (orga),5.91e-127,6.21,821,892,33,1576.65
Evoked Potentials (ortf),4.62e-17,0.07,3,15,0,3.6
Ankle brachial index (diap),5.04e-44,6.51,66,171,15,91.47
frontal lobe (bpoc),7.23e-41,0.2,22,178,0,24.72
